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CHAPTER 1 
INTRODUCTION 
1.1. General Overview 
Cancer causes the highest number of deaths worldwide. Each year, over 8 million people 
perish from this disease.
1
 It has been estimated that by 2030 the number of patients dying from 
cancer will increase by 80%.
2
 Prostate cancer is the most common cancer affecting males, while 
the most common cancer affecting females is breast cancer. According to the American Cancer 
Society in 2014, approximately 233,000 new cases of prostate cancer are estimated to be 
diagnosed in males. About 232,670 new cases of breast cancer are projected to be diagnosed in 
females.
3 
In their lifetime, 1 in every 7 American men will be diagnosed with prostate cancer and 
1 in every 8 American women will be diagnosed with breast cancer.
3
 To date lung and bronchus 
cancer have the highest death rates with an estimated 159,260 in 2014.
4
  
Diagnosis and treatment of cancer has been developed throughout the years. Most of 
these methods include use of radiation, photodynamic therapies, surgical removal, laser, 
chemotherapy, and targeted therapy. This later method has been widely successful in the 
development of organic- and inorganic-based therapeutic drugs that selectively target specific 
genes, growth factors, and proteins, or interfere with different intracellular pathways that cause 
cancer. Understanding the chemical mechanism of action of these drugs and their interaction 
with the intracellular environment has always been a challenge.  
In the last four decades, the field of medicinal inorganic chemistry expanded rapidly 
since metals have proven to be valuable as chemotherapeutic agents for the treatment of various 
tumors.
5
 Ever since the discovery of cisplatin, [Pt
II
(NH3)(Cl)2], in the 1960s
6,7
 research has 
focused on other metal ions including ruthenium,
8
  gold,
9
 and cobalt
10
 as great candidates for 
2 
 
 
 
drug development. Although the intracellular molecular target for most of these metal-based 
drugs is the DNA, other systems such as proteins have proven to be excellent targets in 
anticancer therapy.  
1.2. Proteasome as a Target for Anticancer Therapy 
The chemical degradation of biomolecules in cells is performed by two systems including 
the lysosome and the ubiquitin-proteasome pathway (UPP). Over 80% of the intracellular protein 
degradation is carried out by the ubiquitin-proteasome system (UPS);
11
 the major proteolytic 
mechanism responsible for degradation of misfolded, oxidized, and damaged cellular proteins in 
eukaryotes.   
In 2004, the Nobel Prize in Chemistry was awarded to Aaron Ciechanover, Avram 
Hershko, and Irwin Rose for their excellent work on the discovery of UPS.
12,13
  The ubiquitin-
proteasome pathway involves two major processes: (1) ubiquitination of the damaged or 
misfolded proteins and (2) proteolysis of such proteins by the 26S proteasome (Figure 1.2.1).
14
 
During ubiquitination, misfolded proteins are appended with ubiquitins (Ub), small proteins of 
8.5 kDa which bind to a lysine residue of the substrate.
15
 This process is facilitated through a 
chain of three enzymes: Ub-activating, -conjugating, and -ligating E1, E2, E3, respectively.
16
 
The degradation process by the 26S proteasome is only performed on the poly-ubiquitinated 
(four or more ubiquitins attached to the misfolded protein) species. The second process of the 
ubiquitin-proteasome pathway is proteolysis, an ATP-dependent process, in which ubiquinated 
proteins undergo peptide bond cleavage in the 26S proteasome.
17
 The 26S proteasome is a 
multicatalytic protein complex with molecular weight of 2500 kDa, composed of the 20S 
catalytic part and the two regulatory subunits known as 19S.  
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1. Degradation of the targeted protein by ubiquitin-proteasome system (adapted from 
ref. 14). 
 
Ubiquitination 
19S Regulatory Cap 
α ring  
β ring  
β ring  
α ring  
19S Regulatory Cap 
20S Catalytic Core 
 
Proteolysis 
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The catalytic part of the 26S proteasome is flanked between the two 19S regulatory 
particles and is composed by two α and two β rings (Figure 1.2.1). Each of the four rings 
contains a total of seven subunits.
18
 Only three out of the fourteen β subunits are responsible for 
the catalytic activity of the 20S core and they are known as β1, β2, and β5. The subunit β1 is 
responsible for the caspase-like activity and cleaves a peptide bond after acidic amino acids. The 
β2 subunit performs trypsin-like activity resulting in a peptide bond cleavage after basic amino 
acids. The subunit β5 is responsible for chymotrypsin (CT)-like activity and cleaves a peptide 
bond after hydrophobic amino acids.
19
 Characteristic for the catalytic β subunits is the presence 
of an N-terminal threonine (Thr) residue which is responsible for the nucleophilic attack during 
peptide bond cleavage. The α subunits provide structural support to the overall barrel-like core of 
the 20S proteasome. Parts of the 19S regulatory particles are by two subcomplexes known as the 
lid and the base.
20
  The main function of the lid is to remove the ubiquitin tags from the substrate 
prior to degradation by the catalytic site,
21
 while the base unfolds the targeted substrate and 
directs it towards the 20S core.
22
 Degradation of ubiquitinated proteins through the catalytic 
chamber of the proteasome results in generation of smaller peptide units comprised of 3 to 22 
amino acids.   
Besides the degradation of damaged proteins, the ubiquitin proteasome system is also 
involved in regulation of various nuclear growth factors, signal transduction, and the control of 
cell apoptosis.
23
 Regulation of such cellular growth factors is crucial for normal functioning of 
the cell. One of these growth factors is NF-κB which promotes DNA transcription. Under normal 
cell conditions NF-κB is bound to the IκB inhibitor, which blocks the activation of NF-κB.24 Due 
to external stimuli, such as stress, the IκB complex will be ubiquinated, thus entering the UPP for 
degradation and releasing the NF-κB unit. At this point, the NF-κB factor will enter the nucleus 
5 
 
 
 
and promote transcription; hence, enhancing cellular proliferation. Cancer cells are characterized 
by uncontrolled cell growth,
25
 due to higher levels of proteasome activity
26
  compared to normal 
cells. Therefore, inhibition activity of the proteasome presents an excellent mechanism in 
anticancer therapy.  
To date, most of the known proteasome inhibitors are designed to inhibit the activity of 
the catalytic subunits of the proteasome, particularly the chymotrypsin-like activity. Classes of 
the most common proteasome inhibitors include: peptide aldehydes,
27
 boronic acid,
28
 vinyl 
sulfones,
29
 and epoxyketones.
30
 The most studied 20S proteasome inhibitor is bortezomib 
(Figure 1.2.2, top) known as VELCADE or PS341.
31
 It is the first FDA approved proteasome 
inhibitor for treatment of non-Hodgkin lymphoma and various myeloma.
32
 The chemical 
structure of this boronic acid contains the fragment of Pyz-Phe-Leu (pyrazinoic acid-
phenylalanine-leucine) which gives this drug highest affinity towards the terminal threonine the 
β5 subunit of the catalytic core.
33
 The mechanism of inhibition activity of the chymotrypsin-
pocket involves formation of a tetrahedral adduct
18
 (pharmacophore) with the terminal threonine 
residue (Figure 1.2.2, bottom). Even though bortezomib has shown much success with 
treatment of hematological malignancies, it has failed in treatment of solid tumors.
34
 This drug is 
expensive and exhibits high levels of toxic side effects, including fatigue, nausea, diarrhea, 
thrombocytopenia, and lymphopenia.
35,36
 Hence, there is a quest for the development of other 
drug candidates with higher potency against solid tumors, and to understanding the mechanisms 
of action towards the proteasome. Appropriate candidates would be metal-containing drugs 
which consist of the ligand carrier and the metal ion. The ultimate goal of the current research is 
to develop novel anti-cancer proteasome inhibitors that display multiple inhibition mechanisms 
and less toxicity. The advantage of developing metal-containing proteasome inhibitors rests on 
6 
 
 
 
the versatility in tuning the coordination number, charge, redox activity, geometry, and 
intracellular selectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.2. Chemical structure of bortezomib (top) and tetrahedral adduct (bottom) (adapted 
from ref. 18). 
 
 
 
 
Bortezomib 
Bortezomib-enzyme complex 
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1.3. Metal Complexes as Potential Pro-Drugs  
The first efforts made towards the development of metal-based proteasome inhibitors 
were presented from the Dou Lab where different ligands including disulfiram,
37
 clioquinol,
38
 
and dithiocarbamate
39
 were mixed with copper salts and tested against the inhibition of 
proteasomal activity in LNCaP, C4-2B, and PC-3 prostate cancer cells,
40
 followed by in vivo 
studies.
34
 These results showed considerable inhibition activity of the proteasome and induction 
of cell apoptosis for all complexes. Inspired by these findings, we focused our efforts in the 
development of novel stochiometrically defined metal-containing anticancer pro-drugs with the 
aim of understanding the solution-based behavior of these compounds by addressing: (1) the 
chemical nature of the ligands, (2) the role of metal ions, (3) the appropriate ratio between metal 
ions and ligands, (4) the chemical structure of the pharmacophore.
41,42
 
For the past few years, we have reported on the synthesis and characterization of a series 
of gallium(III) complexes [Ga
III
(L
X
)2]ClO4, where X = methoxy (MeO–), nitro (NO2–), chloro 
(Cl–), bromo (Br–), and iodo (I–) occupy the 4th and 6th position of the phenolate ring in the 
asymmetric NN
’
O-containing ligand (Scheme 1.3.1).
43
  
 
 
 
 
 
 
 
Scheme 1.3.1. Chemical structure of gallium(III)-containing complexes. 
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Anti-cancer properties of these complexes were tested against the growth of 
neuroblastoma cells. The halogen-containing species on the phenolate ring possessed superior 
antineoplastic properties compared to the methoxy- and nitro-containing species. This study 
concluded that functionalization of the phenolate ring with the halogen groups (I, Br, Cl) 
enhances the anti-proliferative effects of these gallium complexes. To address the cause of 
apoptosis induction in cancer cells, the abovementioned five gallium(III) complexes were tested 
as inhibitors of the activity of proteasome.
41
 Results with purified proteasome demonstrated that 
the halogen-containing gallium(III) complexes were more potent, with the best inhibition shown 
by the iodo-substituted gallium complex.  
Consistent results were obtained when the halogen-containing gallium(III) complexes 
were tested in various prostate cancer cell lines. The [Ga
III
(L
I
)2]ClO4 complex showed the 
highest inhibitory effects of the CT-like activity of the 26S proteasome with IC50 (concentration 
at 50% cell death) = 17 µM. In addition, this complex showed promising results in vivo, by 
reducing the tumor growth in PC-3 xenografted nude mice by 66% due to proteasome 
inhibition.
44
 This data allowed us to conclude that functionalization of the phenolate ring by 
iodo-substituents is effective towards the inhibition activity of the proteasome in cancer cells.  
In order to address how the stoichiometry of metal to ligand ratio affects the inhibition 
activity of the proteasome, three copper-containing
47
 complexes were synthesized with 1:1 
[Cu
II
(L
I
)Cl],  [Cu
II
(L
I
)OAc] and 1:2 [Cu
II
(HL
I
)(L
I
)]OAc metal to ligand ratios (Scheme 1.3.2), 
where L is the deprotonated form of (2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol) 
ligand. Spectroscopic and spectrometric characterization of these complexes confirmed the four 
and five coordination arrangement of the Cu(II) (d
9
 configuration) ion around the ligand.
42
 The 
anticancer properties of these copper-containing complexes resulted in comparable IC50 values of 
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~4.0 µM against the growth of human leukemia cells.
47
 Consistently, inhibition of CT-like 
activity in C4-2B cancer cells resulted in over 80% at 15 µM for all three copper complexes.  
 
 
 
 
 
 
 
Scheme 1.3.2. Chemical structures of four- and five-coordinate copper(II)-containing 
complexes. 
Due to these pharmacological results, it is suggested that 1:1 metal-to-ligand species is 
the proposed pharmacophore that could possibly interact with the threonine residue of the 
chymotrypsin-like activity of 20S core.
45
 To evaluate this hypothesis, two complexes [Zn
II
(L
I
)2] 
and [Ni
II
(L
I
)2] were synthesized and characterized (Scheme 1.3.3).
46
  
 
 
 
 
 
 
 
Scheme 1.3.3. Chemical structures of nickel(II)- and zinc(II)-containing complexes. 
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The pharmacological effects of these species have been investigated in vitro, in cultured 
human cancer cells C4-2B. The zinc-containing complex inhibits the 26S proteasome activity in 
prostate cancer cells with IC50 = 4.4 µM, whereas no such inhibition was observed for the nickel-
containing complex. The differences in the cytotoxic effects of these complexes could be 
possibly explained by the nature of the metal ion. The labile the zinc(II) ion due to lack of 
ligand-field stabilization energy (LFSE) allows the formation of 1:1 metal-to-ligand species in 
solution. On the other hand, the inert character of nickel(II) ion due to a non-zero LFSE does not 
favor the formation of 1:1 metal-to-ligand species.
43
 From these studies, we have concluded that 
the presence of an [ML
1
]
+
 species as the pharmacophore, is necessary for proteasomal inhibition. 
This observation supports the current hypothesis that ligand dissociation is required in the 
mechanism to form species capable of interacting with the proteasome (Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3. Proposed dissociation mechanism of pharmacophore formation. 
This dissertation focuses on understanding the fundamental use of transition and main 
group metal complexes as inhibitors of the 26S proteasome in vitro. Our approach involves: (1) 
the selection of appropriate metal ions in well-understood ligand moieties for interaction with the 
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proteasome, and (2) ligand optimization that allows for the elucidation of mechanisms of 
proteasomal inhibition in prostate cancer cell lines, since prostate cancer is classified as an 
aggressive carcinoma
47
 with even higher proteasomal activity. Therefore, prostate cancer cells 
are expected to be more sensitive against inhibition of the proteasome activity. Some of the 
factors that promote prostate cancer are related to the environment. For instance, cadmium is a 
human carcinogen
48 
and patients with smoking habits develop more aggressive forms of prostate 
cancer than non-smokers due to cadmium accumulation in the prostate.
49
 Other toxic metals such 
as mercury
50
 and lead
51
 have been found to promote prostate cancer. Hence, part of this research 
investigates whether the toxicity of these heavy metal ions can be correlated with their 
interaction with proteasome in non-cancerous epithelial prostate cells.
12 
 
 
 
1.4. Research Statements 
The principal motivation behind this research project is defined within the scope 
of the following research statements: 
I. To understand the mechanisms of metal-based inhibition of the 26S 
proteasome by developing metal-containing anticancer pro-drugs for 
the treatment of prostate cancer. This approach takes advantage of the 
tunability of the electronic properties and reactivity of the resulting 
pharmacophores. For this research, we studied the use of transition and 
main group metal complexes as inhibitors of the 26S proteasome in 
vitro, by: (1) the selection of appropriate metal ions (inert/labile, redox 
active, charge) in known ligand moieties for interaction with the 
proteasome and (2) optimization of the ligand that allows for 
elucidation of mechanisms for proteasomal inhibition.  
II. To investigate whether the proteasome is one of the targets for the 
toxicity of heavy metal ions in non-cancerous epithelial prostate cells. 
Synthesis and characterization of these complexes along with the 
biological studies will be evaluated. 
These aims will be accomplished via four research objectives presented in the next 
section. 
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1.5. Research Objectives 
The strategies and different solutions used to address the Research Statements 
will be presented as the following research objectives, described in Chapters 3-6. 
 
Objective #1: To interrogate the mechanism of inhibition of the 26S 
proteasome using inert/labile metal ions coordinated to NN
’
O tridentate and 
N2N2
’
O2 hexadentate ligands. This aim focuses on the role of the metal ion 
(kinetically inert or labile) and the nature of the chelating ligands on the 
inhibition of CT-like activity of the purified proteasome and intact prostate 
cancer cells. The results of this objective will be introduced in Chapter 3. A 
thorough analysis of synthetic and chemical characterization procedures will be 
discussed, as well as an extensive evaluation of the biological testing in purified 
proteasome and prostate cancer cells.   
Objective #2: To investigate chemical reduction as a viable mechanism for 
the generation of pharmacophore species involved in the inhibition of the 26S 
proteasome. This aim focuses on evaluating the viability of ligand dissociation 
in order to form the active pharmacophore [ML
1
]
+
 species of an inert cobalt(III) 
complex as an inhibitor of the chymotrypsin-like activity of the 26S proteasome. 
Chapter 4 details the investigation of the electrochemical behavior of this 
complex in solution. 
Objective #3: To probe the effect of the ion charge towards the inhibition 
activity of 20S proteasome. In order to advance this objective a new series of 
gallium(III) and zinc(II) ions coordinated to a hexadentate N2N2
’
O2 ligand were 
14 
 
 
 
prepared and the activity of these complexes towards purified proteasome and 
prostate cancer cells are studied. These findings are discussed in Chapter 5. 
Objective #4: To evaluate the effect of aluminum and heavy metal ions on the 
inhibition activity of the 20S and 26S proteasome in non-cancerous prostate 
cells. In this study we are interested in the comparison of the activity of the 
proteasome in CRL2221 transformed human prostate epithelial cells, which 
mimic the behavior of normal prostate cells treated with complexes containing 
toxic metal ions; such as, Al(III), Cd(II), Hg(II), Pb(II), and Sn(IV). A detailed 
discussion on the purpose of this study is provided in Chapter 6 and includes 
validation of the potential role of such heavy metal species towards the 
inhibition activity of the proteasome.  
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CHAPTER 2 
MATERIALS, METHODS, AND CHARACTERIZATION TECHNIQUES 
2.1. General     
Reagents and solvents used in Chapters 3 – 6 were obtained from commercial sources 
and handled without further purification. Infrared spectra were measured from 4000 to 400 cm
−1
 
on a Tensor 27 FTIR spectrophotometer as KBr pellets. Electrospray ionization mass spectra 
were measured in the positive mode (ESI positive) using Micromass Quattro LC triple 
quadrupole mass spectrometer. Nuclear Magnetic Resonance (NMR) experiments including 
1
H- 
and 
13
C-NMR were measured using a Varian Mercury-400 and VNMRS-500 MHz spectrometers 
in CDCl3, DMSO-d6, and DMF-d7 at 298 K. Specific experimental conditions including 2D-
NMR are described in Chapter 3. Elemental analyses were performed by Midwest Microlab, 
Indianapolis, using V2O5 for complete combustion Indiana. Diffraction data were measured on a 
Bruker X8 APEX-II kappa geometry diffractometer with Mo radiation and a graphite 
monochromator. UV–visible spectroscopy from 1.0 × 10−4 M N,N-dimethylformamide (DMF) 
solutions and 9.0 × 10
−5
 M DMF/H2O (90:10%, v/v) were run using a Cary 50 
spectrophotometer in the range of 250–1100 nm. Cyclic voltammetry (CV) experiments were 
performed at room temperature under anaerobic conditions using argon gas in HPLC grade N,N-
dimethylformamide at concentration of 1.0 × 10
−3
 and 9.0 × 10
−4
 M DMF/H2O (90:10%, v/v) 
solutions. The experiments were carried out using a standard three-electrode cell with an 
Ag/AgCl as the reference electrode, a glassy-carbon working electrode, a Pt-wire as the auxillary 
electrode, and. Voltammograms were recorded using a BAS 50 W voltammetric analyzer at a 
scan rate of 100 mV s
−1
. The supporting electrolyte of tetra-n-butylammonium 
hexafluorophosphate (TBAPF6) was used 0.1 M concentration. The reversibility of the redox 
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processes for the cobalt ion was determined by the peak to peak separation (ΔEp = |Epc − Epa|) 
values and |ipc/ipa| ratio. 
The fluorogenic peptide substrate SucLLVY-AMC for the proteasomal chymotrypsin-
like activity measurements was purchased from Calbiochem, Inc. (San Diego, CA). Trypan blue 
exclusion dye was purchased from Sigma Aldrich (St. Louis, MO). Mouse monoclonal antibody 
against human poly (ADP-ribose) polymerase (PARP) was purchased from BIOMOL 
International LP (Plymouth Meeting, PA). RPMI 1640, penicillin, and streptomycin were 
purchased from Invitrogen (Carlsbad, CA), whereas fetal bovine serum was purchased from 
Aleken Biologicals (Nash, TX). Antibodies against ubiquitin (P4D1), actin (C-11), and 
secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Biological assays and cellular culture techniques included in Chapters 3, 5, and 6, were 
performed by Sara Schmitt in the Dou Lab at Barbara Ann Karmanos Cancer Institute. 
Computational calculations for Chapter 4 were performed by Dr. Marco M. Allard, a 
former student in the Verani Lab, using Gaussian 09 suite of programs
1
 with density functional 
theory (DFT). These calculations were carried out with the B3PW91
2
 functional basis set. 
2.2. Cyclic Voltammetry 
Cyclic voltammetry is an electroanalytical technique that measures the electron transfer 
(current) of a complex solution upon an applied potential.
3
 It best describes oxidation-reduction 
reactions and the flow of electronic charge in solution. The system consists of a standard three-
electrode cell connected to a potentiostat. The three electrodes, namely working, reference, and 
auxiliary are employed in the electrochemical cell containing the complex solution of interest 
and supporting electrolyte. The electrolyte used for our experiments is tetra-n-butylammonium 
hexafluorophosphate (TBAPF6) at 0.1 M. A typical cyclic voltammogram
3
 for a reversible one 
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electron process is shown in Figure 2.2. At point E, only the oxidized form of the redox couple 
is present in solution. As the forward negative scan of the potential progresses towards point F, 
the oxidized species start to convert to its reduced form. Once the net cathodic current (ipc) is 
reached, any of the oxidized species will be quickly reduced on the surface of the electrode. At 
point G, only the reduced form of the initial species is present in solution on the electrode 
surface. When the scan is reversed towards point H, the reduced species starts to convert back to 
its oxidized form, while a net anodic current (ipa) is reached at point H. As the anodic current 
approaches zero, only the oxidized species is present in solution (point E). The equilibrium 
concentration between the oxidized and reduced species is expressed using the Nernst equation.
4
 
For a reversible one electron process the current ratio | ipc/ipa | has to equal 1.0. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Cyclic voltammogram for one electron process (adapted from ref. 3). 
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2.3. Spectroelectrochemistry 
The experimental setup of spectroelectrochemistry involves the concerted use of 
electrochemical and UV-visible techniques. This technique was employed to measure the 
reduction of a cobalt complex in solution by monitoring the disappearance of the ligand to metal 
charge transfer band (LMCT) upon an applied fixed potential. Spectroelectrochemical 
experiments were performed at room temperature by employing an optically transparent thin-
layer cell (ca. 0.1 mm) inside of which a U-shaped flat platinum wire acting as the working 
electrode was placed between two glassy slides and was extended outside of the slides for 
electrical contact. The inner parts of these slides were coated with indium-tin oxide (ITO) (8-2 
Ω/sq). A second platinum wire was used as the counter electrode and the Ag/AgCl wire was the 
reference electrode. The cobalt complex was dissolved in DMF and the solution was purged with 
argon before it was introduced into the cell through a capillary. The electrochemical potential 
applied to the cell was higher (−1200 mV versus Fc/Fc+) than the cathodic potential for the 
cobalt(III)/(II) couple. This potential was achieved using a BAS 50 W potentiostat and the 
spectra were collected using a Varian Cary 50 apparatus within a time interval of 30 s frames 
following the disappearance of the phenolate to cobalt(III) charge transfer (LMCT).  
2.4. Chemical Reduction  
Chemical reduction experiments were performed by UV-visible spectroscopy to observe 
the disappearance of the LMCT band of the cobalt complex in presence of ascorbic acid 
reductant to mimic the reductive intracellular environment. The chemical reduction experiments 
were carried out at room temperature in a freshly prepared DMF/H2O (90:10%, v/v). Each 
spectrum was recorded within an interval of 30 min in the range of 300–900 nm following the 
decrease of the ligand to metal charge transfer (LMCT) band over a time period of 18 h. The 
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experimental setup employed a 4 mL quartz cuvette (1 cm optical path) where 2700 μL of the 
cobalt complex was dissolved in DMF under anaerobic conditions ([complex 1] = 1.0 × 10
−4
 M) 
and then mixed with 300 μL of an aqueous oxygen-free ascorbic acid solution ([AA] = 1.0 × 10−2 
M) stabilized with nitric acid. The final concentration of the complex solution inside the cell was 
([complex 1 + AA]final = 9.0 × 10
−5
 M), under apparent pH 3. The control samples were prepared 
under the same conditions without the addition of the reductant (AA) ([complex 1]final = 9.0 × 
10
−5
 M) and DMF/H2O (90:10%, v/v) solution) under pH 3 and pH 1, respectively. Data was 
treated as a pseudo-first order reaction, where the excess AA is maintained near constant through 
time. The concentration of the cobalt(III) complex is monitored as a function of time and fitted 
as a pseudo-first order exponential decaying equation, [C]t = [C]o × ekt. In order to evaluate the 
rate constant, the natural log of the decay data is plotted versus time and fitted with the following 
equation: ln[C]t = −kt + ln[C]o where [C]o, is the initial concentration (mol L−1), [C]t is the 
concentration at a given time, k is the first order rate constant (s
−1
), and t is time in seconds. The 
half-life of the cobalt(III) complex upon reduction was calculated using the t1/2 = ln 2/kobs 
equation. 
2.5. Western Blot Analysis 
 Western blotting was used to isolate and identify proteins of interest based on the 
principle of antibody-antigen binding. It was first discovered in 1979 by the scientist Harry 
Towbin.
5
 In this chapter Western blotting technique is described based on the experiments 
performed to identify levels of ubiquinated proteins and the enzyme poly ADP ribose 
polymerase (PARP) which are extracted from treated prostate cancer cells with various 
concentrations of metal-based compounds synthesized in the Verani Lab. This section includes a 
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description of how cells were prepared for the Western blot analysis, and how this technique was 
used to identify the proteins of interest. 
Preparation of Cell Extracts 
Prostate cancer cells (PC-3) were grown in a RPMI 1640 cell culture (100*20 mm) tissue 
culture dish containing sterile media treated with 10% fetal bovine serum, 100 µg/mL of 
streptomycin, and 100 units/mL of penicillin incubated overnight with 5% CO2 at 37
o 
C. After 
they reached 80% confluence, PC-3 cells were treated with increasing concentrations of the 
metal complexes and incubated for 18-24 hours. The cells were detached from the culture plates 
and spun at 1500 rpm for 3 min in order to separate the cell media; e.g., serum. Collected cell 
pellets were washed three times with phosphorus buffer saline (PBS) solution and then were 
centrifuged at 5000 rpm for 3 min. Cells were lysed with Tris-HCl lysis buffer in order to break 
the cellular wall of the phospholipid bilayer and vortexed for 20 min at 4
o 
C followed by 
centrifugation for 12 min at 1200 rpm. This process separates proteins from the genetic material. 
The proteins of interest were collected from the supernatant (cell lysates). 
Gel Electrophoresis 
Separation of proteins based on their charge and molecular size was performed by gel 
electrophoresis.
6
 Cell lysates were treated with a loading buffer which was used to denature the 
proteins. This enables the cell lysates to travel easily through the 10% polyacrylamide gel under 
the applied voltage. Bromophenol blue dye was added to the cell lysates to track how far the 
proteins have migrated through the gel. Cell lysates (40 µg of proteins) were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under 26-35 Volts. The 
SDS detergent was used due to its anionic nature, thus giving the proteins an overall negative 
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charge. Therefore, protein migration through the gel upon an applied voltage was solely based on 
their molecular size. The smaller weight proteins will travel farthest down the gel.  
Once the proteins were separated via gel electrophoresis, they were transferred to a 
nitrocellulose membrane to isolate the proteins of interest including ubiquinated proteins and 
PARP. The protein transfer process (blotting) was performed by placing the nitrocellulose 
membrane between the gel and the positive electrode where upon an applied electric field the 
negatively charged proteins migrated towards the membrane.
7
 The nitrocellulose membrane was 
incubated overnight at 4
o 
C with the primary mouse monoclonal antibody against ubiquitin 
(P4D1). Following the next day, the membrane was washed three times with Tris buffer saline 
solution to eliminate any unbound proteins, and then incubated overnight at 4
o 
C with the 
secondary antibody which specifically binds to the primary antibody, as shown in Figure 2.5. 
The nitrocellulose membrane was washed three times with Tris buffer saline solution followed 
by the addition of enhanced chemiluminescence (ECL) substrate which was cleaved by the 
enzyme horseradish peroxidase, thus emitting light.
8,7 
The same procedure is applied for isolation 
of PARP by using mouse monoclonal antibody against human PARP.
 
 
 
 
 
 
 
 
Figure 2.5. Isolation of Ub-proteins by Western blot analysis (adapted from ref. 8). 
 
26 
 
2.6. References 
                                                          
1         Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. 
R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; 
Li, L.; Hratchian, H. P.; Izmaylov, A.F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, 
M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, 
Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A.; Peralta, J. E.; Ogliaro, F.; 
Bearpark, M.; Heyd, J.; Brothers, J. E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; 
Normand, J.; Raghavachari, A.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; 
Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; 
Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; 
Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R.L.; Morokuma, K.; Zakrzewski, V.G.; 
Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Dapprich, S.; Parandekar, P.V.; Mayhall, N.J.; 
Daniels, A.D.; Farkas, O.; Foresman, J.B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 
G09 Wallingford CT, 2009. 
2        Krishnan, R; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650. 
3        Wang, J. Analytical Electrochemistry; Chapter 2, Wiley & Sons, Inc. New York, 2000. 
 
4          Chang, R.; Goldsby, K.; Chemistry, 11
th
 edition, Chapter 18, Electrochemistry, The  
          McGraw-Hill Companies, Inc., New York, NY 10020, 2013, pp. 830.     
5        Towbin, H.; Staehelin, T.; Gordon, J. Proc. Natl. Acad.Sci. 1979, 76, 4350. 
6        Kryndushkin, D. S.; Alexandrov, I. M.; Ter-Avanesyan, M. D.; Kushnirov, V. V. J. Biol.  
          Chem. 2003, 278, 49636.  
7         Mahmood, T.; Yang, P.-C. N. Am. J. Med. Sci. 2012, 4, 429. 
 
 
27 
 
                                                                                                                                                                                           
8        http://www.piercenet.com/method/overview-western-blotting#introduction 
 
28 
 
CHAPTER 3 
EFFECTS OF TETHERED LIGAND AND OF METAL OXIDATION STATE ON THE 
INTERACTION OF COBALT COMPLEXES WITH THE 26S PROTEASOME  
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
CHAPTER 3 
EFFECTS OF TETHERED LIGAND AND OF METAL OXIDATION STATE ON THE 
INTERACTION OF COBALT COMPLEXES WITH THE 26S PROTEASOME  
Published with minor changes as Tomco, D.; Schmitt, S,; Ksebati, B.;  Heeg, M. J.; Dou, Q. P.; 
Verani, C. N.* J. Inorg. Biochem, 2011, 105, 1759.   
3.1. Introduction 
Our groups have been interested in the development of coordination complexes capable 
of inhibiting the activity of the 26S proteasome in tumorous prostate cells. The 26S proteasome 
is a large protein complex responsible for the destruction of faulty proteins and enzymes.
1,2
 In 
tumor cells the activity of the 26S proteasome goes in overdrive fostering the proteolysis of 
inhibition factors such as IκB releasing NFκB nuclear factor that support the development of 
blood vessels and promote tumor cell growth.
3,4
 Inhibition of this activity leads to cellular 
apoptosis, or programmed cell death.   
 We have demonstrated recently that a series of gallium complexes [Ga(L
NN’O
)2] with the 
substituted ligand 2,4-di-X-6-((pyridine-2-ylmethylamino)methyl)phenol (where X = bromo or 
iodo)
5,6
 were active against the proteasome, as measured by the inhibition of its chymotrypsin-
like activity (CT)  and resulting accumulation of ubiquitinated proteins. This activity triggered 
cell death both in vitro and in vivo. Thus, we proposed that in order to inhibit the proteasome 
activity, this species would likely bind to available amino acids along the α channels of the 
proteasome, or to the terminal threonines of the β active sites in a similar way as reported to the 
antineoplastic agent bortezomib (valcade).
7
 The [ML2]
+
 species would need to be converted into 
a [ML]
+
 species, in order to establish a metal/amino acid chemical bond. Evidence for such 
mechanism was gathered when 2:1 and 1:1 copper(II) complexes showed comparable CT 
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inhibition activities in purified 20S and 26S proteasomes, in C4-2B and PC-3 cell extracts, as 
well as in intact cells.
8
 Consistently we have also observed that [ML2] complexes with labile 
zinc(II) ions show considerable activity, whereas more inert and redox-inactive metal ions such 
as nickel(II) show negligible results.
9
  
In this chapter, we further this investigation by comparing the inhibition activity of three 
cobalt complexes described as [Co
II
(L
1
)2] (1), [Co
II
(L
2
)] (2), and [Co
III
(L
1
)2ClO4] (3) (Scheme 
3.1). We are interested in the comparison of 1 and 2 that allows further analysis for the need of 
ligand dissociation, where the newly designed ligand used in 2 hinders such dissociation. 
Similarly we want to compare 1 and 3 to examine the role of the oxidation states and the 
potential of redox changes in proteasome inhibition. The antitumor activity of cobalt species is 
fairly understudied,
10
 but activity against prostate cancer has been recently demonstrated by 
McNeil et al. for bivalent cobalt.
11
 On the other hand, Teicher, Ware, Hambley,
12
 and more 
recently Donelly
13
 have taken advantage of bioreductive activation of its trivalent counterpart for 
the treatment of hypoxic tumors. In this case, intracellular redox conversion of Co(III) into 
Co(II) releases alkylating mustards. 
 
 
 
 
 
 
 
 
                                                      
 
Scheme 3.1. Cobalt complexes. 
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3.2. Results and Discussion 
 3.2.1. Synthesis and Characterization 
Both ligands HL1 and H2L
2 were synthesized in moderate yields following procedures 
available in the literature.14,15 The condensation reaction of picolinaldehyde with ethane-1,2-
diamine produced the corresponding Schiff base ligand. This was followed by reduction with 
sodium borohydride to generate the intended N1,N2-bis(pyridin-2-ylmethyl)ethane-1,2-diamine 
precursor. Formation of the new H2L
2
 ligand, as shown in Scheme 3.2.1, was obtained by 
reaction of this amino-pyridine precursor with 2-(chloromethyl)-4,6-diiodophenol in the presence 
of base. The 
1
H-NMR spectra of the ligands were measured and will be relevant for future 
comparisons. The spectrum for HL
1 
was recorded in DMSO-d6 in order to compare with the 
1
H 
NMR of 3. A complete characterization of HL
1
 ligand including the 
1
H-NMR spectra and 
1
H-
1
H 
COSY is given in Figures A.3.2.1.1, A.3.2.1.2, and A.3.2.1.3. From the 
1
H-NMR spectra, the 
two methylene protons from both the pyridine rings (H5, H5
’
) and phenol (H6, H6
’
) appear as 
two distinct singlet resonances centered at 3.83 ppm and 3.87 ppm, respectively, whereas the 
aromatic protons lie between the 7.28-8.60 ppm region. The exchangeable protons from the 
aliphatic nitrogen atom (H9) and the phenol group (H10) are observed as a broad resonance 
between 6.60-7.10 ppm. The (H1) proton from the pyridine ring resonates as a doublet at 8.54 
ppm.  
 
 
 
 
Scheme 3.2.1. Synthesis of the H2L
2
 ligand.  
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The spectrum for H2L
2
 recorded in CDCl3, provides evidence for a symmetric ligand in 
the solution, as Orvig et al
16
 and Neves et al
17
 have similarly observed with other related 
H2bbpen ligands. Therefore, three sharp singlet resonances are shown at 2.67 ppm, 3.61 ppm, 
and 3.72 ppm representing the four protons from ethane-1,2-diamine, phenolic-methyl, and 
pyridyl-methyl groups, respectively; whereas the aromatic protons are displayed between the 
region of 7.11-8.60 ppm. Complexes 1-3 were synthesized by the reaction of the metal salt with 
the appropriate ligand in methanol or dichloromethane in the presence of triethylamine base. 
Characterization of all of the metal complexes includes spectroscopic and spectrometric 
techniques consisting of IR, NMR, ESI-MS, and elemental analyses. Infrared analysis confirms 
that both C=N and C=CAr stretching modes shift ca. 40-60 cm
-1 to lower frequencies due to 
metal coordination. Characteristic for the infrared spectrum of the [CoIII(L1)2]ClO4 (3) complex 
is the presence of a strong broad band at 1098 cm-1, corresponding to the perchlorate counterion. 
Spectrometric analysis for complexes 1-3 was performed by ESI-MS in the positive mode and in 
methanol solutions. The results showed excellent agreement between the experimental and the 
simulated data as presented in Figure 3.2.1. As previously published,14 complex 1 shows the 
presence of the molecular ion peak observed at m/z+ = 989.9 (100%) which corresponds to the 
{[Co(L1)2] + H
+}+ species. Alternatively, for complex 3 the main peak is detected at m/z+ = 988.9 
(100%) and assigned to the [Co(L1)2]
+ species providing strong evidence for the coordination of 
the cobalt(III) ion. ESI-MS for complex 2 shows the parent peak for {[Co(L2)] + H+}+ species at 
m/z+ = 1015.7 (100%). The isotopic distribution for both complexes 2 and 3 are shown in Figure 
3.2.1. All of the above data confirm the expected configurations of 1:2 and 1:1 metal-to-ligand 
species containing six-coordinate cobalt ions bound to HL1 or H2L
2, respectively. 
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Figure 3.2.1. Isotopic distribution for complex 2 (left) and 3 (right). The bars indicate the 
experimental results and the continuous spectra indicate the simulated results. 
 
3.2.2 Molecular Structural Characterization of [Co
II
L
2
] (2) 
X-ray diffraction was used to determine the molecular structure of single crystals of 
compound 2 isolated from slow solvent evaporation of a 1:1 mixture of dichloromethane and 
methanol. Figure 3.2.2 displays the ORTEP diagram for complex 2 with selected bond lengths 
and angles. Compound 2 consists of a neutral cobalt(II) species with coordination environment 
arranged about a fully deprotonated hexadentate ligand (L
2
)
2-, containing two [NN′O] donor sets. 
The pseudo-octahedral cobalt(II) center is oriented in a two-fold rotation axis with each half of 
the ligand in a facial arrangement. We have previously reported on similar coordination spheres 
for cobalt(II) complexes containing two independent [NN
′
O] ligands, in which all equivalent 
donors are positioned trans to each other.
14,18
 In contrast, complex 2 displays an arrangement of 
cis phenolates, trans pyridines, and cis nitrogen atoms, rather observed for iron(III) and 
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manganese(III) complexes with similar hexadentate ligand.
19,20,21
 The short cobalt-donor bonds, 
along with the absence of counterions support the bivalent nature of the metal ion. The observed 
Co-Ophenolate distance is 2.00 Å, whereas Co-Npyridine is 2.14 Å, and Co-Namine is 2.23 Å. These 
values are in good agreement with the literature.
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. ORTEP diagram at 50% probability level for 2. Selected bond lengths include 
Co(1)-O(1) = 2.003(3), Co(1)-N(1) = 2.139(3), Co(1)-N(2) = 2.234(3) Å. Selected angles include 
N(1)-Co(1)-N(2) = 76.57(12), O(1)-Co(1)-N(1) = 90.32(12), O(1)-Co(1)-N(2) = 89.65(11). 
Goodness of fit is given by R(F) (%) = 3.13. 
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3.2.3. NMR Spectroscopic Studies 
The 
1
H-NMR spectra for compound 3 were taken in DMSO-d6 at 298 K, and are shown 
in Figure 3.2.3.  A comparison of the proton chemical shifts of HL
1
 and 3 is given in Table 
3.2.3 and (Table A.3.2.3). 
 The 
1
H-NMR spectrum of 3 showed eleven distinctive resonances between 3.41 and 
9.00 ppm, indicating that the compound has a diamagnetic 3d
6
low-spin electronic configuration. 
The 
13
C-NMR spectrum of complex 3 confirmed the presence of thirteen different carbon 
chemical peaks corresponding with half the number of carbons present in the molecule, 
suggesting that this complex is symmetric in solution. A combination of DEPT, COSY (Figures 
A.3.2.3.1 and A.3.2.3.2), and HMQC experiments were used to establish proton and carbon 
connectivity in the isolated spin systems for 3, whereas NOE was employed to confirm the 
proposed structure. DEPT analysis revealed two signals corresponding to two methylene groups, 
and six distinct CH peaks giving a total of ten protons, whereas 
13
C-NMR/DEPT studies 
confirmed the presence of five fully-substituted aromatic carbons.  
Characteristic for the 
1
H NMR spectra for complex 3 is the observation of the chemical 
shifts and splittings of the proton resonances attributed to metal coordination for the two 
methylene protons Figure 3.2.3 (a). The original singlet peak observed at 3.83 ppm (H5) in the 
non-metallated ligand now appears as the two doublets observed at 4.39 and 5.58 ppm for the 
complex, possibly due to the coupling with the aliphatic amine proton (H9). The same 
phenomenon was observed for the initial singlet peak at 3.87 ppm (H6), which transforms into 
two distinct resonances appearing as doublets at 3.48 and 3.66 ppm for 3. 
The connectivity of the protons to the carbons for complex 3 was supported by the 
HMQC experiment, as shown in (Figure 3.2.3 (b) and Figure A.3.2.3.3; where the identity of 
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the exchangeable proton attached to the aliphatic nitrogen atom (H9) was revealed. In this 
spectrum, one resonance corresponding to the proton on the aliphatic amine (H9) appears as a 
broad singlet and is shifted downfield to 8.33 ppm. Also, in comparison to the 
1
H NMR spectra 
of the ligand HL
1
, where the exchangeable proton of the phenol group is centered between 6.60 
and 7.10 ppm, complex 3 has no such peak present which indicates ligand deprotonation.  
The aromatic proton found on the 1-position of the pyridine ring (H1) shifts downfield to 
8.99 ppm and appears as a doublet of a doublet due to metal coordination. Only slight changes of 
the proton chemical shifts were observed for all aromatic protons as shown in Table 3.2.3, and 
no broadening of the signal indicative of dynamic equilibria
22
 were observed.  
To confirm the thermodynamic stability of 3 in solution, variable-temperature 
1
H-NMR 
experiments were performed in DMSO-d6 (25 to 80 °C, not shown), as well as in DMF-d7 (25 
to − 40 °C, Figure A.3.2.3.4). No significant changes were observed, thus supporting the idea 
that the 3d
6
low spin assignment for 3 is the stable conformation in the timeframe of these 
experiments. 
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Table 3.2.3. 
1
H NMR assignment for HL
1
 and [Co(L
1
)2]ClO4 (3) in DMSO-d6. 
 
 
 
 
 
 
 
Proton 
H 
  HL
1
                   
(ppm) 
[Co
III
(L
1
)2ClO4] 
(ppm) 
H1 8.54 (d) 8.99 (dd) 
H2 7.29 (dd) 7.46 (t) 
H3 7.8 br (dt) 7.95 (t) 
H4 7.37 (d) 7.57 (d) 
H5 H5
’ 
3.83 (s) 4.39(d) 5.58 (dd) 
H6 H6
’ 
3.87 (s) 3.48(dd) 3.66 (d) 
H7 7.33 (d) 7.39 (s) 
H8 7.78 (d) 7.34 (s) 
H9 6.60-7.10 br (s) 8.33 (s) 
H10 6.60-7.10 br (s) no peak 
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Figure 3.2.3. NMR spectroscopic measurements for complex 3; (a) 
1
H-NMR spectrum and (b) 
HMQC spectra. 
 
 
 
 
 
 
 
 
39 
 
3.2.4. UV-visible Spectroscopy 
The UV–visible spectra of complexes 1–3 were taken in 1.0 × 10−4 M DMF solutions to 
assure consistency of solubility properties (Figure 3.2.4). The noticeable absence
18
 of a ligand-
to-metal charge transfer band at about 450 nm is diagnostic of the 3d
7
high spin cobalt(II) center in 
complexes 1 and 2. This very characteristic process is observed for complex 3 at 441 nm 
corresponding to a pπphenolate – dσ
*
cobalt (III) charge transfer. Another band at 630 nm usually 
attributed to d-d transitions is also present, confirming the trivalent character of the 3d
6
low spin 
cobalt(III) species. Other observed features include the intense π – π* intraligand bands at about 
320 nm for all species. These results are in good agreement with the previously published data 
on cobalt complexes containing [NN′O] donor ligands10,23. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4. UV–visible spectra of complexes 1–3 in N,N-dimethylformamide, 1.0 × 10−4 M. 
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3.2.5. Biological Results 
Biological data were gathered regarding the inhibition activity of species 1–3 toward cell 
proliferation, the purified 20S proteasome, and intact PC-3 prostate cancer cells. Inhibition of 
cell proliferation in human PC3 cells was successful with species 3. Cell proliferation was 
decreased by 40% upon treatment with 20 μM, and reached nearly 100% inhibition at a 
concentration of 30 μM. A less remarkable activity was observed for 1, where noticeable 
inhibition required considerably higher concentrations, e.g. ~ 30% inhibition at 50 μM (Figure 
3.2.5.1). Initially, this observation seems to contradict the proposed ligand exchange mechanism 
observed for similar copper, nickel and zinc complexes with similar ligand.
8,9 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5.1. MTT, PC-3 cells after 18 h treatment. Control is DMSO, for each concentration 
from 10 to 50 μM, compound 1 is indicated in the left column and 3 is indicated in the right 
column. 
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To test the in vitro 20S proteasome inhibition ability of these species, a comparison of the 
inhibitory activity of 1, 2 and 3 to the 20S proteasomal activity was performed under cell-free 
conditions. Human purified 20S proteasome was incubated with the Co(ClO4)2·6H2O salt as 
control, as well as with 1, 2, and 3 at different concentrations, followed by measurement of CT-
like activity. This activity was marginally inhibited by the ligands and was inhibited by the 
highest concentration (50 μM) of cobalt salt at a 50% level. This result confirms that in 20S 
proteasome – where the regulatory 19S caps have been removed – metal ions will show some 
inhibitory effect, as previously observed for gallium salts.
24
 In spite of modest activities, 
comparison between complexes 1 and 2, displayed in Figure 3.2.5.2 (top) shows the highest 
inhibition for 1 (40% at 10 μM), where two independent ligands are present. This result 
reinforces the notion that facilitated ligand exchange will foster inhibition. No activity is 
observed for 2 even at 50 μM. The activities of 1 and 3 were also compared, as shown in Figure 
3.2.5.2 (bottom). These species show constant 1:2 metal-to-ligand ratio but allow for the 
respective comparison between a labile 3 d
7
 and an inert 3 d
6
 metal center. The latter is expected 
to display little or no inhibitory effects, as observed for the equally inert nickel(II) ion.
9
 
Unexpectedly, species 3 displays remarkably better CT-like activity inhibition of the 20S core 
than its labile counterpart. 
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Figure 3.2.5.2. Chymotrypsin-activity inhibition in human purified 20S proteasome; DMSO and 
Co
II
(ClO4)2 are controls. Top: comparison between 1 (left column) and 2 (right column); bottom 
comparison between 1 (left column) and 3 (right column). 
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Intrigued by the previous results, proteasome inhibition and apoptosis induction were 
tested in intact PC-3 human prostate cancer cells to confirm the potential activity of 3. Cells were 
first treated with different concentrations (up to 50 μM) of 1 and 3 for 18 h, followed by 
measurement of proteasome inhibition. PC-3 cells treated with 3 showed a dose-dependent 
inhibition of the proteasomal activity by ~ 35% at 30 μM and ~ 95% at 50 μM (Figure 3.2.5.3). 
Consistently, levels of ubiquitinated proteins were increased in a dose-dependent manner in PC-3 
cells for 3, whereas 1 showed negligible inhibition. 
 
 
 
 
 
 
 
 
Figure 3.2.5.3. Chymotrypsin-activity inhibition in PC-3 cell lysates after 18 h treatment. 
Compound 1 was measured at 40 and 50 μM and is shown in the left column. Compound 3 is 
shown as a single column for 1–30 μM and in the right column for 40 and 50 μM. DMSO is the 
control. 
 
Previous reports have indicated that inhibition of proteasomal chymotrypsin-like activity 
in tumor cells may result in the induction of apoptosis.
25
 To investigate whether proteasome 
inhibition is associated with apoptotic cell death, apoptotic-specific caspase-3 induction (Figure 
3.2.5.4) and related PARP disappearance (Figure 3.2.5.5) were measured spectrophotometrically 
and by Western blotting, respectively. Dramatic induction of caspase-3 was observed in cells 
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treated with 3 at 40 μM. As expected, abrogation of full length PARP only occurred in cells 
treated with 30–50 μM of 3, whereas cells treated with 1 at the highest concentration tested had 
little visible effect. These results show that induction of apoptosis by 3 in PC-3 cells is associated 
with inhibition of proteasomal chymotrypsin-like activity. 
 
 
 
 
 
 
Figure 3.2.5.4. Comparison between 1 (left column) and 3 (right column) for Caspase-3 
(apoptosis) Induction in PC-3 cell lysates after 18 h treatment. DMSO is the control. 
 
 
These results confirm the need for ligand dissociation, as shown by comparison between 
the activities of 1 and 2, both with a labile 3 d
7
 configuration. However, it is puzzling that 
compound 1 has proven to be less active than the inert 3 d
6
 metal-containing complex 3. Unlike 
the previously studied inert 3 d
8
 nickel(II) ion, cobalt(III) is a redox-active species capable of 
being reduced to cobalt(II) within the reducing cellular environment by available reductants. 
This reduction has been demonstrated individually by several groups
12,13
 and utilized for release 
of alkylating agents such as nitrogen mustards. The redox potential for the cytosolic environment 
is reported to be around − 0.3 V vs. NHE by Østegaard.26 A preliminary cyclic voltammogram 
for 3 in DMSO/TBAPF6 suggests the Co(III)/Co(II) couple at around − 0.5 V vs. NHE. Although 
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more negative, the result suggests bioreductive activation as a valid working hypothesis in need 
of further exploration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5.5. Western blot for PC-3 cell lysates after 18 h treatment. 
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3.3. Conclusions 
In this paper we have investigated the interaction of cobalt complexes with the 26S 
proteasome. We have compared the behavior of 1:2 and 1:1 metal-to-ligand six-coordinate cobalt 
species toward cell proliferation, the purified 20S proteasome, and intact PC-3 prostate cancer 
cells. The 1:2 species described as 1 and 3 are formed respectively between cobalt(II) or 
cobalt(III) ions and two deprotonated [NN′O] ligands (L1)-, whereas the 1:1 species 2 is based on 
a cobalt(II) ion and the new [N2N′2O2] ligand H2L
2
 in its deprotonated form. Detailed 
characterization along with a crystal structure allows for unquestionable identification of 2, 
whereas meticulous NMR spectroscopic evaluation indicated configurational stability of 3 from 
80 to − 40 °C. The CT-like activity inhibition is severely hampered for the 1:1 species 2, 
reinforcing the current hypothesis of ligand dissociation as a requirement for proteasome 
inhibition. Surprisingly, the kinetically inert 3 showed remarkable proteasome inhibition, far 
superior to that observed for the labile 1. We hypothesize that this difference is due to the fact 
that cobalt is redox-active and species 3 is likely to be reduced intracellularly. In this process a 
labile cobalt(II) species would be generated, favoring ligand dissociation and interaction with the 
proteasome. We also hypothesize that species 1, already containing a labile cobalt(II) species 
will not remain intact intracellularly in order to reach the targeted proteasome. The possibility of 
using redox-active metals that can be intracellularly bioreduced opens a stimulating window of 
opportunity to explore proteasome inhibition, both by metal activation as demonstrated here and 
as suggested by Scarpellini
10
 as well as by using metal ions as carriers for drug delivery.
12
 Such 
studies are currently under investigation in our group. 
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3.4. Experimental  
3.4.1. Materials and Methods 
Chemical solvents and reagents were used as described in Chapter 2.  
  
3.4.2. X-ray Structural Determination of [Co
II
L
2
] (2) 
Diffraction data were measured on a Bruker X8 APEX-II kappa geometry diffractometer 
with Mo radiation and a graphite monochromator. Frames were collected at 100 K with the 
detector at 40 mm and 0.3° between each frame and were recorded for 10 s. APEX-II
27
 and 
SHELX 
28
 software were used in the collection and refinement of the model. Crystals of [Co
II
L
2
] 
(2) appeared as amber plates. A total of 23770 reflections were measured, yielding 3750 unique 
data (Rint = 0.049). Hydrogen atoms were placed in calculated positions. The asymmetric unit 
contains one neutral complex without solvate. The complex crystallized in 1:1 ratio of 
dichloromethane and methanol solution Table 3.4.2. 
3.4.3 NMR Spectroscopic Measurements 
NMR spectra were measured using a Varian Mercury-400 and VNMRS-500 MHz 
spectrometers. Proton, carbon-13, distortionless enhancement by polarization transfer (DEPT), 
homonuclear correlation spectroscopy (COSY), and heteronuclear multiple quantum coherence 
(HMQC), and nuclear Overhauser effect (NOE) spectroscopy experiments were acquired in 
CDCl3, DMSO-d6 at 298 K and DMF-d7 between 233 and 273 K. 
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 [Co
II
(L
2
)] (2) 
Formula C28H24CoI4N4O2 
M 1015.04 
Space group C2/c 
a / Å 13.8089(4) 
b/ Å 9.9958(4) 
c/ Å 22.0818(9) 
α/ o  
β/ o 96.013(2) 
γ/ o  
V/ Å
3
 3031.20(19) 
Z 4 
T/ K 100(2) 
λ/ Å 0.71073 
Dcalc/ g cm
-3
 2.224 
µ/ mm
-1
 4.673 
R(F)
 
(%) 3.13 
Rw(F) (%) 6.82 
a
 R(F) = ∑║Fo│-│Fc║ ∕ ∑│Fo│ for I > 2s(I); Rw(F) = [∑w(Fo
2
 – Fc
2
)
2 / ∑w(Fo
2
)
2
]
1/2 
for I > 2s(I). 
Table 3.4.2. Crystal data and structure refinement results for [Co
II
L
2
] (2). 
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3.4.4. Biological Assays 
 3.4.4.1 Proteasomal activity in purified 20S proteasome 
Purified human 20S proteasome (35 ng) was incubated with 10 μM of CT substrate, 
SucLLVYAMC, in 100 μL of assay buffer [20 mM Tris–HCl (pH 7.5)] in the presence of 
complexes 1–3 at various concentrations, as well as the salt [Co(H2O)6](ClO4)2 and DMSO 
solvent as control experiments. After 2 h of incubation at 37 °C, the production of hydrolyzed 
AMC groups was measured using a Wallac Victor3 multilabel counter with an excitation filter of 
365 nm and an emission filter of 460 nm.
29 
3.4.4.2 Cell cultures and whole cell extract preparation 
PC-3 human prostate cancer cells were grown in RPMI1640 supplemented with 10% 
fetal bovine serum and maintained at 37 °C and 5% CO 
2. A whole cell lysate was prepared as previously described.
30 
3.4.4.3 Cell proliferation assay 
Cells were seeded in quadruplicate in a 96 well plate and grown to 70−80% confluence, 
followed by treatment with the indicated agents for 18 h followed by measurement of cell 
proliferation by the 3(4,5dimethylthiazol-2-yl)2,5diphenyltetrazolium bromide (MTT) assay as 
described previously.
31 
3.4.4.4 Proteasome CT-like activity in cells 
Proteins extracted from cells after each treatment were incubated for 2 h at 37 °C in 
100 μL of assay buffer (50 mM Tris–HCl, pH 7.5) with 10 μM of fluorogenic CT substrate 
SucLLVYAMC, as described previously.
31 
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3.4.4.5 Western blot analysis  
Cell extracts were separated by SDS-PAGE and transferred to a nitrocellulose membrane. 
A western blot analysis was performed using specific antibodies to PARP or ubiquitin, followed 
by visualization using the HyGLO reagent (Denville Scientific, Metuchin, NJ). 
3.4.5. Syntheses 
3.4.5.1. Ligand syntheses 
The iodo-substituted ligand HL
1
 was synthesized as previously described
14,32
 by the 
treatment of 2-hydroxy-3,5-diiodobenzaldehyde with pyridin-2-ylmethanamine in methanol 
followed by reduction with sodium borohydride. 
The organic precursor 2,4-di-iodo-6-(chloromethyl)phenol was synthesized as previously 
reported [21]. Yield: 90%. IR (KBr, cm
−1
, s = strong) 1450(s) (C = Car); 1265 (s) (C − O); 
1
H − NMR [δ, ppm; s = singlet, 400 MHz, CDCl3, 300 K] = 4.60, [2x s 2x 1H (CH2)]; 7.60 [s, 1 
H (aryl) ]; 7.93 [s, 1 H (aryl)]. 
The new tethered ligand 6,6′-((ethane-1,2-diylbis((pyridin-2-ylmethyl)azanediyl)) 
bis(methylene))bis(2,4-diiodophenol) H2L
2
 was synthesized by adapting available procedures for 
similar species [22]. The precursor N1,N2-bis(pyridin-2-ylmethyl)ethane-1,2-diamine was 
obtained when a 40 mL methanolic solution (0.9 g, 15 mmol) of ethane-1,2-diamine, was treated 
with two equivalents of picolinaldehyde (3.21 g, 30 mmol) and refluxed for 2 hours. The 
resulting yellow Schiff base was reduced by addition of sodium borohydride (1.4 g, 37 mmol) at 
0 °C. The solvent was rotoevaporated and the crude product was dissolved in 100 mL of brine. 
Extraction with 4 × 25 mL of dichloromethane followed, and the combined extracts were dried 
over MgSO4. The solution was rotoevaporated and the product was obtained as a viscous oil. 
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The precursor N
1
,N
2
-bis(pyridin-2-ylmethyl)ethane-1,2-diamine (0.31 g, 1.3 mmol) was 
dissolved in 40 mL dichloromethane, when triethylamine base (0.6 g, 6.4 mmol) was added 
dropwise and followed by the addition of 2-(chloromethyl)-4,6-diiodophenol (1.0 g, 2.5 mmol). 
The solution was refluxed for 48 h. The product was extracted with 3 × 25 mL of 
dichloromethane to remove the triethylammonium chloride salt. The organic layer was dried 
over MgSO4 and rotoevaporated to give a yellow amorphous foamy solid which was then 
recrystallized in methanol to yield a microcrystalline solid. Yield: 75%. Mp 158–160 °C; IR 
(KBr, cm
−1
, s = strong, m = medium) 2818(s) (C-H), 1596(s), 1540(s) (C = NPy, C = CAr); 
1363(m) (C-O); 1250 (s), (C-N); 
1H NMR [δ, ppm; s = singlet, d = doublet, dd = doublet of 
doublet, 400 MHz, CDCl3, 300 K] 2.67, [4x s, 4x 1H (2 CH2) -N-CH2-CH2-N-]; 3.61, [4x s, 4x 
1H (2 CH2) –N-CH2-phenol]; 3.72, [4x s, 4x 1H (2 CH2) –N-CH2-pyridyl]; 7.11-7.13, [4x 4x 1H 
(phenol)]; 7.20-7.23, [2x dd, 2x 1H (py-2)]; 7.66-7.70, [2x dd, 2x 1H (py-3)]; 7.91, [2x d, 2x 1H 
(py-4)]; 8.59, [2x d, 2x 1H (py-1)]; ESI
+
 in MeOH: m/z (100%) = 959.1 for [H2L
2
 + H
+
]
+
. 
3.4.5.2. Complex syntheses  
[Co
II
(L
1
)2] (1). Synthesis of this complex followed the previously described procedure.
14
  
Yield: 85%; IR data: (KBr, cm
−1
, s = strong, m = medium) 1603(m), 1560(s), 1446(s) (C = NPy, 
C = CAr); 1328(m) (C-O); ESI
+
 in MeOH: m/z (100%) = 990.1 for [Co
II
(L
1
)2 +H
+
]
+
; Anal. Calc. 
(%) for 1·H2O (%, C26H24CoI4N4O3, FW = 1007.04 g.mol
-1
) C, 31.01; H, 2.40; N, 5.56. Found 
(%): C, 31.14; H, 2.16; N, 5.39. 
[Co
II
L
2
] (2). [Co(H2O)6](ClO4)2 (0.12 g, 0.31 mmol) was dissolved in 5 mL of methanol and was 
added dropwise under anaerobic conditions to a 10 mL dichloromethane solution containing 
(0.3 g, 0.31 mmol) of the H2L
2
 ligand and Et3N (0.079 g; 79.2 mmol). The solution was stirred at 
room temperature for 3 h, when a color change was observed from yellow to brown. No 
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precipitate was formed observed. The solution gave orange colored crystals after 48 h. Yield: 
65%; IR data: (KBr, cm
−1
, s = strong, m = medium) 2839(m) (C-H), 1558(s), 1483(s) (C = NPy, 
C = CAr); 1363(m) (C-O); ESI
+
 in MeOH: m/z (100%) = 1015.7 for [Co
II
L
2
]
+
; Anal. Calc. for 2 
(%, C28H24CoI4N4O2, FW = 1014.74 g.mol
−1)
; C, 33.13; H, 2.38; N, 5.52. Found (%): C, 33.25; 
H, 2.44; N, 5.44. 
[Co
III
(L
1
)2]ClO4(3). The [Co(H2O)6](ClO4)2 salt (0.37 g, 1.0 mmol) was dissolved in 5 mL of 
methanol and added to a 30 mL dichloromethane solution containing the ligand HL
1
 (0.98 g, 
2.0 mmol) and Et3N (0.28 mL; 2.0 mmol) under aerobic condition. The solution was refluxed for 
4 h, when a brownish product was vacuum filtered and washed with cold methanol and ether. 
Yield: 70%; IR data (KBr, cm
−1
, s = strong, m = medium): 1603(m), 1560(s), 1446(s) (C = NPy, 
C = CAr); 1099(s) cm
−1
 (ClO4
-
) 1328(m) (C-O); ESI
+
 in MeOH: m/z (100%) = 989 for 
[Co
III
(L
1
)2]
+
 ; Anal. Calc. for 3 (%,C26H22CoI4N4O6Cl, FW = 1088.48 g.mol
−1
) C, 28.69; H, 2.04; 
N, 5.15. Found (%): C, 28.72; H, 2.17; N, 5.05. 
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CHAPTER 4  
PROBING CHEMICAL REDUCTION IN A COBALT(III) COMPLEX AS A VIABLE 
ROUTE FOR THE INHIBITION OF THE 20S PROTEASOME  
Published with minor changes as Tomco, D.; Xavier, F.; Allard, M. M.; Verani, C. N.* Inorg. 
Chim. Acta, 2012, 393, 269. 
4.1. Introduction 
In the previous chapter, we compared the inhibition activity of the complex [Co
II
(L
1
)2] 
and its counterpart [Co
III
(L
1
)2ClO4]
1
 (Scheme 4.1). The former species contains a relatively 
labile bivalent high-spin cobalt ion,
2
 whereas the latter contains an inert trivalent low-spin cobalt 
ion that has shown unexpectedly better CT inhibition in cells. Considering the evidence for a 
relationship between cytotoxic activity and metal ion lability observed for [Ni
II
(L
1
)2],
3
 the 
biological accessibility of different oxidation states in the abovementioned cobalt complexes is 
the most relevant mechanism to allow for the switching between an inert d
6
 low-spin and a labile 
d
7
 high-spin character. In spite of the rich cobalamin chemistry
4,5
 the use of cobalt species for 
antitumor applications remains underdeveloped.
6,7 
Evidence for cobalt(III) complexes used as chaperones to carry specific matrix 
metalloproteinases including marimastat
8
 drug have been reported by Hambley
9
 and co-
workers,
10,11,12
 where enhanced antitumor activity was observed once marimastat was chelated to 
a Co
III
-tris(methylpyridyl)amine complex. The inert character of the cobalt(III) ion increases the 
intracellular transportation of the complex, and depending on the redox potential of 
Co(III)/Co(II) couple bioreductive activation allows for conversion to a more labile Co(II) 
species, hence release of the drug. In this chapter, we evaluate the chemical and electrochemical 
reduction of the cobalt complex [Co
III
(L
1
)2]ClO4 (1) and the viability of ligand dissociation in 
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order to form an active pharmacophore [ML]
+
. We aim to (i) evaluate the redox potentials for the 
Co(II)/Co(III) couple, (ii) observe the spectroelectrochemical and chemical reduction behavior at 
controlled pH via monitoring of the phenolate-to-cobalt LMCT band observed at 440 ± 5 nm in 
the UV–Vis spectrum, and (iii) assess resulting products of reduction by HR-ESI+ mass 
spectrometry. These results will be presented and discussed in detail. 
 
Scheme 4.1. Structure of complex [Co
III
(L
1
)2]ClO4 (1). 
4.2. Results and Discussion 
Complex 1 was synthesized according to a previously published procedure in our group.
1
 
UV–Vis spectroscopy in DMF confirms the presence of pπphenolate → dσ∗cobalt(III) charge transfer 
band at 440 nm. The CT-like activity inhibition of 1 was measured in purified 20S proteasome 
showing over than 90% inhibition at a concentration of 25 μM. Cell proliferation inhibition tests 
resulting with IC50 ⩽ 25 μM were obtained in PC-3 cells once treated with 1. 
4.2.1 Cyclic Voltammetry  
The redox properties of complex 1 were recorded in two solvent systems namely DMF 
and DMF/H2O (90:10% v/v) under argon, where TBAPF6 was used as a supporting electrolyte. 
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The potential values are measured versus Ag/AgCl and reported against the Fc/Fc
+
 redox couple 
as an internal standard.
13
 This data is summarized in Table 4.2.1. For the DMF solution, 
complex 1 demonstrates a quasi-reversible metal-centered Co
III
/Co
II
 couple (Figures B.4.2.1.1 
and B.4.2.1.2) at E½ = −705 mV versus Fc/Fc
+
 (ΔEp = 105 mV; |ipc/ipa| = 1.12). This redox 
potential changes slightly for the DMF/H2O (90:10% v/v) solvent system (Figure 4.2.1 and 
Figure B.4.2.1.3), where E½ = −668 mV versus Fc/Fc
+
 (ΔEp = 120 mV; |ipc/ipa| = 0.90). The 
reversibility of the Co
III
/Co
II
 couple given by the |ipc/ipa| is nearly equivalent between the two 
solvent systems. It has been observed that the Co
III
/Co
II
 reduction potential is highly effected by 
the substituents (electron withdrawing/donating) present on the ligand.
14
 Previously published 
cobalt(III) complexes
15
 with similar ligands containing t-butyl groups decreased the redox 
potential on the cobalt ion, whereas the chloro-substituents increased such potential.
16,17 
 The redox potential for bioactivated cobalt(III) complexes is found between −600 and 
−800 mV versus Fc/Fc+ (−200 to −400 mV versus NHE).18 Therefore, the observed potential for 
1 is well within this range and the complex is a viable candidate for intracellular reduction. 
 
 
Table 4.2.1. Electrochemical values for complex 1 in DMF and DMF/H2O (90:10% v/v) 
solvents. Potentials are measured for Co(III)/Co(II) couple vs. Ag/AgCl and plotted vs. Fc/Fc
+
 
reference standards in mV. 
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Figure 4.2.1. Cyclic voltammograms of complex (1) in DMF/H2O 90:10% v/v solvent system 
with concentration of 9.0 × 10
−4
 M. TBAPF6 was used as supporting electrolyte. The redox 
potential for Co(III)/(II) couple is measured vs. Ag/AgCl and plotted using Fc/Fc
+
 as an internal 
reference at room temperature. 
 
 
4.2.2. Computational Studies  
Polyphenolate complexes with metal centers are long known to be difficult for 
differentiating and identifying their formal redox centers.
19,20
 We have previously
21
 used 
computational methods for this purpose, and reported on the electronic structure of similar 
cobalt,
15,22
 zinc,
3
 and iron(III) complexes. In this report, we are interested in the redox 
properties relating to the reduction of these complexes. Calculations were performed on the 
[Co(L
1
)2]
+
 (S = 0) and high-spin [Co(L
1
)2]
0
 (S = 3/2) to assess information on bonding 
interactions and identify the frontier orbitals involved in both the electrochemistry and 
electronic spectroscopy. It is clearly indicated in Figure 4.2.2 that the initial Co(III) complex is 
consistent with a low-spin Co d
6
 with no unpaired electron (left). Upon reduction, the resulting 
 
-300 -400 -500 -600 -700 -800 -900 -1000 -1100
 Potential (mV) vs. Fc/Fc
+
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complex is consistent with a Co(II) d
7
 high-spin complex with three unpaired electrons, as can 
be shown in the spin density plot (right). The Co(III) shows that the first two empty unoccupied 
orbitals, namely LUMO and LUMO+1 are cobalt-based, consistent with empty anti-bonding d 
orbitals expected for a low-spin d
6
 metal complex. The first two occupied orbitals (HOMO, and 
HOMO−1) are phenolato-based, consistent with our previously shown assessments.15,22,23  
It is interesting to note that unlike our previous electronic structure on –H substituted 
[35] phenolate groups, it seems the –iodo groups are heavily involved in some of the frontier 
orbitals in HOMO−2, −3, −4, and −5. As expected, the remaining three d metal cobalt orbitals 
are low in energy. Upon addition of an electron to reduce [Co
III
(L
1
)2]
+
, one would expect the 
population of the LUMO, which is cobalt centered, and upon oxidation we would expect to 
form a phenoxyl radical as per the nature of the HOMO. Indeed, for the reduced species, namely 
[Co
II
(L
1
)2]
0
, we observed a Co(II) d
7
 high-spin complex with the three magnetically relevant 
orbitals shown in Figure 4.2.2 on the right (Table B.4.2.2), consistent with our cyclic 
voltammetry assignment. 
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Figure 4.2.2. Relevant frontier orbitals for [Co
III
(L
1
)2]
+
 (left) and [Co
II
(L
1
)2]
0
 (right) including 
their spin density (top). TD-DFT electronic transitions for [Co(L
1
)2]
+
 are shown in the middle. 
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4.2.3. Electronic Spectroscopy  
According to time-dependent density functional theory (TD-DFT) the spectra of the 
cobalt(III) complexes are dominated by three low energy charge transfer bands. The 
HOMO → LUMO transition at 612 nm is identified as a phenolate → cobalt LMCT, and the two 
bands close in energy are associated with HOMO−1 → LUMO and HOMO−1 → LUMO+1 at 
405 and 395 nm, respectively (see inset Figure 4.2.2). These prominent bands are the result of 
phenolato-to-cobalt charge transfer bands, and are consistent with the frontier orbitals discussed 
in the previous section. This behavior is expected for Co(III) complexes with electroactive 
ligands, in which charge transfer from fully occupied ligand orbitals to low energy Co(III) empty 
d orbitals can be expected to dominate the low energy end of the spectra (>350 nm). The higher 
energy (<350 nm) is dominated by intra-ligand π → π∗ inter-valence charge transfers (IVCT). 
Thus upon reduction of these complexes, the change from a singlet d
6
 metal complex to a quartet 
high-spin d
7
 complex spectra should result in a complex with very low energy (>1000 nm) d–d 
charge transfer bands (mostly absent in the Co(III) spectra), and similar intra-ligand charge 
transfers, but the LMCT charge transfer bands should either be absent or have very small molar 
absorptivity. Our modeling indicates the near absence of bands with wavelengths above 500 nm 
and IVCT bands centering around 375–400 nm; all related to various π → π∗ transitions within 
the ligand. Therefore according to these calculations, we conclude that the bands at 440 and 
625 nm can be assigned to phenolato-to-cobalt charge transfers (LMCT) and both are expected to 
disappear upon reduction. 
In order to investigate the spectroscopic properties of the reduced complex 1, reductive 
room temperature spectroelectrochemical spectra were obtained under argon using TBAPF6 in 
DMF. Upon an applied fixed potential of −1200 mV versus Fc/Fc+, a marked decrease of the 
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LMCT bands was observed over time Figure 4.2.3. The calculated spectra are shown in (Figure 
B.4.2.3). 
 
 
Figure 4.2.3. Spectroelectrochemical spectra for complex 1 in DMF in the presence of TBAPF6 
as supporting electrolyte. The decrease of the phenolate to Co(III) charge transfer band at 
440 nm was followed over time upon the applied fixed potential of −1200 mV vs. Fc/Fc+.  
 
4.2.4. Chemical Reduction  
Chemical reduction using ascorbic acid (AA) was performed in order to evaluate whether 
biological agents can carry on the Co(III)/Co(II) reduction and to assess the timeframe required 
for such process. We conducted these experiments at room temperature under inert conditions 
using a large excess of AA as to mimic a pseudo-first order reaction mechanism. The results 
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allow us to estimate an approximate reduction rate constant and to analyze the resulting products 
of this chemical reduction. The experiment was performed in a freshly prepared DMF/H2O 
(90:10% v/v) solution and followed spectrophotometrically at the maxima (λmax = 440 nm) by the 
decrease of the phenolate to cobalt(III) charge transfer band over time, as well as the decrease of 
the second LMCT band at 625 nm shown in Figure 4.2.4.1.  
 
Figure 4.2.4.1. Chemical reduction experiment of complex 1 with ascorbic acid in DMF/H2O 
(90:10% v/v) with final concentration of 9.0 × 10−5 M. Each spectrum is recorded every 30 min 
and the decrease of pπphenolate → dσ∗cobalt(III) charge transfer band at 440 nm over time was 
observed for a time period of 18 h. 
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Each spectrum was recorded periodically every 30 min for 18 h until the equilibrium 
between the oxidized/reduced species was reached. A control sample was prepared under the 
same conditions without the presence of the reductant AA (Figure B.4.2.4.1). Two other control 
experiments were performed without AA, but the solutions were adjusted to an apparent pH 3 
and pH 1, (Figures B.4.2.4.2 and B.4.2.4.3), respectively. The phenolate-to-cobalt(III) charge 
transfer band was monitored spectrophotometrically overnight. These data showed no change in 
the absorbance, position, or shape of the LMCT band thus indicating that the stability of 1 is 
maintained in both of the acidic solutions. This observation implies that even under these 
conditions the phenolato groups from the ligand are not being protonated. Both experiments 
strengthen the conclusion that AA is reducing the metal center rather than promoting the 
protonation of the ligand. The concentration dependence of complex 1 versus time was measured 
following the decrease of the LMCT band and the data was fitted using a pseudo-first order 
approach and treated using a first order rate equation (Figure 4.2.4.2). The approximate rate 
constant (kobs) value was obtained from the linearized data (curve slope) and half-life (t½) was 
calculated. The values for kobs = 2.03 ± 0.04 × 10−5 s
−1
 and t½ ∼ 9.5 h which indicates that the 
reduction of the cobalt center is occurring at a considerably slow pace. This time window falls 
well within the observed time frame for biological experiments.
1 
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Figure 4.2.4.2. Linearized plot of the pseudo-first order rate law. 
 
4.2.5. Product Analysis via HR-ESI
+
-MS After Chemical Reduction 
High resolution mass spectrometry, HR-(+)-ESI-MS, was used in fresh solutions of 1 in 
order to evaluate the products of chemical reduction and possibly detect ligand dissociation. All 
the experimental m/z results were in good agreement with calculated m/z values and with the 
expected isotopic distributions for the species of interest (Figure 4.2.5.1). 
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Figure 4.2.5.1. Mass spectrometry results for 1 after treatment with AA; peak position and 
isotopic distribution for (a) [Co
II
(L
1
)+2DMF]
+
 and (b) [HL
1
+H
+
]
+
. The bars represent the 
experimental data, whereas the continuous spectra show the simulated data. 
 
Immediately after the completion of the chemical reduction, an aliquot of the reaction 
was diluted in methanol and injected in the mass spectrometer and relevant peak clusters were 
detected. The molecular ion peak observed at m/z = 988.72 (100%) corresponds to the 
[Co
III
(L
1
)2]
+
 complex (Figure B.4.2.5.1). We were unable to detect the reduced [Co
II
(L
1
)2] 
species by mass spectrometry, both due to its neutral charge as well as to in situ oxidation. In 
fact, the mass spectrometry data for the isolated and previously published [Co
II
(L
1
)2] complex 
showed the presence of [Co
III
(L
1
)2]
+
 at m/z = 988.64 rather than the peak at 989.64 attributed to 
[Co
II
(L
1
)2+H
+
]
+
 even a lower cone voltages (Figure B.4.2.5.2).
22
 These results strongly suggest 
that the [Co
II
(L
1
)2] complex obtained by chemical reduction would be easily reoxidized in the 
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mass spectrometer. Thus, the observed peak at m/z = 988.72 is associated with the [Co
III
(L
1
)2]
+
 
species from non-reduced 1 as well as from reoxidation of [Co
II
(L
1
)2]. Therefore, we looked for 
other species in which the cobalt(II) ion can be detected; we observed a peak at m/z = 669.98 
(Fig. 6a, S8) attributed to [Co
II
(L
1
)+2DMF]
+
 species. The presence of DMF solvent in the peak 
confirms that this species is formed in the original solution. This peak has not been detected in 
the control solution (Figure B.4.2.5.3) and  reinforces the idea of ligand dissociation due to 
metal reduction. The ligand itself is observed exclusively in the chemically reduced sample as 
the [HL
1
+H
+
]
+
 species at m/z = 466.91 (Figure 4.2.5.1 (b) and Figure B.4.2.5.1). The presence 
of these peaks suggests that ascorbic acid has indeed reduced the inert cobalt(III) ion to the more 
labile cobalt(II) ion, thus increasing the probability of the loss of one ligand in the solution 
generating the biologically active pharmacophore species. Based on the available 
spectroelectrochemical, chemical reduction, and product analysis evidence, a plausible scheme 
for these transformations is offered in Figure 4.2.5.2. 
 
Figure 4.2.5.2. Proposed mechanism for the ligand release upon chemical reduction in the 
presence of ascorbic acid. 
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4.3. Conclusions 
In this chapter we have investigated a possible way on how complex 1, containing an 
inert cobalt(III) ion, can be reduced into a more labile Co(II) species, as well as the viability of 
ligand dissociation from this labile species in order to form a pharmacophore able to inhibit the 
20S proteasome such as the [Co
II
L(DMF)2]
+
 species. We evaluated the redox potentials for the 
Co(III)/Co(II) couple in DMF and DMF/H2O and found them to be compatible with the range for 
bioactivation and spectroelectrochemical results support this assessment with a decrease of the 
phenolate-to-cobalt MLCT band. The experimental results were corroborated by DFT 
calculations. Chemical reduction with ascorbic acid also indicated a decrease of the LMCT band 
and MS data confirmed the presence of [Co
II
L(DMF)2]
+
 along with the dissociated ligand. These 
species were not observed in control samples lacking the reducing agent even if at considerably 
acidic conditions. These results point out to biological reduction as a viable way to promote 
ligand dissociation and, therefore, pharmacophore formation in cobalt(III) prodrugs. 
4.4. Experimental Section 
Materials and methods were used as described in Chapter 2. Electronic structure 
calculations were carried out with the GAUSSIAN 09 suite of programs
24
 using density functional 
theory (DFT) calculations with the B3PW9
25,26
 and SDDAll basis set.
27,28,29
 The closed shell 
cobalt(III) (S = 0) complexes are calculated as singlets, using spin restricted wavefunctions, 
whereas the cobalt(II) (S = 3/2) complexes were calculated as quartets using open-shell 
unrestricted wavefunctions. The geometries were fully optimized and vibrational frequencies 
were computed to confirm that the structures were energy minima.
30,31
 Solvent effects in DMF 
were estimated using the IEF-PCM polarizable continuum model.
32
 Vertical electronic excitation 
energies and intensities were calculated by time-dependent density functional theory (TD-
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DFT).
33,34
 Molecular orbitals were plotted with GaussView.
35
 All geometries match well with 
previously reported
15,22
 crystallographic data. 
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CHAPTER 5 
IN VITRO STUDIES OF GALLIUM(III) AND ZINC(II) SPECIES ON THE INHIBITION 
ACTIVITY OF THE 26S PROTEASOME  
Tomco, D.; Schmitt, S.; Heeg, M. J.; Dou, Q. P.; Verani, C. N.* 
5.1. Introduction 
In Chapters 3 and 4, we concluded that the inhibition activity of the 20S proteasome is 
highly dependent on the redox properties of the metal ion of choice and the ligand design. The 
hexadentate H2L
2 
ligand coordinated to a cobalt(II) metal ion showed no inhibition properties 
towards purified 20S and 26S proteasome. Because the increased chelation effect of the H2L
2
 
ligand prevented the inhibition of the chymotrypsin-like (CT) activity of the proteasome, the 
question remains whether this ligand will possess the same properties if it is coordinated to a 
more labile metal ion with higher oxidation state. To address this issue, we synthesized and 
characterized two complexes coordinated to the H2L
2
 ligand, namely [Ga
III
(L
2
)]ClO4 (1) and 
[Zn
II
(L
2
)] (2), (Scheme 5.1), and investigated the inhibition properties towards purified human 
proteasome and proteasome in prostate cancer cells. The selection of gallium(III) and zinc(II) 
ions
1
 is related not only by their wide therapeutic properties towards of various diseases,
2
 but 
also by their redox inertness. 
A gallium nitrate salt has been used in treatment of hypercalcemia, a metabolic disorder 
related to increased concentration of the calcium ions in blood. Gallium nitrate inhibits calcium 
resorption from bones and stimulates bone formation.
3
 To date, the coordination compound 
gallium maltolate has completed phase I clinical trials in treatment of renal cancer.
4
 One of the 
possible mechanisms of action for gallium maltolate is generation of reactive oxygen speciesin 
mitochondria.
5
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As a trace element zinc is associated with various metabolic processes in cells including 
structural stabilization of various proteins such as zinc fingers, signal transduction, and 
regulation of cellular apoptosis.
6 
The ability of both gallium- and zinc-containing complexes as 
proteasome inhibitors has been successfully demonstrated by the Verani and Dou labs,
7,8,9
 and 
the following study will investigate the effect that redox-inactive metal ions have on the CT-
inhibition activity of the proteasome in PC-3 cells. 
 
 
 
 
 
 
 
 
 
Scheme 5.1. Chemical structures of [Ga
III
(L
2
)]ClO4 (1) and [Zn
II
(L
2
)] (2) complexes. 
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5.2. Results and Discussion 
 5.2.1. Synthesis and Characterization 
The H2L
2 ligand was synthesized and characterized using methods from previously 
reported procedures.10 Synthesis of the complexes was accomplished following procedures as 
shown in Scheme 5.2. Complex 1 was synthesized using Schlenk technique under nitrogen gas 
by dissolving the ligand H2L
2 (0.3 g, 0.31mmol) in 15 mL methanol while stirring and heating 
the solution followed by addition of triethylamine base (0.063 g, 0.62 mmol). A methanolic 
solution of GaCl3 salt (0.06 g, 0.34 mmol) was added to the ligand dropwise under anaerobic 
conditions and the reaction was refluxed for three hours. Concentrated sodium perchlorate 
solution was then added to the reaction mixture for counterion exchange which resulted in 
formation of a white precipitate. The solution was concentrated until most of the methanol 
solvent was removed and the crude product was filtered and washed with cold methanol and 
distilled water. The collected precipitate was dissolved in methanol and set for crystallization 
under room temperature for 48 hours. This resulted in formation of rod-shaped crystals.  
Complex 2 was synthesized by dissolving the H2L
2 ligand (0.2 g, 0.21 mmol) and 
triethylamine base (0.043 g, 0.42 mmol)  in 15 mL methanol while heating and stirring (Scheme 
5.2.1). ZnCl2 salt (0.032 g, 0.23 mmol) was dissolved in 3 mL methanol and then added slowly 
to the deprotonated ligand. The solution was refluxed under aerobic conditions for 3 hours and 
then concentrated under vacuum. No precipitate was obtained, so the solution was set for 
crystallization at room temperature. Rod shaped crystals were collected within 72 hours and 
characterized by X-ray crystallography. 
Chemical characterization of complexes 1 and 2 was performed by spectroscopic and 
spectrometric techniques to confirm the composition and purity of both complexes. Infrared 
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analysis shows strong bands at 1602-1611, 1560-1569, and 1433-1444 cm-1 attributed to 
C=Npyridine and C=CAromatic stretches. The perchlorate counterion shift at 1088 cm
-1 
is present as a 
broad band for complex 1. Elemental analysis for complexes 1 and 2 were found to be in good 
agreement between the theoretical and the experimental values. Characterization of both 
complexes by mass spectrometry in the positive mode resulted in excellent agreement between 
the experimental and simulated data. The molecular ion peak for complex 1 is detected at m/z+ = 
1024.76 (100%) and attributed to the [GaIII(L2)]+ species without the perchlorate ion. For 
complex 2, the molecular ion peak associated with {[ZnII(L2)] + H
+}+ species is found at m/z+ = 
1020.85 (100%) and confirms the bivalent nature of the zinc ion. The above spectrometric data 
support the assignment of 1:1 metal ion to ligand ratio for both complexes 1 and 2. 
Scheme 5.2. Synthetic routes for complexes 1 and 2. 
5.2.2. Crystal Structure Characterization for [Ga
III
(L
2
)]ClO4 (1) and [Zn
III
(L
2
)] (2) 
X-ray diffraction analysis was used to determine the chemical structures of complexes 1 
and 2 which are displayed in Figures 5.2.2.1 and 5.2.2.2, respectively. Both structures reveal 
the presence of the deprotonated hexadentate (L
2
)
2-
 ligand chelating the gallium(III) and zinc(II) 
ions in a pseudo-octahedral geometry. The arrangement of the donor sets around the both metal 
ions can be described as cis phenolates, cis aliphatic amines, and trans pyridines which is in 
agreement with the previously reported [Co
II
(L
2
)] complex
10
 and other complexes from the 
literature.
11,12 
The presence of the perchlorate counterion in complex 1 neutralizes the 3+ charge 
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of the gallium ion (Figure 5.2.2.1) and confirms the fully deprotonated form of the ligand. In 
contrast to complex 1, no counterions are observed for complex 2 (Figure 5.2.2.2). Average 
bond lengths between the gallium ion and the donor sets are as follows: Ga-Ophenolate as 1.890 Å, 
Ga-Naliphatic as 2.138 Å, and Ga-Npyridine as 2.102 Å. These values are slightly shorter compared 
to the zinc analog with bond distances of 1.992 Å for Zn-Ophenolate, 2.259 Å for Zn-Naliphatic, and 
2.169 Å for Zn-Npyridine. These corresponding bond distances are similar to those found in the 
[Co
II
(L
2
)] complex
10
 and other reported zinc-containing complexes.
9
 Such shortening of bond 
distances in the [Ga
III
(L
2
)]ClO4 complex could be explained due to the higher charge of the 
metal ion. Selected bond lengths and angles are presented in the figures below. 
Figure 5.2.2.1. Crystal structure for Ga complex (1). ORTEP diagram reported at 50% 
probability level. Selected bond lengths include: Ga(1)-O(2) = 1.880(3), Ga(1)-O(1) = 1.900(3), 
Ga(1)-N(4) = 2.091(5), Ga(1)-N(1) = 2.113(5), Ga(1)-N(2) = 2.127(4), Ga(1)-N(3) = 2.149(4) Å. 
Selected angles include: O(2)-Ga(1)-O(1) = 95.65(15), N(4)-Ga(1)-N(1) = 170.69(16), N(2)-
Ga(1)-N(3) = 82.66(16), O(1)-Ga(1)-N(4) = 90.62(16), O(2)-Ga(1)-N(1) = 87.07(16). Goodness 
of fit is given by R(F) (%) = 4.20. 
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Figure 5.2.2.2. Crystal structure for Zn complex (2). ORTEP diagram reported at 50% 
probability level. Selected bond lengths include: Zn(1)-O(1) = 1.992(2), Zn(1)-N(2) = 2.169(3), 
Zn(1)-N(1) = 2.259(3) Å. Selected angles include: O(1)-Zn(1)-N(2) = 90.38(11), N(2)-Zn(1)-
N(1) = 75.88(11), O(1)-Zn(1)-N(1) = 89.99(10). Goodness of fit is given by R(F) (%) = 3.95. 
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5.2.3. Biological Results 
The biological activity of both complexes against the 20S purified proteasome and 26S 
proteasome from both PC-3 and non-cancerous CRL2221 cells were measured and the results 
are discussed. The anti-proliferative effect of the gallium- and zinc-containing complexes on 
prostate cancer cells were evaluated by MTT assay treating PC-3 cells with 1 and 2 (Figure 
5.2.3.1). The results reveal a distinct difference in the percent cell proliferation remaining after 
treatment with both complexes. Complex 1 is highly potent against the growth of these cells 
even at lower concentrations (20 µM and 30 µM with 15% and 8.0% respectively of cellular 
proliferation left after treatment). Almost no cell growth is observed after treatment with the 
highest concentration of 50 µM. On the contrary, complex 5 shows insignificant anti-
proliferative effects at lower concentrations and ~85% cell growth remaining at the highest 
concentration of 50 µM (Figure 5.2.3.1). These results suggest that the gallium-containing 
complex suppresses the proliferation of the prostate cancer cells very effectively even at lower 
concentrations.  
The inhibitory properties of complexes 1 and 2 against the chymotrypsin-like activity 
have been investigated (Figure 5.2.3.2). Treatment of human purified proteasome with both 
complexes at concentrations from 5-50 µM resulted in unexpected findings. Complex 1 
demonstrates excellent CT-like activity inhibition in a concentration dependent manner with 
97% at 10 µM, 99% at 25 µM, and ~100% at 50 µM, and overall IC50 ≈ 0.6 µM. Complex 2 
shows much less inhibitory effect against purified proteasome with the following values: 23%, 
31%, and 50% at 10, 25, and 50 µM concentrations, respectively, and IC50 ≈ 50 µM. 
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Figure 5.2.3.1. Anti-proliferative effects of complexes 1 and 2 in prostate cancer PC-3 cells.  
 
 
 
 
 
 
 
 
 
 
Figure 5.2.3.2. Chymotrypsin-like activity inhibition of purified 20S proteasome after treatment 
with complexes 1 and 2. 
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The ability of complexes 1 and 2 to inhibit chymotrypsin-like activity of cellular 
proteasome was measured by treatment of PC-3 cells with different concentrations of both 
complexes following 24 hours incubation. Consistent with the purified proteasome results, 
complex 1 showed excellent inhibitory effects against chymotrypsin-like activity of the 
proteasome in PC-3 cells, as shown in Figure 5.2.3.3. These results indicate a direct relationship 
of CT-inhibition activity and the increase in concentration of complex 1 pro-drug. Complex 1 
showed IC50 ≈ 22 µM comparable to the values of the [Co
III
(L
1
)2]ClO4 complex
10
 with IC50 ≈ 23 
µM. On the other hand, complex 2 did not show any chymotrypsin-like activity inhibition even 
at high concentrations. These findings correspond with the previously published results of the 
[Co
II
(L
2
)] complex which showed no inhibition properties against CT-like activity of the 
proteasomes in PC-3 cells. Based on these results, we suggest that the higher oxidation state 
metal ions present higher inhibition levels of chymotrypsin-like activity of the proteasome. 
To determine whether proteasome inhibition induces cancer cell apoptosis, PC-3 cells 
were treated with both complexes 1 and 2 at various concentrations. Upon cell lysis, Western 
blot analysis was performed to detect increased levels of ubiquitianted (Ub) proteins and PARP 
cleavage or disappearance. As observed in Figure 5.2.3.4, increased levels of Ub-proteins are 
present for complex 1 specifically at 30-50 µM concentrations indicated by the appearance of 
darker bands in the gel. These results strongly support that complex 1 does indeed inhibit the 
proteasome activity in the PC-3 cells. Surprisingly, complex 2 shows increased levels of 
ubiquitinated proteins at 40 and 50 µM concentrations. These are unexpected results because 
complex 2 does not inhibit the chymotrypsin-like activity of the proteasome in PC-3 cells, yet the 
proteasome is not active since Ub-proteins are present. These findings suggest that complex 2 
could possibly inhibit the activity of the proteasome by interacting with other proteolytic sites 
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including caspase- and trypsin-like activities. Another possible target could be the 19S regulatory 
subunit particularly, the JAMM domain.
13,14
  Further studies have to be performed in the future 
in order to investigate whether the Zn-containing complex 2 could inhibit the activity of such 
catalytic or regulatory sites of the 26S proteasome.  
To prove that proteasome inhibition activity leads to prostate cancer cell apoptosis, poly 
ADP ribose polymerase (PARP) cleavage was measured (Figure 5.2.3.4.). The data confirms 
that at 30 µM and 50 µM concentrations, complex 1 shows PARP cleavage (reduced band) and 
disappearance, respectively. No such results were obtained for complex 2.  
Figure 5.2.3.3. Comparison of the chymotrypsin-like activity levels of the proteasome in PC-3 
cells after treatment with complexes 1 and 2 at different concentrations. 
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Figure 5.2.3.4. Comparison of Western blot analysis for complexes 1 and 2. Increased levels of 
Ub-proteins are shown for complex 1 at 30-50 µM. PARP cleavage is observed for complex 1. 
 
 
Confirmation of cellular apoptosis was demonstrated by monitoring the prostate cancer 
cellular morphological changes upon treatment with complexes 1 and 2. As expected, the 
gallium-containing species caused apoptotic bleeding of the PC-3 cells at increasing 
concentrations; whereas, the zinc-containing analog showed no such effects (Figure 5.2.3.5). 
Thus, we conclude, that prostate cancer cells undergo apoptosis through the inhibition activity of 
the chymotrypsin-like activity of the proteasome due to treatment with complex 1.  
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Figure 5.2.3.5. Morphological changes of PC-3 cells upon treatment with 1 and 2. Rounded 
detached cells have undergone apoptosis. 
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Toxicity of [Ga
III
(L
2
)]ClO4 and [Zn
II
(L
2
)] complexes was tested against non-cancerous 
immortalized human epithelial prostate cell extracts upon treatment with different concentrations 
of both compounds. Inhibition of the chymotrypsin-like activity was measured and the results are 
included in Figure 5.2.3.6. Neither of the complexes shows inhibition activity at lower 
concentrations and the Ga-containing compound shows only 20% inhibition at the highest 
concentration of 50 µM. These findings are significant because they confirm selectivity of 
complex 1 towards cancer cells.   
 
 
 
 
 
 
 
 
 
Figure 5.2.3.6. Selectivity of complexes 1 and 2 towards non-cancerous CRL2221 cells.  
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5.3. Conclusions 
In this chapter, we evaluated the inhibitory effects of two complexes [Ga
III
(L
2
)]ClO4 and 
[Zn
II
(L
2
)] against proteasome activity. The chemical structures of both complexes were 
confirmed by X-ray crystallography. From these studies we concluded that the Ga-containing 
complex is considerably more potent towards inhibition of the CT-like activity compared to the 
zinc analog in both purified and cellular proteasome. Complex 1 induces prostate cancer cellular 
apoptosis as supported by PARP cleavage resulting from the inhibition activity of the 
proteasome. On the contrary, the Zn-containing complex 2 showed insignificant CT-like 
activity inhibition in prostate cancer PC-3 cells, but increased levels of the ubiquinated proteins. 
This suggests that other proteolytic sites could be the targets of action. Cytotoxic properties of 
both complexes were tested in non-cancerous CRL2221 cells showing minimal CT-like activity 
inhibition even at the highest concentration of 50 μM. Based on these findings, we conclude that 
the complex containing the higher oxidation state metal ion gallium(III) induces inhibition of 
CT-like activity at higher levels compared to metal ions with lower oxidation states; such as the 
zinc counterpart. 
Compared to the other metal-based proteasome inhibitors reported by the Verani and Dou 
groups, complex 1 is the most effective CT-inhibitor in purified proteasome with IC50 values of 
0.6 μM which makes this pro-drug an excellent candidate for in vivo studies.  
 
5.4. Experimental Procedures 
Chemical characterization of both complexes was performed using the techniques 
described in Chapter 2. The biological assays were run under the same conditions as described 
in Chapter 3, Section 3.4.4. 
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5.4.1. Crystal Structure Analysis of [Ga
III
(L
2
)]ClO4 and [Zn
II
(L
2
)] Complexes 
 
         (1)          (2) 
Formula C30.75H32.25ClGaI4N4O7.38   C28H24I4N4O2Zn 
M 1188.63   1021.48 
Space group Monoclinic, P21/c   Monoclinic, C2/c 
a / Å 16.8166 (9)   13.8723 (4) 
b/ Å 26.2253 (14)   9.9255 (4) 
c/ Å 19.3957 (10)   21.9417 (7) 
α/ o 90   90 
β/ o 113.43 (2)   95.772 (2) 
γ/ o 90   90 
V/ Å
3
 7848.9 (7)   3005.8 (18) 
Z 8    4 
T/ K 100 (2)   100 (2) 
λ/ Å 0.71073   0.71073 
Dcalc/ g cm
-3
 2.012   2.257 
µ/ mm
-1
 3.964   4.958 
R(F)
 
(%) 4.20   3.95 
Rw(F) (%) 8.98   8.76 
a
 R(F) = ∑║Fo│-│Fc║ ∕ ∑│Fo│ for I > 2s(I); Rw(F) = [∑w(Fo
2
 – Fc
2
)
2 / ∑w(Fo
2
)
2
]
1/2 
for I > 2s(I). 
Table 5.4.1. Crystal data and structure refinement results for complexes 1 and 2. 
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5.4.2. Characterization of [Ga
III
(L
2
)]ClO4 and [Zn
II
(L
2
)] Complexes  
[Ga
III
(L
2
)]ClO4 (1). Yield: 90%; IR data: (KBr, cm
-1
) 1611, 1569, 1433, (C=NPyridine 
C=CAromatic); 1302, (C-O); ESI
+
 in MeOH: m/z (100%) = 1024.73 for to [GaIII(L2)]+; Anal. Calc. 
(%) for ([Ga
III
(L
2
)]ClO4, C28H24ClGaI4N4O6) C, 29.89; H, 2.15; N, 4.98 Found (%): C, 29.60; H, 
2.21; N, 4.78. 
[Zn
II
(L
2
)] (2). Yield: 80%; IR data: (KBr, cm
-1
) 1602, 1560, 1444, (C=NPyridine 
C=CAromatic); 1328, (C-O); ESI
+
 in MeOH: m/z (100%) = 1020.85 for {[ZnII(L2)] + H
+}+; Anal. 
Calc. (%) for ([Zn
II
(L
2
)]·H2O, C28H26ZnI4N4O3) C, 32.35; H, 2.52; N, 5.39 Found (%): C, 32.29; 
H, 2.52; N, 4.81. 
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CHAPTER 6 
INHIBITION OF THE 26S PROTEASOME AS A POSSIBLE MECHANISM FOR 
TOXICITY OF HEAVY METAL SPECIES  
Published with minor changes as Tomco, D.; Schmitt, S.; Heeg, M. J.; Dou, Q. P.; Verani, C. 
N.* J. Inorg. Biochem. 2014, 132, 96. 
6.1. Introduction 
In this chapter, we hypothesize that heavy metal ions associated to the toxic 
organoaluminum, organocadmium, organomercury, organolead and organotin species might 
inhibit the proteasome as a secondary mechanism for toxicity in non-cancerous cells. These 
species are associated with a number of conditions that affect normal cell function. It is well 
established that organoaluminum species are linked to bone and central nervous system 
accumulation by interaction with erythrocytes and desferrioxamine, as well as to mitochondrial 
functions accompanying globular astrocyte generation.
1,2
 Cadmium poisoning
3
 is related to lack 
of specificity towards cell organelles, interactions with the DNA, and increased oxidative 
stress.
4,5
 Organomercury species can accumulate in the mitochondria and irreversibly inhibit 
selenoenzymes
6
, leading to the damage of the nervous system.
7,8
 Organolead species substitute 
divalent metal ions and disrupt homeostasis, thus affecting the central nervous system as a 
substitute for calcium in ATPase pumps.
9
 Finally, organotin
10
 species are related to the 
incorporation of cationic tin to the Golgi apparatus, as well as in the coordination to intracellular 
phospholipids.
11 
 Although considerable knowledge on the primary toxicity mechanisms for such 
species has been established, some evidence is available linking proteasome inhibition to 
cadmium and lead in erythrocytes
12
 and with organometallic polyphenyl and polybutyl tin 
species,
13
 and it is likely that other cellular secondary targets are involved.  
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In order to verify our hypothesis we have generated five new coordination complexes 
containing aluminum, cadmium, mercury, lead and tin with the proteasome-innocuous ligand 
HL
iodo
. We report on the new species [Al
III
(L
iodo
)2]ClO4 (1), [Cd
II
(L
iodo)Cl]•H2O (2), 
[Hg
II
(L
iodo
)2]•4DMSO (3), [Pb
II
(L
iodo
)NO3] (4), and [Sn
IV
(L
iodo
)Cl3] (5), Scheme 6.1, thoroughly 
characterized by spectrometric, spectroscopic, and structural methods, and their action on 
CRL2221 transformed human prostate epithelial cells. These cells mimic the behavior of normal 
non-cancerous prostate cells. We conclude discussing the validity of the potential role of such 
heavy metal species on proteasome inhibition. 
 
 
 
 
 
 
 
 
 
 
Scheme 6.1. Metal complexes. 
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6.2. Chemical Results and Discussion 
 6.2.1. Synthesis and Characterization 
Complexes 1-5 were synthesized by adding the appropriate metal salt to a methanol or 
ethanol solution of the [NN’O] ligand HLiodo previously treated with triethylamine. The purity of 
the complexes was confirmed by standard characterization techniques including IR, ESI-MS, and 
elemental analyses. Species 3 and 5 had their structures solved by X-ray crystallography. 
Infrared spectroscopy indicates that strong ligand bands at 1593, 1570, 1428 cm
-1
 associated with 
C=Npy and C=CAr vibrations, show characteristic shifting upon coordination with the metal ions. 
A strong broad band at 1095 cm
-1
 observed for the aluminum-containing 1 is assigned to the 
perchlorate counterion. All species were analyzed by room temperature 
1
H- and 
13
C-NMR 
spectroscopy and show the expected ligand peaks shifted by metal coordination. Details, 
including the stability of the compounds in solution, are discussed in Section 6.2.3. Good 
agreement was found between elemental analyses and the proposed compositions for 1-5. ESI-
MS results were taken in the positive mode and show good agreement with the expected 
fragmentation and isotopic distribution for complexes 1-5. Complex 1 shows the presence of the 
cationic species [Al
III
(L
iodo
)2]
+
observed at m/z
+
 = 956.8 (100 %), whereas complex 3 shows the 
molecular ion peak assigned to the [Hg
II
(L
iodo
)2 + H
+
]
+
 at m/z
+
 = 1132.77 (100 %). ESI-MS for 
complex 4 reveals the main peaks present at m/z (100 %) = 672.8 for [Pb
II
(L
iodo
)]
+
. Simulation 
assignments for the peak to peak position between the experimental and calculated values for 
complexes 3 and 4 are included in the supplementary material (Figure D.6.2.1). Complex 5 
shows some variance in its fragmentation patterns, indicating that solvent molecules can replace 
one of the chlorido coligands, as seen for species [Sn
IV
(L
iodo
)Cl2(CH3OH)]
+
 detected at m/z (100 
%) = 686.8. Equally distinctive, the isotopic distributions for complexes 1 and 3-5 are a 
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reflection of their compositions. As such the [Al
III
(L
iodo
)2]
+
 fragment displays a simpler profile 
than that of [Hg
II
(L
iodo
)2 + H
+
]
+
. Whereas the former has three main peaks associated with the 
contributions of 100 % 
27
Al and the ligand, the latter displays seven peaks associated with the 
contributions of mercury (
196
Hg, 0.5 %;  
198
Hg, 34.1 %; 
199
Hg, 57.3 %; 
200
Hg, 77.9 %; 
201
Hg, 
44.5 %; 
202
Hg, 100 %; 
204
Hg, 22.9 %) and the ligand. Similar results are found for [Pb
II
(L
iodo
)]
+
 
and [Sn
IV
(L
iodo
)Cl2(CH3OH)]
+
.  
6.2.2 Solid State Structural Information 
The structures of 3 and 5 were determined using X-ray crystallography.Their ORTEP 
diagrams along with selected bond lengths and angles are shown in Figures 6.2.2.1 and 6.2.2.2, 
respectively. Complex 3 crystallized as single colorless crystals under slow solvent evaporation 
from a concentrated dimethylsulfoxide solution at room temperature. The X-ray data reveals a 
single mercury(II) ion coordinated to two deprotonated HL
iodo
 ligands in a pseudo-octahedral 
geometry. Each ligand displays a facial arrangement around the Hg(II) ion, as previously 
described for other metal ions
11,14 
with the same HL
iodo
 ligand. The equivalent 
[NpyrdineNamineOphenolate] donor sets from each ligand are trans-oriented to each other, and the 
Hg
II–Npyridine and Hg
II–Namine bond distances reach 2.50 and 2.22 Å. The Hg
II–Ophenolate bond 
lengths are 2.51 Å, thus in good agreement with other available mercury(II) species in the 
literature.
15,16
 Due to an inversion center, all angles comprised of equivalent trans donors are 
180° from each other. Complex 5 was isolated as colorless crystals from an ethanolic solution. 
The tin ion is chelated to one deprotonated HL
iodo 
ligand and three anionic chlorido ligands 
complete the octahedron occupying the fourth, fifth and sixth position. Considering the overall 
charges, as well as the lack of counterions, this arrangement confirms the tetravalent character of 
the metal center. The bond lengths of Sn
IV–Npyridine, Sn
IV–Namine, and Sn
IV–Ophenolate are 2.21, 
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2.24, and 2.06 Å respectively; whereas Sn
IV–Cl bond distances average to 2.38 Å. These values 
are comparable to those found in the literature.
17,18
 As expected, the ligand is facially coordinated 
to the tin(IV) cation, which is favored over the meridional arrangement due to the structural 
flexibility of the [NN’O] ligand.19,20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.2.1. ORTEP diagram for complex 3. Selected bond lengths: Hg(1)-O(1) = 2.506(19), 
Hg(1)-N(1) = 2.505(2), Hg(1)-N(2) = 2.225(2) Å. Selected angles: N(1)-Hg(1)-O(1) = 96.51(7), 
N(2)-Hg(1)-N(1) = 72.42(8), N(2)-Hg(1)-O(1) =  87.14(8). Hydrogen atoms have been omitted. 
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Figure 6.2.2.2. ORTEP diagram for complex 5. Selected bond lengths: Sn(1)-O(1) = 2.056(18), 
Sn(1)-N(1) = 2.215(2), Sn(1)-N(2) = 2.243(2), Sn(1)-Cl(4) = 2.423(7), Sn(1)-Cl(5) = 2.348(7), 
Sn(1)-Cl(6) = 2.356(7) Å. Selected angles: O(1)-Sn(1)-N(1) = 83.87(8), N(1)-Sn(1)-N(2) = 
76.41(9), O(1)-Sn(1)-N(2) = 87.27(8), Cl(5)-Sn(1)-Cl(4) = 92.70(3), Cl(5)-Sn(1)-Cl(6) = 
97.99(3), Cl(6)-Sn(1)-Cl(4) = 93.34(2). Hydrogen atoms have been omitted. 
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6.2.3. Structural Information in Solution 
Proton and carbon NMR spectra for complexes 1-5 were recorded in DMSO-d6 at 
ambient temperature. In addition, time-dependent NMR spectra were measured over a period of 
48 hours to determine the stability of the complexes in solution. Both 
1
H- and 
13
C-NMR spectra 
showed peak signals associated with the ligand between 3.00 to 9.90 and 45.0 to 170 ppm, 
respectively. These spectra were compared to the chemical shifts of the ligand HL
iodo
 in DMSO-
d6, as previously reported [15]. 
 
Selected NMR data for the complexes are included in Appendix 
D where the recorded spectra showed considerable peak shift when compared to the 
unmetallated and protonated ligand due to metal coordination. The data is summarized in Table 
6.2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1
0
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2.3. 
1
H-NMR spectra assignments for complexes 1-5 compared to the HL
iodo
 ligand in DMSO-d6 at room temperature. Table 
legend: br. = broad; d = doublet; dd = doublet of doublet; dt = doublet of triplet; m = multiplet; s = singlet; Ex. = exchangable. 
 
 H1 
(ppm) 
H2 
(ppm) 
H3 
(ppm) 
H4 
(ppm) 
H5,5’/H6,6’ 
(ppm) 
H7 
(ppm) 
H8 
(ppm) 
H9 
(ppm) 
HL
iodo
 d  (8.54) dd  (7.29) br. dt 
(7.80) 
d  (7.37) s (3.83) 
s (3.87) 
d (7.33) d (7.78) s br. 6.60 – 
7.10 
1 d  (9.68) (7.26 – 8.13) (3.60 – 4.79) (7.26 – 8.13) 
2 d  br. 
(8.58) 
m br.  
(7.34-7.41) 
t br. (7.87) m br.  
(7.34-7.41) 
d br. (3.75 
&3.61) 
s br. (4.16) 
s br. (3.98) 
s br. (7.12) s br.  (7.54) s br. (8.28) 
3 (7.25 – 8.75) (3.55 – 4.51) (7.25 – 8.75) 
4 d (8.66) m (7.31-
7.34) 
dt (7.79) m (7.31-
7.34) 
d (4.54) 
s br. (4.07) 
s (7.23) s (7.55) Ex. proton 
5 d (8.87) t (7.69) dt (8.09) d  (7.40) dd (4.53) 
d (4.42) 
d (4.36) 
dd (3.85) 
s (7.44) s (7.53) s br. (7.77) 
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The 
1
H- and 
13
C- NMR spectra for the aluminum-containing complex 1 show twice the 
number of signals related to the ligand, as in the previously reported [Zn
II
(L
iodo
)2] complex [13]. 
This behavior is suggestive of lack of symmetry about the aluminum(III) ion indicating the 
presence of non-equivalent ligands with different geometries in solution. The 
1
H-NMR spectrum 
is shown in Figure D.6.2.3.1 In the case of [Zn
II
(L
iodo
)2], an available X-ray crystallographic 
structure allowed us to confirm the cis geometry among the phenolates. In absence of structural 
information for 1 in the solid state, confirmation of geometry is challenging. Nonetheless, a 
similar spectrum is observed after 48 hours, as shown in Figure D.6.2.3.2, and we tentatively 
attribute this behavior to the orientation of the phenolates and nitrogen donor sets. 
For both the cadmium(II)- and lead(II)-based complexes 2 and 4 the methylene protons display 
peak broadening upon metal coordination (Figure D.6.2.3.3). For the tin-complex 5 the 
coordinated L
iodo
 yields a well-behaved spectrum comparable to that of the unmetallated ligand. 
The methylene protons appear as multiplets between 3.8 and 4.5 ppm, suggesting ligand 
rearrangement (Figure D.6.2.3.4). Since there is only one ligand present, the generation of 
different isomeric species in solution cannot be ruled out, as expected for a main group ion.  The 
solid state structure of the mercury-containing complex 3 shows two equivalent ligands 
positioned around the Hg(II) ion, where the phenolates and nitrogen donor sets are trans-oriented 
to each other. This geometry relates to the described geometry for the counterpart 
[Co
III
(L
iodo
)2]ClO4 as measured by heteronuclear multiple quantum coherence (HMQC) in 
DMSO-d6 and also in agreement with the X-ray structure for other [Co
III
(L
tBu
)2]ClO4 species 
reported by our group.
21
 In spite of the general agreement on the positions of bonds, species 3 
shows considerably broad signals indicative of a non-rigid structure in solution.
22
 Nonetheless 
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time-dependent NMR data confirms the stability of 3 at ambient conditions, as these peaks 
persist over a 48 hour period, indicating that no major decomposition takes place in DMSO-d6, 
as shown in Figure 6.2.3. The stability of all complexes was also verified over a 48 hour period, 
where the position and intensity of the proton peaks remained unchanged. 
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Figure 6.2.3. Time dependent 1H-NMR spectra for complex 3 in DMSO-d6 at room temperature. 
Each spectrum was taken under the highlighted time over a period of 48 h. 
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6.3. Biological Results  
 6.3.1. Cell Viability 
In order to evaluate the effect of the heavy metal complexes on cell proliferation, 
CRL2221 transformed human prostate epithelial cells were treated with various concentrations 
of 1-5 and DMSO as a control for 72 h followed by measurement by MTT assays, as shown in 
Figure 6.3.1. The complexes show a dose-dependent decrease in cell proliferation.  The IC50 
values for complexes 1-5 are 2 µmol/L, 4 µmol/L, 6 µmol/L, 3 µmol/L, and 4 µmol/L 
respectively. At lower concentrations the aluminum-containing 1 and the lead-containing 4 show 
the highest inhibition of cell proliferation (89 and 95% and 84 and 86%, at 5 and 10 µmol/L, 
respectively), followed by complex 2 (99% at 10 µmol/L). Treatment with 2, 3, and 4 resulted in 
even higher inhibition of cellular proliferation (97-99%) at 25 and 50 µmol/L. Complex 5 shows 
a dose-dependent decrease of cell proliferation with the highest inhibition of 95% at 50 µmol/L. 
The above results allow us to draw some conclusions about the action of complexes 1-5 on 
toxicity in epithelial CRL2221 prostate cells. These MTT results suggest that all species are toxic 
towards intact cells and lead to cell death.  The aluminum-containing 1 is rather toxic at all tested 
concentrations, while the cadmium-containing 2 and the lead-containing 4 show similar profiles 
where toxicity is marked at concentrations  of 10, 25, 50 μmol/L. The mercury- and tin-
containing species 3 and 5 exhibit pronounced toxicity at higher concentrations. These results 
indicate cell toxicity, although per se, they cannot be directly linked to proteasome activity.  
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Figure 6.3.1. Percent cell proliferation in CRL2221 cells. Cells were treated with complexes 1-5 
for 72 h at the given concentrations of 5-50 µmol/L incubated under 37 ˚C. DMSO is used as a 
control. 
 
6.3.2. Inhibition of the Chymotrypsin-like Activity in Purified 20S Proteasome  
To confirm the ability of these complexes to inhibit chymotrypsin-like activity of the 
proteasome, species 1-5 were incubated with purified human 20S proteasome under cell-free 
conditions and the CT fluorogenic substrate N-Succinyl-Leucine-Leucine-Valine-Tyrosine-(7-
amino-4-methyl-coumarin) (SucLLVYAMC) followed by measurement of the hydrolyzed 7-
amino-4-methylcoumarin groups. Figure 6.3.2 summarizes the data. At lower concentrations of 
1 and 5 µmol/L the mercury-containing complex 3 shows the highest CT-like activity inhibition 
of 88 % and 98 % respectively, followed by the cadmium-containing 2 with 70 % and 84 % for 
the same concentrations. Both complexes 1 and 4 show dose-dependent decreases of 84% and 
83%, respectively, in CT-like activity in purified proteasome at the highest concentration of 25 
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Figure 3. Percent cell proliferation in CRL2221 cells after 72 h treatment with complexes 1-5 at various 
concentrations, and control DMSO.
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µmol/L, whereas 5 showed only 30-40% inhibition regardless of the concentration. Complexes 
1-5 show toxicity towards 20S proteasome, whereas previously reported results indicated that the 
ligand HL
iodo
 had negligible effect on the CT-like activity of the 20S proteasome even at higher 
concentrations.
14 
By monitoring the inhibition of CT-like activity in purified 20S proteasome, a 
better correlation between the toxicity of species 1-5 and the proteasome can be observed. It 
becomes evident that high concentrations of 1, 4, and 5 are needed for inhibition of the purified 
20S proteasome, and while 2 shows increased potency, 3 is extremely potent from 10 to 50 
μmol/L, thus suggesting a potential link between proteasome inhibition and cell toxicity.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.2. Measurement of chymotrypsin-like activity inhibition in human purified 20S 
proteasome upon treatment with complexes 1-5 at concentrations 1-25 µmol/L.  
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6.3.3. Inhibition of Proteasomal Chymotrypsin-like Activity in Intact CRL2221 Cells 
To verify the ability of 2-5 to inhibit proteasome activity, intact transformed human 
prostate epithelial cells CRL2221 were treated with different concentrations (up to 25 μmol/L) of 
complex for 48 h, followed by measurement of proteasome inhibition, as shown in Figure 6.3.3. 
CRL2221 cells treated with the lead-containing 4 showed dose-dependent inhibition of 
proteasomal CT-like activity by 41 % at 5 μmol/L, 46 % at 10 μmol/L, and 73 % at 25 μmol/L. 
Consistently, levels of proteasomal CT-like activity were decreased after treatment with the 
cadmium- and mercury-species 2 and 3 at 10 μmol/L by 52 % and 43 %, respectively. On the 
other hand, cells treated with the tin-containing 5 showed negligible proteasome inhibition at 
lower concentrations, and only at 25 μmol/L was about 50% inhibition of CT-like activity 
observed. The results with intact cells suggest that higher concentrations of 2-5 are necessary for 
CT-inhibition of the proteasome, implying that some of these toxic species might be prevented 
from crossing the cell membrane or be deterred by other intracellular targets before reaching the 
proteasome. Nonetheless, at 5 and 10 μmol/L , the cadmium- , mercury-, and lead-containing 
species 2, 3, and 4 show inhibition of about 40-60 %, whereas 4 shows a noticeable 70 % 
inhibition at higher concentrations. 
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Figure 6.3.3. Chymotrypsin-like activity inhibition in intact CRL2221 cells. Proteins extracted 
from the CRL2221 cells after 48 h treatment with complexes 2-5 at concentrations 5-10 µmol/L 
were incubated at 37 ˚C with the chymotrypsin substrate for 4 h. DMSO is used as control. 
 
 
 
6.3.4. Inhibition of Proteasomal Chymotrypsin-like Activity Cell Extracts 
Inhibition of proteasomal CT-like activity was also measured in CRL2221 cell extracts 
after 24 h treatment with complexes 1-5, as shown in Figure 6.3.4. Data indicate that the 
mercury-containing complex 3 showed the highest CT-like inhibition values in a dose-dependent 
manner reaching 99% inhibition at 25 μmol/L. On the contrary, complex 1 demonstrated no 
proteasome inhibitory effect even at the highest concentration of 25 μmol/L. We found that when 
these CRL2221 cell extracts were treated with 4 and 5 only about 30 % of the CT-like activity 
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was inhibited at 25 μmol/L. Our data suggest that 3 is the most potent proteasome inhibitor in 
cell extracts, further supporting the hypothesis that toxicity towards epithelial prostate cells 
might be associated with proteasome inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.4. Chymotrypsin-like activity inhibition in CRL2221 cell extracts. CRL2221 protein 
extract was treated with complexes 1-5 at various concentrations 5-10 µmol/L. DMSO as a 
control. 
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6.4. Overview and Conclusions 
The toxicity of five metal complexes was investigated towards transformed human 
prostate epithelial CRL2221 cells at various concentrations.  The percent cell proliferation after 
treatment with complexes 1-5 was measured and all five species demonstrated high levels of 
inhibition of cell growth in a concentration-dependent manner. Particularly, aluminum-
containing species 1 seemed to be the most toxic against cell viability even at lower 
concentrations, whereas the tin-containing complex 5 showed toxicity only at very high 
concentrations. The ability of species 1-5 to inhibit the proteasomal activity was tested and the 
results indicate that the cadmium, mercury and lead species 2, 3, and 4 have the highest 
inhibitory ability against the chymotrypsin-like activity of purified 20S, as well as in intact 
CRL2221 cells. In cell extracts, the mercury species 3 proved to be the most potent against CT-
like activity, with 2 and 4 as distant next candidates.  
Considering the above results, the toxicity of the aluminum species, albeit high, cannot be 
directly associated to the proteasome. A similar conclusion can be drawn regarding the tin-
containing complex. On the other hand, the toxicity of other species such as cadmium and lead 
are potentially associated with proteasome inhibition, although CT-activity inhibition in cell 
extracts makes it difficult to be categorically affirmative. The mercury species, particularly at 
higher concentrations, has shown cell toxicity and CT-like inhibition in purified proteasome, cell 
extracts and intact cells, and its relationship towards the proteasome is strongly suggested. 
Therefore, in spite of the known prevalent mechanisms of cellular toxicity for mercury species, 
in particular the inhibition of selenoenzymes, proteasome inhibition is a viable secondary route 
for toxicity. Further studies will be necessary to elucidate the nature of the final agent of 
inhibition, either as a complex or ionic entity. 
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6.5. Experimental  
6.5.1. Materials and Methods 
Reagents and solvents were purchased from commercial sources. Time-dependent NMR 
experiments were recorded over 48 hours at room temperature. Other characterization methods 
were used as described in Chapter 2.  
6.5.2. X-ray Structural Determination of [Hg
II
(L
iodo
)2]•4DMSO (3) and 
[Sn
IV
(L
iodo
)Cl3] (5) 
Diffraction data were measured on a Bruker APEX-II kappa geometry diffractometer
23 
with Mo radiation and a graphite monochromator at 100 K. Frames were collected as a series of 
sweeps with the detector at 40 mm and 0.3 degrees between each frame. All structures were 
refined using Sheldrick's SHELX-97 software.
24
 A summary of the crystal structure parameters is 
contained in Table 6.5.2. The species [Hg
II
(L
iodo
)2]•4DMSO (3) was crystallized as tiny 
colorless rods. A sample 0.17 x 0.08 x 0.07 mm
3 
was used for data collection. A total of 3759 
frames was collected at 10 s/frame, yielding 19903 reflections, of which 5455 were independent. 
Hydrogen atoms were placed at calculated positions. The asymmetric unit contains one half 
complex with Hg occupying an inversion center plus two DMSO solvates. [Sn
IV
(L
iodo
)Cl3] (5) 
crystallized as colorless rod fragments. A sample 0.20 x 0.16 x 0.10 mm
3 
was used for data 
collection. A total of 3445 frames was collected at 10 s/frame, yielding 14665 reflections, of 
which 4368 were independent. Hydrogen positions were calculated. The asymmetric unit 
consists of 1 neutral molecule without ions or solvates. 
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         (3)          (5) 
Formula C34H46HgI4N4O6S4 C13H11SnI4N4OCl3 
M 1443.18 690.08 
Space group Triclinic, P-1 Triclinic, P-1 
a / Å 10.3784 (4) 7.8380 (5) 
b/ Å 10.7497 (4) 10.1607 (6) 
c/ Å 11.0349 (4) 11.8911 (7) 
α/ o 77.982 (2) 101.008 (2) 
β/ o 89.147 (2) 103.100 (2) 
γ/ o 71.429 (2) 97.885 (2) 
V/ Å
3
 1139.67 (7) 889.11 (9) 
Z 1 2 
T/ K 100 (2) 100 (2) 
λ/ Å 0.71073 0.71073 
Dcalc/ g cm
-3
 2.103 2.578 
µ/ mm
-1
 6.312 5.361 
R(F)
 
(%) 2.26 2.07 
Rw(F) (%) 4.48 4.98 
a
 R(F) = ∑║Fo│-│Fc║ ∕ ∑│Fo│ for I > 2s(I); Rw(F) = [∑w(Fo
2
 – Fc
2
)
2 / ∑w(Fo
2
)
2
]
1/2 
for I > 2s(I). 
Table 6.5.2. Crystal data and structure refinements for [Hg
II
(L
iodo
)2] •4DMSO (3) and 
[Sn
IV
(L
iodo
)Cl3] (5) 
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6.5.3. Syntheses 
6.5.3.1. Ligand syntheses 
The HL
iodo
 ligand has been previously synthesized according to well established procedures 
in our lab.
21,25
 
6.5.3.2. Complex syntheses  
[Al
III
(L
iodo
)2]ClO4 (1). The HL
iodo
 ligand (0.50 g, 1.1 mmol) was dissolved in 30 mL of 
methanol followed by the dropwise addition of Et3N (0.16 g, 1.6 mmol). Anhydrous AlCl3 salt 
(0.072 g, 0.54 mmol) dissolved in minimum amount of methanol was added slowly to the ligand 
solution while stirring under heating. The reaction mixture was refluxed for 2 h under aerobic 
conditions then cooled to room temperature. Counterion exchange was followed by addition of a 
methanolic solution containing NaClO4 to the reaction mixture. A yellow precipitate formed 
immediately, which was isolated and washed with cold methanol and water to eliminate the 
excess salts. After washing with ether, the product was vacuum dried and characterized. Yield: 
93%; IR data: (KBr, cm
-1
) 1616, 1574, 1451, (C=NPy, C=CAr); 1319, (C-O); 1095, (Cl-O, 
perchlorate); 
1
H-NMR (MR-400, DMSO, 298 K) δ 9.68 (d, 1H, J = 5.40 Hz), δ 8.05-8.13 (m, 
2H), δ 7.86-7.92 (m, 1H),  δ 7.68 (t, 1H, J = 6.16 Hz), δ 7.53 (d, 2H, J = 2.35 Hz), δ 7.47 (s, 1H), 
δ 7.42 (d, 1H, J = 7.33 Hz), δ 7.35-7.41 (m, 2H), δ 7.27 (d, 2H, J = 3.81 Hz),  δ 6.59 (d, 1H, J = 
6.56), δ 5.75 (s, 1H),  δ 4.78 (dd, 1H, J = 10.72, 5.46 Hz, –CH2), δ 4.54 (d, 1H, J = 11.79 Hz, –
CH2), δ 4.44 (d, 1H, J = 13.40 Hz, –CH2), δ 3.87-4.02 (m, 4H, –CH2),  δ 3.81 (d, 1H, J = 11.25 
Hz, –CH2), δ 3.58 (d, 1H, J = 13.40 Hz, –CH2), ESI
+
 in MeOH: m/z (100%) = 956.8 for 
[Al
III
(L
iodo
)2]
+
; Anal. Calc. for 2 (%, C26H22AlI4N4ClO6, FW = 1056.53 g.mol
-1
); C, 29.56; H, 
2.10; N, 5.30. Found (%): C, 29.51; H, 2.02; N, 5.20. 
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[Cd
II
(L
iodo
)Cl]·H2O (2). The metal salt CdCl2 (87 mg, 0.48 mmol) was dissolved in 5 
mL of ethanol and slowly added to a 30 mL ethanol solution containing the ligand HL
iodo
 (0.20 g, 
0.43 mmol) and Et3N (0.07 g; 0.69 mmol). The solution was refluxed for 24 h under aerobic 
conditions, when a light yellow precipitate was formed and then filtered and washed with cold 
ether. Yield: 70%; IR data (KBr, cm
-1
): 1601, 1564, 1422, (C=NPy, C=CAr); 1303, (C-O);  
1
H-
NMR (MR-400, DMSO, 298 K) δ 8.58 (d br., 1H, J = 2.74 Hz), δ 7.87 (t br., 1H, J = 7.33, 7.10 
Hz), δ 7.54 (s br., 1H), δ 7.34-7.41 (m br., 3H), δ 7.12 (s br., 1H), δ 4.16 (s br., 1H, –CH2), δ 3.98 
(s br., 1H, –CH2), δ 3.75-3.61(d br., 5H, –CH2),   Anal. Calc. (%) for (%,C13H13CdI2N2O2Cl, FW 
= 630.93 g.mol
-1
)  C, 24.75; H, 2.08; N, 4.44. Found (%): C, 25.09; H, 1.95; N, 4.36. 
  [Hg
II
(L
iodo
)2]·4DMSO (3). To a methanolic solution containing HL
iodo
 ligand (0.31 g, 
0.66 mmol) and Et3N (0.10 g, 0.99 mmol), Hg(NO3)2·H2O salt (0.11 g, 0.31 mmol) was added 
and the reaction was stirred for 2 h under 30 °C. The solvent was rotoevaporated until half of the 
solvent was removed, and the resulting yellow precipitate was filtered and washed with cold 
methanol. The product was dissolved in a minimum amount of dimethylsulfoxide, and colorless 
crystals were obtained after 48 h under slow solvent evaporation.  Yield: 70%; IR data: (KBr, 
cm
-1
) 1599, 1559, 1421, (C=NPy C=CAr); 1318, (C-O); ESI
+
 in MeOH: m/z (100%) = 1132.8 for 
[Hg
II
(L
iodo
)2 + H
+
]
+
; Anal. Calc. (%) for [Hg
II
(L
iodo
)2]·2DMSO (ground, vacuum dried sample: 
%, C30H34HgI4N4O4S2, FW = 1286.95 g.mol
-1
) C, 28.00; H, 2.66; N, 4.35. Found (%): C, 28.06; 
H, 2.21; N, 4.57. 
[Pb
II
(L
iodo
)NO3] (4). The Pb(NO3)2 salt (0.40 g, 1.2 mmol) was dissolved in 5 mL 
ethanol and added to a 30 mL ethanolic solution containing the ligand HL
iodo
 (0.50 g, 1.1 mmol) 
and Et3N (0.17 g; 1.7 mmol) under aerobic condition. The solution was refluxed for 24 h, when a 
white product was vacuum filtered and washed with cold ethanol and ether. Yield: 86%; IR data 
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(KBr, cm
-1
): 1602, 1562, 1421, (C=NPy, C=CAr); 1301, (C-O); 
1
H-NMR (MR-400, DMSO, 298 
K) δ 8.66 (d, 1H, J = 5.18 Hz), δ 7.79 (dt, 1H, J = 7.12 Hz), δ 7.55 (s, 1H), δ 7.31-7.34 (m, 2H), 
δ 7.23 (s, 1H), δ 4.54 (d br., 3H, –CH2), δ 4.07 (s br., 1H, –CH2); ESI
+
 in MeOH: m/z (100%) = 
672.8 for [Pb
II
(L
iodo
)]
+
; Anal. Calc. for 3 (%,C13H11PbI4N3O4, FW = g.mol
-1
)  C, 21.27; H, 1.51; 
N, 5.72. Found (%): C, 21.30; H, 1.50; N, 5.55. 
[Sn
IV
(L
iodo
)Cl3] (5). The HL
iodo
 ligand (0.50 g, 1.1 mmol) was dissolved in 30 mL of 
ethanol and Et3N (0.14 g, 1.3 mmol) was added dropwise. SnCl2·2H2O (0.24 g, 1.1 mmol) was 
dissolved in minimum amount of ethanol and added slowly to the ligand solution while stirring. 
The reaction mixture was then refluxed for 48 h under aerobic conditions. No precipitate was 
observed; hence the solution was concentrated by rotoevaporation and set for crystallization. 
Colorless crystals were afforded after 72 h under room temperature by slow solvent evaporation. 
Yield: 88%; IR data: data (KBr, cm
-1
): 1609 1568, 1432 (C=NPy, C=CAr); 1294 (C-O); 
1
H-NMR 
(MR-400, DMSO, 298 K) δ 8.87 (d, 1H, J = 6.46 Hz), δ 8.09 (dt, 1H, J = 7.81, 1.70 Hz), δ 7.77 
(s br., 1H), δ 7.69 (t, 1H, J = 7.03 Hz), δ 7.53 (s, 1H), δ 7.44 (s, 1H), δ 7.40 (d, 1H, J = 8.09 Hz),  
δ 4.53 (dd, 1H, J = 16.73, 6.23 Hz, –CH2), δ 4.42 (d, 1H, J = 12.84 Hz, –CH2), δ 4.32 (d, 1H, J = 
17.51 Hz, –CH2), δ 3.85 (dd, 1H, J = 13.23, 1.95 Hz, –CH2), ESI
+
 in MeOH: m/z (100%) = 686.8 
for [Sn
IV
(L
iodo
)Cl2CH3OH]
+
; Anal. Calc. for 2 (%, C13H11SnI2N2OCl3, FW = 690.12 g.mol
-1
); C, 
22.63; H, 1.61; N, 4.06. Found (%): C, 22.85; H, 1.78; N, 3.92. 
6.5.4. Biological Assays 
6.5.4.1. Inhibition of Proteasomal Activity in Purified 20S Proteasome 
Purified human 20S proteasome (35 ng; Boston Biochem; Cambridge, MA) was 
incubated with 10 μM of CT substrate, SucLLVYAMC (AnaSpec; Fremont, CA) , in 100 μL of 
assay buffer [20 mM Tris-HCl (pH 7.5)] in the presence of complexes 1-5 at various 
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concentrations, with DMSO as the solvent control. After 2 h incubation at 37 °C, the production 
of hydrolyzed AMC groups was measured using a Wallac Victor3 multilabel counter 
(PerkinElmer; Waltham, MA) with an excitation filter of 365 nm and an emission filter of 460 
nm.
25
 
6.5.4.2. Cell Cultures and Whole Cell Extract Preparation 
CRL2221 transformed human prostate epithelial cells were grown in RPMI1640 
supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin 
and maintained at 37 °C with 5% CO2. Whole cell lysates were prepared as previously 
described.
26
 
6.5.4.3. Cell Proliferation Assay 
Cells were seeded in quadruplicate in a 96-well plate and grown to 70−80% confluence, 
followed by treatment with the indicated agents for 72 h followed by measurement of cell 
proliferation by the 3(4,5dimethylthiazol-2-yl)2,5diphenyltetrazolium bromide (MTT) assay as 
described previously.
27
 
6.5.4.4. Proteasome CT-like Activity in Intact CRL2221 Cells  
Proteins extracted from cells after each treatment were incubated at 37 °C for 2-4 h in 
100 μL of assay buffer (50 mM Tris-HCl, pH 7.5) with 10 μM of fluorogenic CT substrate 
SucLLVYAMC, and production of hydrolyzed AMC groups was measured using a Wallac 
Victor3 multilabel counter with an excitation filter of 365 nm and an emission filter of 460 nm, 
as described previously.
27 
6.5.4.5. Proteasome CT-like Activity in Cell Extracts 
CRL2221 protein extract (10 µg) was treated with complexes 1-5 at various 
concentrations (or DMSO as solvent control) for 24h at 37 °C with 10 µM of CT substrate in 100 
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μL assay buffer [20 mM Tris-HCl (pH 7.5)]. After incubation, the production of hydrolyzed 
AMC groups was measured using a Wallac Victor3 multilabel counter (PerkinElmer; Waltham, 
MA) with an excitation filter of 365 nm and an emission filter of 460 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
 
6.6. References 
                                                          
1          Jeffery, E. H. Biochemical mechanisms of aluminum toxicity, Toxicology of Metals in    
            Handbook of Experimental Pharmacology, 1995, 115, 139-161. 
2          Lemire, J.; Appanna, V. D. J. Inorg. Biochem. 2011, 105, 1513.  
3          Wolfgang, M.; Jean-Marc, M. The Bioinorganic Chemistry of Cadmium in the Context of  
           its Toxicity, Cadmium: From Toxicology to Essentiality Metal Ions in Life Sciences,    
           Springer, 2013, 11, pp. 1-30. 
4          Larregle, E. V.; Ferranola, M. L. Molecular mechanisms of cadmium toxicity in mammals  
            in Metals in Biological Systems, Gimenez Maria Sofia ED. 2010, pp.163-185. 
5          Moulis, J.-M. Bio. Metals 2010, 23, 877. 
6          Yang, D.-Y.; Chen, Y.-W.; Gunn, J.M.; Belzile, N. Environ. Rev. 2008, 16, 71. 
7          Neustadt, J.; Pieczenik, S. Integ. Medic. 2007, 6, 26. 
8          Guzzi, G.; La Porta, C. A. M. Toxicology 2008, 244, 1.   
9          Yasuhiro, S.; Toshiyuki, K. Biol. Pharm. Bull. 2012, 35, 1885.  
 
10        Blunden, S.; Wallace, T. Food Chem. Toxicol. 2003, 41, 651.  
11         Arakawa, Y. Biomed. Res. Trace Elements 2000, 11, 259. 
12         Neslund-Dudas, C.; Mitra, B.; Kandegedara, A.; Chen, D.; Schmitt, S.; Shen, M.; Cui,  
             Q.; Rybicki, B. A.; Dou, Q. P. Biol. Trace Elem. Res. 2012, 149, 5. 
13         Shi, G.; Chen, D.; Zhai, G.; Chen, M. S.; Cui, Q. C.; Zhou, Q.; He, B.; Dou, Q. P.; Jiang,  
             G. Environ. Health Perspect. 2009, 117, 379. 
14         Shakya, R.; Hindo, S. S.; Wu, L.; Allard, M.; Heeg, M. J.; Hratchian, H. P.; McGarvey,  
             B. R.; da Rocha, S.; Verani, C. N. Inorg. Chem. 2007, 46, 9808. 
 
121 
 
 
                                                                                                                                                                                           
15         Xavier, F. R.; Peralta, R. A.; Bortoluzzi, A. J.; Drago, V.; Castellano, E. E.; Haase, W.;  
             Tomkowicz, Z.; Neves, A. J. Inorg. Biochem. 2011, 105, 1740. 
16         Biswas, S.; Saha, R.; Ghosh, A. Organometallics 2012, 31, 3844. 
17         Chen, Z.-F.; Peng, Y.; Gu, Y.-Q.; Liu, Y.-C.; Liu, M.; Huang, K.-B.; Hu, K.; Liang, H.  
              Eur. J. Med. Chem. 2013, 62, 51. 
18         Momeni, B. Z.; Kia, R.; Ghanbarzadeh, S. Monatsh. Chem. Springer 2012, 143, 1479. 
19         Shakya, R.; Peng, F.; Liu, J.; Heeg, M. J.; Verani, C. N. Inorg. Chem. 2006, 45, 6263. 
20         Lesh, F. D.; Hindo, S. S.; Heeg, M. J.; Allard, M. M.; Jain, P.; Peng, B.; Hryhorczuk, L.;  
             Verani, C. N. Eur. J. Inorg. Chem. 2009, 345. 
21         Shakya, R.; Imbert, C.; Hratchian, H. P.; Lanznaster, M.; Heeg, M. J.; McGarvey, B. R.;      
             Allard, M. M.; Schlegel, H. B.; Verani, C. N. Dalton Trans. 2006, 2517. 
22         Mugesh, G.; Singh, H. B.; Butcher, R. J. Eur. J. Inorg. Chem. 2001, 669.  
23         APEX II collection and processing programs are distributed by the manufacturer. Bruker  
            AXS Inc., Madison WI, USA, 2009. 
24        Sheldrick, G. M. Acta Cryst. 2008, A64, 112. 
25         Daniel, K. G.; Gupta, P.; Harbach, R. H.; Guida, W. C.; Dou, Q. P. Biochem. Pharmacol.  
             2004, 67, 1139. 
26         Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Cancer Res. 2006, 66, 10425. 
27         Daniel, K. G.; Chen, D.; Orlu, S.; Cui, Q. C.; Miller, F. R.; Dou, Q. P. Breast Cancer  
             Res. 2005, 7, R897. 
 
122 
 
CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
7.1. Conclusions 
My contributions through this research have furthered our understanding of the 
metal-based behavior proteasome inhibitors. We have successfully demonstrated the 
appropriate selection of the metal ions based on their oxidation state, redox properties, 
coordination numbers, and chemical properties including the inertness and lability of 
these metal ions. We have also showed that tuning the properties of the ligand can 
dramatically change the effects of these complexes against the inhibition of the 26S 
proteasome activity.  
In Chapter 3, the first Research Objective of interrogating the mechanism of 
inhibition of the 26S proteasome using inert/labile metal ions coordinated to 
tri/hexadentate ligands has been accomplished by the synthesis and characterization of 
three cobalt complexes described as [Co
II
(L
1
)2], [Co
II
(L
2
)], and [Co
III
(L
1
)2]ClO4. These 
complexes contain the deprotonated forms of the [NN′O] tridentate ligand HL1 and its 
newly synthesized [N2N′2O2] hexadentate counterpart H2L
2
, namely, 2,4-diiodo-6-
((pyridine-2-ylmethylamino)methyl)phenol and 6,6′-((ethane-1,2-diylbis((pyridin-2-
ylmethyl)azanediyl))bis(methylene))bis(2,4-diiodophenol). Characterizations of these 
three complexes included electrospray ionization (ESI) spectrometry, infrared and UV–
visible spectroscopies, and elemental analyses. A detailed 
1
H-NMR study was conducted 
for [Co
III
(L
1
)2]ClO4 and X-ray structural data was obtained for [Co
II
(L
2
)] complex. The 
viability of this series as potential agents for proteasome inhibition and cell apoptotic 
induction involving PC-3 cancer cells is presented comparing the behavior of the 
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untethered [NN′O]2 six-coordinate [Co
II
(L
1
)2] and [Co
III
(L
1
)2]ClO4 and the tethered 
counterpart [Co
II
(L
2
)]  with a 1:1 metal-to-ligand ratio. It is observed that the tethering in 
[Co
II
(L
2
)] decreases inhibition activity. When [Co
II
(L
1
)2] and [Co
III
(L
1
)2]ClO4 were 
compared, the most inert, but redox-active, cobalt(III) species showed the highest 
chymotrypsin-like activity inhibition on purified proteasome and PC-3 cancer cells. 
In the second Research Objective, described in Chapter 4, we have evaluated the 
chemical reduction as a viable mechanism for the inhibition of the 20S proteasome. The 
viability of ligand dissociation in the cobalt complex [Co
III
(L
1
)2]ClO4 following 
biological reduction has been established. We performed detailed electrochemical 
characterization of [Co
III
(L
1
)2]ClO4 in several solvents, along with 
spectroelectrochemical and chemical reduction to monitor the phenolate-to-cobalt(III) 
LMCT band observed at 440 nm in the UV–Vis region in presence and absence of a 
sacrificial reductant. DFT calculations were performed to confirm the nature of this band. 
Species [Co
III
(L
1
)2]ClO4 displays no signs of ligand protonation at pH 3 over a period of 
24 h while probing its stability in solution. Spectrophotometric monitoring at pH 3 in 
presence of ascorbic acid shows clearly a decrease of the LMCT band, implying that 
reduction of the metal center has taken place. 
The products of chemical reduction were analyzed by high resolution ESI
+
 mass 
spectrometry and support a mechanism in which biological reduction leads to ligand 
dissociation. This mechanism explains why the substitutionally inert cobalt (III) complex 
[Co
III
(L
1
)2]ClO4 revealed high levels of proteasomal inhibition via deactivation of 
chymotrypsin-like activity; hence, induction of cellular apoptosis in PC-3 cells compared 
to the more labile Co(II) containing species [Co
II
(L
1
)2]. These promising results support 
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our hypothesis that loss of one ligand from 2:1 ligand to metal ratio is required for the 
pharmacophore species [ML]
+
 to be formed. Such pharmacophore species provides the 
available open coordination sites for the appropriate amino acid chains such as threonine, 
tyrosine, and histidine containing hydroxyl or imidazole functional groups in the 
chymotrypsin pocket to coordinate to the metal ion center.  
Chapter 5 covers the third Research Objective of comparing the effect of the ion 
charge towards the inhibition activity of the 26S proteasome. Two new complexes 
containing a higher oxidation state gallium(III) metal ion [Ga
III
(L
2
)]ClO4 and a lower 
oxidation state zinc(II) ion [Zn
II
(L
2
)] with the deprotonated form of H2L
2
 ligand 6,6′-
((ethane-1,2-diylbis((pyridin-2-ylmethyl)azanediyl))bis(methylene))bis(2,4-
diiodophenol) were successfully synthesized and characterized. The structural 
information of the deprotonated hexadentate ligand coordinated to the Ga and Zn ions 
was confirmed by X-ray crystallography where both complexes are arranged in a 1:1 
metal to ligand ratio. Their biological effect against the proliferation of prostate cancer 
PC-3 cells via proteasome inhibition activity was measured. From the biological results it 
is concluded that the Ga-containing complex is highly potent towards the inhibition 
activity of the purified 20S proteasome (IC50 = 0.6 µM) and 26S proteasome as well as 
apoptosis induction in PC-3 cells, compared to the zinc-containing analog. Western 
blotting analysis reveals that both complexes inhibit the 26S proteasome activity by the 
increased levels of the ubiquitinated proteins. Thus, we can hypothesize that the 
[Zn
II
(L
2
)] complex possibly inhibits the activity of the proteasome not by the inhibition of 
chymotrypsin-like activity, but by other proteolytic sites such as trypsin- or caspase-like. 
Further studies have to be completed in order to fully support such a hypothesis.  
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Chapter 6, which includes the fourth Research Objective, addresses the effect of 
aluminum and heavy metal ions on inhibition activity of the 20S and 26S proteasome in 
non-cancerous prostate cells. In this chapter, we report on the synthesis of five metal 
complexes coordinated to the [NN′O] ligand HLiodo (2,4-diiodo-6-((pyridine-2-
ylmethylamino)methyl)phenol), namely [Al
III
(L
iodo
)2]ClO4, [Cd
II
(L
iodo
)Cl]·H2O, 
[Hg
II
(L
iodo
)2]·4DMSO, [Pb
II
(L
iodo
)NO3], and [Sn
IV
(L
iodo
)Cl3]. These species are 
thoroughly characterized by spectroscopic and spectrometric methods, as well as by 
elemental analysis. X-ray crystallographic results for complex [Hg
II
(L
iodo
)2]·4DMSO 
indicate the presence of Hg(II) ion hexacoordinated to two facially oriented [NN′O] 
ligands, whereas for complex [Sn
IV
(L
iodo
)Cl3] an Sn(IV) ion chelates to one deprotonated 
ligand and three chlorido coligands. The toxicity of these complexes is tested against 
transformed human prostate epithelial cells CRL2221 and we observed that the five 
complexes demonstrate high levels of cell growth inhibition in a dose-dependent manner. 
In order to evaluate the relationship between these species and the proteasome, we test 
them against purified 20S, CRL2221 cell extracts, and intact cells, followed by the 
measurement of the percent chymotrypsin-like activity inhibition levels. Results suggest 
a good correlation between the toxicity of [Hg
II
(L
iodo
)2]·4DMSO and proteasome 
inhibition. 
7.2. Future Directions 
 Innovative ideas in development of the next generation metal-based proteasome 
inhibitors are focused on the challenges of increasing drug selectivity and introducing 
low levels of intracellular toxicity. These challenges will be addressed by designing and 
synthesizing 26S proteasome inhibitors incorporating new ligand scaffolds. Since the 
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ligand HL
iodo
 (2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol)  has been proven 
to successfully carry various metal ions intracellulary, it is wise to link this ligand with 
the peptide unit of bortezomib and MG132 aldehyde inhibitor. The secondary amine 
group found in the HL
iodo
 ligand will serve as the attachment site of these peptide-based 
fragments. Therefore, we should develop these new ligands  Pyz-Phe-Leu-L
iodo
H, (Pyz = 
pyrazinoic acid), and Z-Leu-Leu-Leu-L
iodo
H, (Z = benzyloxycarbonyl) by incorporating 
amino acid sequences of Pyz-Phe-Leu- and  Z-Leu-Leu-Leu- found in highly selective 
proteasome inhibitors such as bortezomib and the aldehyde MG132
1 , 2  
(Figure 7.2.). 
Synthesis of the Pyz-Phe-Leu-L
iodo
H ligand series can be obtained by Suzuki
3
 or Stille
4
 
coupling, whereas the Z-Leu-Leu-Leu-L
iodo
H series can be synthesized by Schiff 
condensation/alkylation. Such amino acid chains are accepted to form hydrogen bonding 
with the chymotrypsin-like pocket of the 20S proteasome, therefore increasing drug 
selectivity for such site.
 
  
 
 
 
 
 
 
 
 
Figure 7.2. New ligands containing bortezomib (top) and MG132 (bottom) derivatives. 
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Also, the interesting results obtained in Chapter 5 where the zinc-containing 
complex [Zn
II
(L
2
)] did not show inhibition activity of chymotrypsin in purified 20S and 
cellular 26S proteasome, but demonstrated increased levels of ubiquitinated proteins from 
PC-3 cell extracts, should be further investigated for proteasome inhibition activity. The 
next step is to validate [Zn
II
(L
2
)] complex against other proteolytic sites of the 
proteasome including trypsin-, and caspase-like activity as well as the JAMM domain of 
the 19S particle of the proteasome.
5 
The Verani group also needs to address the proteasome inhibition activity in vivo. 
Considering our best proteasome inhibitor pro-drugs [Ga
III
(L
2
)]ClO4 and [Co
III
(L
1
)2]ClO4 
in vitro, we will continue these studies following the protocols established in the Dou Lab 
for in vivo measurements.
6,7,8 
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APPENDIX A 
Supplementary Material for Chapter 3 
 
 
Figure A.3.2.2.1 
1
H-NMR of HL
1
 ligand. 
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Figure A.3.2.1.2. 
1
H-
1
H COSY for HL
1
 ligand. 
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Figure A.3.2.1.3. Expanded picture of the aromatic region of 
1
H-
1
H COSY for HL
1
 ligand. 
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Figure A.3.2.3.1. 
13
C NMR / DEPT for complex 3. 
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Figure A.3.2.3.2. 
1
H-
1
H COSY for complex 3. 
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Proton 
H 
HL
1
   (ppm) 
J-coupling (Hz) 
[Co
III
(L
1
)2ClO4] (ppm)                        
J-coupling (Hz) 
H1 8.54 d (J1-2 = 4.8) 8.99 dd (J1-2 = 5.5) 
H2 7.29 dd (J2-3 = 7.7) 
(J2-4 = 4.8) 
7.46 t (J2-3 = 6) 
H3 7.8 br dt (J3-2 = 7.7) 
(J3-1 = 1.8) 
7.95 t (J3-4 = 7.7) 
H4 7.37 d (J4-3 = 7.7) 7.57 d (J4-3 = 7.7) 
H5 H5
’ 
3.83 (s) 4.39 d (J = 16.6) 
5.58 dd (J = 16.6, 5.5) 
H6 H6
’ 
3.87 (s) 3.48 dd (J = 16.6, 4.1) 
3.66 br d (J = 11.6) 
H7 7.33 d (J7-8 = 2.1) 7.39 (s) 
H8 7.78 d (J8-7 = 2.1) 7.34 (s) 
H9 6.60-7.10 br (s) 8.33 (s) 
H10 6.60-7.10 br (s) no peak 
 
Table A.3.2.3 
1
H NMR assignment including J-coupling values for HL
1
 and [Co(L
1
)2]ClO4 (3) 
in DMSO-d6. 
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Figure A.3.2.3.3 HMQC for complex 3. 
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Figure A.3.2.3.4. Low Temperature 
1
H NMR for complex 3. 
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Table S2.  Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for 2. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          I(1)         8862(1)       5403(1)        311(1)       29(1)  
          I(2)         6038(1)       2026(1)       1522(1)       30(1)  
          Co(1)        5000          5900(1)       2500          17(1)  
          N(1)         4436(2)       5877(3)       1560(2)       21(1)  
          C(1)         3841(3)       4895(4)       1330(2)       27(1)  
          C(2)         3621(4)       4700(4)        711(2)       31(1)  
          C(3)         4019(3)       5558(5)        314(2)       33(1)  
          C(4)         4633(3)       6562(4)        545(2)       30(1)  
          C(5)         4825(3)       6698(4)       1172(2)       23(1)  
          C(6)         5459(3)       7808(4)       1449(2)       25(1)  
          N(2)         5784(2)       7586(3)       2101(2)       21(1)  
          C(7)         5548(3)       8754(4)       2467(2)       26(1)  
          C(8)         6838(3)       7256(4)       2193(2)       24(1)  
          C(9)         7087(3)       6086(4)       1808(2)       21(1)  
          C(10)        7733(3)       6238(4)       1367(2)       23(1)  
          C(11)        7932(3)       5164(4)       1001(2)       24(1)  
          C(12)        7476(3)       3941(4)       1053(2)       21(1)  
          C(13)        6831(3)       3802(4)       1490(2)       20(1)  
          C(14)        6634(3)       4831(4)       1893(2)       18(1)  
          O(1)         6071(2)       4654(2)       2324(1)       20(1)  
         ________________________________________________________________  
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           Table S3.  Bond lengths [A] and angles [deg] for 2.  
           _____________________________________________________________  
   
            I(1)-C(11)                    2.106(4)  
            I(2)-C(13)                    2.091(4)  
            Co(1)-O(1)                    2.003(3)  
            Co(1)-O(1)#1                  2.003(3)  
            Co(1)-N(1)#1                  2.139(3)  
            Co(1)-N(1)                    2.139(3)  
            Co(1)-N(2)#1                  2.234(3)  
            Co(1)-N(2)                    2.234(3)  
            N(1)-C(5)                     1.339(5)  
            N(1)-C(1)                     1.346(5)  
            C(1)-C(2)                     1.382(6)  
            C(2)-C(3)                     1.381(6)  
            C(3)-C(4)                     1.376(7)  
            C(4)-C(5)                     1.389(6)  
            C(5)-C(6)                     1.503(6)  
            C(6)-N(2)                     1.480(5)  
            N(2)-C(7)                     1.476(5)  
            N(2)-C(8)                     1.485(5)  
            C(7)-C(7)#1                   1.535(8)  
            C(8)-C(9)                     1.506(5)  
            C(9)-C(10)                    1.396(5)  
            C(9)-C(14)                    1.424(5)  
            C(10)-C(11)                   1.389(6)  
            C(11)-C(12)                   1.385(6)  
            C(12)-C(13)                   1.388(5)  
            C(13)-C(14)                   1.405(5)  
            C(14)-O(1)                    1.302(4)  
   
            O(1)-Co(1)-O(1)#1           103.12(15)  
            O(1)-Co(1)-N(1)#1            88.91(11)  
            O(1)#1-Co(1)-N(1)#1          90.32(12)  
            O(1)-Co(1)-N(1)              90.32(12)  
            O(1)#1-Co(1)-N(1)            88.91(12)  
            N(1)#1-Co(1)-N(1)           178.76(18)  
            O(1)-Co(1)-N(2)#1           160.79(12)  
            O(1)#1-Co(1)-N(2)#1          89.65(11)  
            N(1)#1-Co(1)-N(2)#1          76.57(12)  
            N(1)-Co(1)-N(2)#1           104.40(12)  
            O(1)-Co(1)-N(2)              89.65(11)  
            O(1)#1-Co(1)-N(2)           160.79(12)  
            N(1)#1-Co(1)-N(2)           104.40(12)  
            N(1)-Co(1)-N(2)              76.57(12)  
            N(2)#1-Co(1)-N(2)            82.03(16)  
            C(5)-N(1)-C(1)              118.4(4)  
            C(5)-N(1)-Co(1)             119.0(3)  
            C(1)-N(1)-Co(1)             121.4(3)  
            N(1)-C(1)-C(2)              122.6(4)  
            C(3)-C(2)-C(1)              118.6(4)  
            C(4)-C(3)-C(2)              119.3(4)  
            C(3)-C(4)-C(5)              119.1(4)  
            N(1)-C(5)-C(4)              122.0(4)  
            N(1)-C(5)-C(6)              116.6(4)  
            C(4)-C(5)-C(6)              121.3(4)  
            N(2)-C(6)-C(5)              112.9(3)  
            C(7)-N(2)-C(6)              110.6(3)  
            C(7)-N(2)-C(8)              111.7(3)  
            C(6)-N(2)-C(8)              111.1(3)  
            C(7)-N(2)-Co(1)             103.7(2)  
            C(6)-N(2)-Co(1)             112.8(2)  
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            C(8)-N(2)-Co(1)             106.7(2)  
            N(2)-C(7)-C(7)#1            109.2(3)  
            N(2)-C(8)-C(9)              111.9(3)  
            C(10)-C(9)-C(14)            120.6(4)  
            C(10)-C(9)-C(8)             120.6(3)  
            C(14)-C(9)-C(8)             118.8(3)  
            C(11)-C(10)-C(9)            120.1(4)  
            C(12)-C(11)-C(10)           121.0(3)  
            C(12)-C(11)-I(1)            118.5(3)  
            C(10)-C(11)-I(1)            120.4(3)  
            C(11)-C(12)-C(13)           118.4(4)  
            C(12)-C(13)-C(14)           123.3(3)  
            C(12)-C(13)-I(2)            119.0(3)  
            C(14)-C(13)-I(2)            117.6(3)  
            O(1)-C(14)-C(13)            122.2(3)  
            O(1)-C(14)-C(9)             121.3(3)  
            C(13)-C(14)-C(9)            116.5(3)  
            C(14)-O(1)-Co(1)            124.6(2)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
           #1 -x+1,y,-z+1/2      
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    Table A.3.4.2.1. Anisotropic displacement parameters (A^2 x 10^3) for 2.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    I(1)     25(1)      34(1)      28(1)       4(1)      12(1)      -1(1)  
    I(2)     31(1)      19(1)      41(1)      -5(1)      12(1)      -8(1)  
    Co(1)    21(1)      13(1)      18(1)       0          6(1)       0  
    N(1)     21(2)      18(2)      24(2)       1(1)       7(1)      -1(1)  
    C(1)     32(2)      23(2)      25(2)       2(2)       5(2)      -6(2)  
    C(2)     39(3)      26(2)      27(2)      -4(2)      -4(2)      -2(2)  
    C(3)     43(3)      35(3)      18(2)       2(2)      -3(2)       1(2)  
    C(4)     43(3)      24(2)      24(2)       5(2)       8(2)       8(2)  
    C(5)     30(2)      17(2)      22(2)       4(2)       6(2)       4(2)  
    C(6)     33(2)      16(2)      25(2)       4(2)       8(2)      -3(2)  
    N(2)     27(2)      14(2)      24(2)      -1(1)       7(2)      -3(1)  
    C(7)     33(2)      13(2)      32(2)      -4(2)      11(2)      -2(2)  
    C(8)     24(2)      21(2)      27(2)      -6(2)       4(2)      -8(2)  
    C(9)     20(2)      21(2)      23(2)      -1(2)       3(2)      -4(2)  
    C(10)    20(2)      20(2)      28(2)       1(2)       4(2)      -5(2)  
    C(11)    21(2)      31(2)      20(2)       3(2)       4(2)      -1(2)  
    C(12)    23(2)      23(2)      18(2)      -2(2)       0(2)      -1(2)  
    C(13)    21(2)      15(2)      23(2)       2(2)       1(2)      -5(2)  
    C(14)    18(2)      17(2)      20(2)       1(2)       1(2)      -2(2)  
    O(1)     24(1)      16(1)      21(1)       2(1)      10(1)       0(1)  
    _______________________________________________________________________  
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Table A.3.4.2.1 Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 
10^3) for 2.  
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         3560          4312          1603          32  
          H(2)         3204          3991           562          38  
          H(3)         3872          5456          -113          39  
          H(4)         4920          7155           279          36  
          H(6A)        6038          7895          1222          29  
          H(6B)        5093          8660          1404          29  
          H(7A)        5728          9589          2265          31  
          H(7B)        5922          8712          2874          31  
          H(8A)        7023          7043          2628          29  
          H(8B)        7220          8046          2089          29  
          H(10)        8037          7078          1318          27  
          H(12)        7602          3214           795          26  
         ________________________________________________________________  
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         Table A.3.4.2.3 Torsion angles [deg] for 2.  
         ________________________________________________________________  
   
          O(1)-Co(1)-N(1)-C(5)                                -83.4(3)  
          O(1)#1-Co(1)-N(1)-C(5)                              173.5(3)  
          N(1)#1-Co(1)-N(1)-C(5)                             -135.0(3)  
          N(2)#1-Co(1)-N(1)-C(5)                               84.1(3)  
          N(2)-Co(1)-N(1)-C(5)                                  6.1(3)  
          O(1)-Co(1)-N(1)-C(1)                                 83.6(3)  
          O(1)#1-Co(1)-N(1)-C(1)                              -19.5(3)  
          N(1)#1-Co(1)-N(1)-C(1)                               32.0(3)  
          N(2)#1-Co(1)-N(1)-C(1)                             -108.9(3)  
          N(2)-Co(1)-N(1)-C(1)                                173.2(3)  
          C(5)-N(1)-C(1)-C(2)                                   0.3(6)  
          Co(1)-N(1)-C(1)-C(2)                               -166.8(3)  
          N(1)-C(1)-C(2)-C(3)                                  -0.8(7)  
          C(1)-C(2)-C(3)-C(4)                                   1.0(7)  
          C(2)-C(3)-C(4)-C(5)                                  -0.8(7)  
          C(1)-N(1)-C(5)-C(4)                                  -0.1(6)  
          Co(1)-N(1)-C(5)-C(4)                                167.3(3)  
          C(1)-N(1)-C(5)-C(6)                                 178.0(4)  
          Co(1)-N(1)-C(5)-C(6)                                -14.6(5)  
          C(3)-C(4)-C(5)-N(1)                                   0.3(6)  
          C(3)-C(4)-C(5)-C(6)                                -177.6(4)  
          N(1)-C(5)-C(6)-N(2)                                  16.9(5)  
          C(4)-C(5)-C(6)-N(2)                                -165.0(4)  
          C(5)-C(6)-N(2)-C(7)                                -126.9(3)  
          C(5)-C(6)-N(2)-C(8)                                 108.5(4)  
          C(5)-C(6)-N(2)-Co(1)                                -11.3(4)  
          O(1)-Co(1)-N(2)-C(7)                               -146.5(3)  
          O(1)#1-Co(1)-N(2)-C(7)                               81.3(4)  
          N(1)#1-Co(1)-N(2)-C(7)                              -57.7(3)  
          N(1)-Co(1)-N(2)-C(7)                                123.1(3)  
          N(2)#1-Co(1)-N(2)-C(7)                               16.1(2)  
          O(1)-Co(1)-N(2)-C(6)                                 93.8(3)  
          O(1)#1-Co(1)-N(2)-C(6)                              -38.4(5)  
          N(1)#1-Co(1)-N(2)-C(6)                             -177.4(2)  
          N(1)-Co(1)-N(2)-C(6)                                  3.4(2)  
          N(2)#1-Co(1)-N(2)-C(6)                             -103.5(3)  
          O(1)-Co(1)-N(2)-C(8)                                -28.4(2)  
          O(1)#1-Co(1)-N(2)-C(8)                             -160.6(3)  
          N(1)#1-Co(1)-N(2)-C(8)                               60.4(2)  
          N(1)-Co(1)-N(2)-C(8)                               -118.8(2)  
          N(2)#1-Co(1)-N(2)-C(8)                              134.2(3)  
          C(6)-N(2)-C(7)-C(7)#1                                75.2(4)  
          C(8)-N(2)-C(7)-C(7)#1                              -160.5(4)  
          Co(1)-N(2)-C(7)-C(7)#1                              -45.9(4)  
          C(7)-N(2)-C(8)-C(9)                                -178.5(3)  
          C(6)-N(2)-C(8)-C(9)                                 -54.5(4)  
          Co(1)-N(2)-C(8)-C(9)                                 68.8(3)  
          N(2)-C(8)-C(9)-C(10)                                118.3(4)  
          N(2)-C(8)-C(9)-C(14)                                -60.2(5)  
          C(14)-C(9)-C(10)-C(11)                                0.7(6)  
          C(8)-C(9)-C(10)-C(11)                              -177.8(4)  
          C(9)-C(10)-C(11)-C(12)                                1.8(6)  
          C(9)-C(10)-C(11)-I(1)                               177.6(3)  
          C(10)-C(11)-C(12)-C(13)                              -1.5(6)  
          I(1)-C(11)-C(12)-C(13)                             -177.3(3)  
          C(11)-C(12)-C(13)-C(14)                              -1.5(6)  
          C(11)-C(12)-C(13)-I(2)                              174.2(3)  
          C(12)-C(13)-C(14)-O(1)                             -175.8(4)  
          I(2)-C(13)-C(14)-O(1)                                 8.4(5)  
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          C(12)-C(13)-C(14)-C(9)                                3.8(6)  
          I(2)-C(13)-C(14)-C(9)                              -171.9(3)  
          C(10)-C(9)-C(14)-O(1)                               176.2(4)  
          C(8)-C(9)-C(14)-O(1)                                 -5.2(6)  
          C(10)-C(9)-C(14)-C(13)                               -3.4(6)  
          C(8)-C(9)-C(14)-C(13)                               175.1(4)  
          C(13)-C(14)-O(1)-Co(1)                             -132.7(3)  
          C(9)-C(14)-O(1)-Co(1)                                47.7(5)  
          O(1)#1-Co(1)-O(1)-C(14)                             139.2(3)  
          N(1)#1-Co(1)-O(1)-C(14)                            -130.7(3)  
          N(1)-Co(1)-O(1)-C(14)                                50.3(3)  
          N(2)#1-Co(1)-O(1)-C(14)                             -90.3(4)  
          N(2)-Co(1)-O(1)-C(14)                               -26.3(3)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
         #1 -x+1,y,-z+1/2      
  
 
 
 
 
 Least-squares planes (x,y,z in crystal coordinates) and deviations from them 
 (* indicates atom used to define plane) 
 
  10.9112 (0.0152) x - 6.1256 (0.0142) y - 2.0561 (0.0377) z = 0.9207 (0.0149)  
 
 *   -0.0007 (0.0027)  N1 
 *   -0.0018 (0.0030)  C1 
 *    0.0044 (0.0032)  C2 
 *   -0.0046 (0.0032)  C3 
 *    0.0021 (0.0031)  C4 
 *    0.0005 (0.0028)  C5 
     -0.0454 (0.0066)  C6 
      0.4070 (0.0058)  Co1 
 
 Rms deviation of fitted atoms =   0.0029 
 
 
  9.5697 (0.0166) x - 2.8548 (0.0155) y + 12.9335 (0.0301) z = 7.3948 (0.0141)  
 
 Angle to previous plane (with approximate esd) = 44.30 ( 0.15 ) 
 
 *   -0.0115 (0.0029)  C9 
 *   -0.0071 (0.0030)  C10 
 *    0.0153 (0.0030)  C11 
 *   -0.0038 (0.0029)  C12 
 *   -0.0152 (0.0029)  C13 
 *    0.0223 (0.0028)  C14 
      0.0918 (0.0056)  O1 
     -0.0858 (0.0067)  C8 
     -1.0609 (0.0070)  Co1 
 
 Rms deviation of fitted atoms =   0.0139 
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Figure A.3.4.2.1 Unit cell structure for complex 2. 
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APPENDIX B 
Supplementary Material for Chapter 4 
 
 
Figure B.4.2.1.1 Cyclic voltammograms of complex 1 in DMF with concentration [C] = 9.0 x 
10
-4
 M. TBAPF6 was used as supporting electrolyte.  The redox potential for Co(III)/(II) couple  
is measured vs. Ag/AgCl and plotted vs. Fc/Fc
+
 at room temperature. Potential parameters for the 
cobalt processes are: Epc = -826 mV; Epa = -679 mV; E½ = -753 mV; ΔEp = 147 mV; vs. Fc/Fc
+
. 
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Figure B.4.2.1.2 Cyclic voltammogram of complex 1 in DMF with concentration [C] = 9.0 x 10
-
4
 M. TBAPF6 was used as supporting electrolyte. The redox potential for Co(III)/(II) couple is 
measured vs. Ag/AgCl and plotted vs. Fc/Fc
+
 at room temperature and the data are shown in 
Table 1 in the text. 
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Figure B.4.2.1.3 Cyclic voltammogram of complex 1 in DMF/H2O 90:10% v/v. solvent system 
with concentration [C] = 0.9 x 10
-3
 M. TBAPF6 was used as supporting electrolyte.  The redox 
potential for Co(III)/(II) couple is measured versus Ag/AgCl and plotted vs. Fc/Fc
+
 at room 
temperature. Potential parameters for the cobalt processes are: Epc = -777 mV; Epa = -629 mV; 
E½ = -703 mV; ΔEp = 148 mV; vs. Fc/Fc
+
. 
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Figure B.4.2.3 TD-DFT calculated spectroelectrochemistry. 
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Figure B.4.2.4.1 UV-visible spectroscopy for complex 1 in DMF/H2O (90:10% v/v.) with final 
concentration of 9.0 x 10
-5
 M. The presence of pπphenolate  dσ*cobalt(III) charge transfer band at 
was observed at 440 nm. 
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Figure B.4.2.4.2 Chemical stability of complex 1 in DMF/H2O (90:10% v/v.). with final 
concentration of 9.0 x 10
-5
 M without ascorbic acid at pH 3. Each spectrum is recorded every 30 
min over a time period of 24 h. No decrease of pπphenolate  dσ*cobalt(III) charge transfer band at 
440 nm was observed over time. 
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Figure B.4.2.4.3 Chemical stability of complex 1 in DMF/H2O (90:10% v/v.)  with final 
concentration of 9.0 x 10
-5
 M without ascorbic acid at pH 1.0 adjusted with nitric acid. Each 
spectrum is recorded every 30 min over a time period of 24 h. No decrease of pπphenolate  
dσ*cobalt(III) charge transfer band at 440 nm was observed over time. 
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Figure 4.2.5.1 High resolution ESI
+
 mass spectrometry results for complex 1 after the 
completion of the chemical reduction experiment. Theoretical and experimental data are given 
for species (a) and (b) as indicated, being in good agreement.   
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Figure 4.2.5.2 ESI
+
-MS spectrum for the previously synthesized [Co(L
1
)2] complex. The charge 
on cobalt is (II), therefore the compound is neutral. We expected to observe a peak for [Co(L
1
)2 
+ H
+
]
+
 species m/z = 989.64 at 100%; instead we found the 100% peak at m/z = 988.64 which 
corresponds with the [Co(L
1
)2]
+
 species. Therefore, in the mass spectrometry instrument, 
oxidation of cobalt(II) has occurred. 
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Figure 4.2.5.3 High resolution ESI
+
 mass spectrometry results for 1, the control sample no 
ascorbic acid added.  As shown from the spectrum, there is no indication of the molecular ions 
peaks related to species (a) and (b). 
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Table B.4.2.2 Cartesian Coordinates for [Co(L
1
)2]
+
 and [Co(L
1
)2]
0
 species. 
[Co(L1)2]
+   
 H                  4.50227200    2.43264400   -1.04177000 
 H                  2.37303800    2.94403900    3.17284500 
 H                  1.73950400    3.27808800    0.68982200 
 C                  4.31970000    1.38768100   -0.82001600 
 H                  2.22686100    2.76630400   -1.56259200 
 C                  5.37016000    0.53746600   -0.47619700 
 C                  2.06112400    1.91505500    3.04613000 
 H                  2.89723200    1.21697100    4.90454300 
 C                  0.97335300    2.51240500    0.83436500 
 H                  0.04173700    3.00977900    1.11393600 
 C                  1.88650900    1.74161200   -1.38562000 
 C                  3.01852500    0.88625700   -0.89895300 
 C                  2.35451400    0.95029600    4.00632700 
 C                  1.35994300    1.54526300    1.89937500 
 H                 -0.06040200    2.24785600   -0.89422800 
 H                  1.50201900    1.34455000   -2.33020000 
 C                  5.14361000   -0.81405300   -0.21025600 
 N                  0.71973700    1.77421400   -0.44052500 
 H                  5.95999600   -1.47475400    0.05006100 
 C                  2.75034000   -0.47358200   -0.61156000 
 C                  1.95041500   -0.36767500    3.78472500 
 C                  3.83829900   -1.30035400   -0.27442900 
 N                  0.95592200    0.26611200    1.69598100 
 H                 -0.96489600    1.69333600   -2.42655300 
 H                  2.16888100   -1.15259400    4.49632700 
 C                  1.26098100   -0.67436000    2.61937400 
 O                 -1.49721600    0.96137500    0.68274700 
 Co                -0.00001300   -0.00003600    0.00005500 
 O                  1.49720100   -0.96145100   -0.68263000 
 C                 -1.26114900    0.67432900   -2.61918200 
 H                 -2.16912500    1.15257800   -4.49609500 
 C                 -3.83829200    1.30037100    0.27451100 
 C                 -1.95054000    0.36763500   -3.78455700 
 H                  0.96457200   -1.69333800    2.42683700 
 N                 -0.95594800   -0.26617500   -1.69587000 
 C                 -2.75036400    0.47353800    0.61159500 
 H                 -5.95997000    1.47485600   -0.05005500 
 C                 -5.14361000    0.81410700    0.21022400 
 N                 -0.71974900   -1.77430500    0.44057900 
 H                  0.06034600   -2.24792200    0.89438400 
 C                 -2.35444100   -0.95038000   -4.00626500 
 H                 -1.50226300   -1.34480600    2.33019300 
 C                 -1.35980800   -1.54536300   -1.89934800 
 C                 -3.01859200   -0.88632500    0.89883400 
 H                 -2.89711300   -1.21706400   -4.90450600 
 H                 -0.04142300   -3.00970000   -1.11386700 
 C                 -1.88664300   -1.74175900    1.38552100 
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 C                 -0.97314700   -2.51249700   -0.83435700 
 C                 -2.06092800   -1.91517000   -3.04613500 
 C                 -5.37020100   -0.53743800    0.47600000 
 C                 -4.31977600   -1.38771200    0.81977700 
 H                 -2.22704700   -2.76645800    1.56234900 
 H                 -1.73918800   -3.27830700   -0.68990100 
 H                 -2.37270700   -2.94418500   -3.17292200 
 H                 -4.50238100   -2.43269400    1.04141200 
 I                 -7.36804900   -1.31723700    0.35074800 
 I                 -3.45939500    3.36611100   -0.13642800 
 I                  7.36799900    1.31732000   -0.35114000 
 I                  3.45946200   -3.36605300    0.13676500 
 
[Co(L1)2]
0 
 H                 -4.63187300    2.32272700    1.24551900 
 H                 -2.90913600    3.27263400   -2.68486900 
 H                 -2.02709200    3.40515100   -0.36372200 
 C                 -4.45161500    1.29217400    0.95975300 
 H                 -2.46288600    2.61116200    1.89131200 
 C                 -5.50552500    0.47776400    0.54555500 
 C                 -2.50410800    2.26916000   -2.74577400 
 H                 -3.45038700    1.79235700   -4.62272900 
 C                 -1.24908100    2.66137800   -0.57641200 
 H                 -0.34650600    3.20813600   -0.86738900 
 C                 -2.04435900    1.64697900    1.57329000 
 C                 -3.15090400    0.78687400    1.02346900 
 C                 -2.80639700    1.44038800   -3.82537700 
 C                 -1.66934100    1.79257700   -1.73015000 
 H                 -0.15331200    2.33557800    1.11873200 
 H                 -1.61156900    1.16428200    2.45647400 
 C                 -5.28229600   -0.85414400    0.19669800 
 N                 -0.91354200    1.87067700    0.62668400 
 H                 -6.09687700   -1.49334700   -0.11843800 
 C                 -2.86851600   -0.56586900    0.65682100 
 C                 -2.27423900    0.14841400   -3.85985000 
 C                 -3.98055200   -1.34849900    0.25812600 
 N                 -1.15720700    0.54231200   -1.76842800 
 H                  1.04100300    1.26034700    2.78913500 
 H                 -2.48904600   -0.52767500   -4.67774000 
 C                 -1.46020100   -0.26331600   -2.80911400 
 O                  1.63163500    1.04734800   -0.70120800 
 Co                 0.00000100    0.00000900    0.00000200 
 O                 -1.63163400   -1.04735000    0.70120200 
 C                  1.46021500    0.26334800    2.80912200 
 H                  2.48907600    0.52771300    4.67773800 
 C                  3.98055500    1.34849200   -0.25813600 
 C                  2.27425700   -0.14838100    3.85985500 
 H                 -1.04098000   -1.26031200   -2.78913200 
 N                  1.15720800   -0.54228500    1.76844400 
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 C                  2.86851600    0.56586300   -0.65682400 
 H                  6.09688100    1.49333700    0.11842200 
 C                  5.28229700    0.85413300   -0.19670500 
 N                  0.91353000   -1.87066900   -0.62666100 
 H                  0.15329300   -2.33556400   -1.11870300 
 C                  2.80640400   -1.44036000    3.82538900 
 H                  1.61156600   -1.16430700   -2.45646100 
 C                  1.66933100   -1.79255600    1.73017200 
 C                  3.15089800   -0.78688500   -1.02345600 
 H                  3.45039600   -1.79232800    4.62274000 
 H                  0.34647200   -3.20809900    0.86742800 
 C                  2.04434900   -1.64699300   -1.57326700 
 C                  1.24905600   -2.66136100    0.57644400 
 C                  2.50410100   -2.26913700    2.74579500 
 C                  5.50552200   -0.47777800   -0.54555200 
 C                  4.45160700   -1.29219000   -0.95973600 
 H                  2.46287300   -2.61118300   -1.89127200 
 H                  2.02705500   -3.40515100    0.36376100 
 H                  2.90911900   -3.27261600    2.68489500 
 H                  4.63186100   -2.32274600   -1.24549300 
 I                  7.50088700   -1.28117800   -0.44655700 
 I                  3.63690100    3.40194800    0.27111800 
 I                 -7.50089400    1.28115900    0.44656300 
 I                 -3.63689000   -3.40194800   -0.27114900 
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APPENDIX C 
Supplementary Material for Chapter 5 
Crystal Structure Data for Complex 1 
Table C.1. Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for 1. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          Cl(1)       -3808(1)       1956(1)       -797(1)       60(1)  
          O(5)        -3988(3)       2455(2)      -1104(3)       88(2)  
          O(6)        -3053(3)       1759(2)       -874(3)       92(2)  
          O(7)        -4531(3)       1633(2)      -1184(3)       78(2)  
          O(8)        -3676(3)       1978(2)        -27(3)       95(2)  
          Cl(2)        4821(1)       1369(1)       1954(1)       71(1)  
          O(9)         5437(3)       1270(2)       2679(2)      111(2)  
          O(10)        3968(2)       1426(2)       1893(3)       95(2)  
          O(11)        5043(4)       1830(2)       1708(4)      150(3)  
          O(12)        4886(5)       1039(3)       1413(3)      151(3)  
          Ga(1)       -1336(1)       1575(1)       3077(1)       37(1)  
          N(1)         -875(3)       2331(2)       3328(2)       37(1)  
          C(1)         -311(3)       2558(2)       3093(3)       39(1)  
          C(2)          -51(3)       3057(2)       3272(3)       42(1)  
          C(3)         -416(4)       3330(2)       3676(3)       47(2)  
          C(4)         -989(4)       3099(2)       3928(3)       45(1)  
          C(5)        -1196(3)       2599(2)       3740(3)       38(1)  
          C(6)        -1807(4)       2314(2)       3997(3)       46(1)  
          N(2)        -2251(3)       1906(2)       3450(2)       39(1)  
          C(7)        -2577(3)       1519(2)       3836(3)       43(1)  
          C(8)        -1869(3)       1298(2)       4541(3)       37(1)  
          C(9)        -2066(4)       1216(2)       5162(3)       42(1)  
          C(10)       -1479(4)        984(2)       5800(3)       46(1)  
          C(11)        -703(4)        805(2)       5814(3)       41(1)  
          C(12)        -488(3)        901(2)       5216(3)       37(1)  
          C(13)       -1037(3)       1172(2)       4572(3)       37(1)  
          O(1)         -747(2)       1297(1)       4054(2)       40(1)  
          C(14)       -2987(4)       2105(2)       2788(3)       47(2)  
          C(15)       -2724(3)       2239(2)       2148(3)       42(1)  
          N(3)        -2280(3)       1793(2)       1992(2)       37(1)  
          C(16)       -2918(3)       1375(2)       1637(3)       42(1)  
          C(17)       -2711(3)        892(2)       2070(3)       37(1)  
          C(18)       -3236(4)        467(2)       1839(3)       42(1)  
          C(19)       -2975(4)         15(2)       2233(3)       52(2)  
          C(20)       -2194(4)          0(2)       2848(3)       46(1)  
          C(21)       -1716(3)        438(2)       3068(3)       38(1)  
          N(4)        -1969(3)        881(2)       2693(2)       39(1)  
          C(22)       -1814(3)       1926(2)       1495(3)       37(1)  
          C(23)       -1287(3)       1487(2)       1414(3)       35(1)  
          C(24)       -1453(3)       1282(2)        705(3)       37(1)  
          C(25)        -936(3)        899(2)        629(3)       38(1)  
          C(26)        -244(4)        712(2)       1241(3)       41(1)  
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          C(27)         -91(3)        915(2)       1945(3)       36(1)  
          C(28)        -602(3)       1291(2)       2050(3)       37(1)  
          O(2)         -444(2)       1468(1)       2741(2)       40(1)  
          I(1)        -1787(1)        904(1)       6741(1)       63(1)  
          I(2)          710(1)        655(1)       5257(1)       47(1)  
          I(3)        -1232(1)        549(1)       -422(1)       49(1)  
          I(4)          940(1)        632(1)       2895(1)       47(1)  
          Ga(2)        2544(1)       2857(1)       3556(1)       35(1)  
          N(5)         2131(3)       2494(2)       4309(2)       37(1)  
          C(29)        1490(4)       2147(2)       4116(3)       44(1)  
          C(30)        1238(4)       1928(2)       4651(3)       47(2)  
          C(31)        1662(4)       2070(3)       5385(4)       53(2)  
          C(32)        2313(4)       2430(2)       5582(3)       50(2)  
          C(33)        2537(3)       2634(2)       5026(3)       38(1)  
          C(34)        3235(4)       3020(2)       5187(3)       45(1)  
          N(6)         3591(3)       3017(2)       4602(2)       41(1)  
          C(35)        3972(3)       3522(2)       4567(3)       45(2)  
          C(36)        3355(3)       3960(2)       4430(3)       41(1)  
          C(37)        3696(3)       4414(2)       4809(3)       41(1)  
          C(38)        3191(4)       4846(2)       4700(3)       41(1)  
          C(39)        2338(3)       4841(2)       4192(3)       35(1)  
          C(40)        2007(3)       4391(2)       3831(3)       32(1)  
          C(41)        2474(3)       3938(2)       3938(3)       34(1)  
          O(3)         2083(2)       3509(1)       3596(2)       36(1)  
          C(42)        4273(4)       2616(2)       4750(3)       50(2)  
          C(43)        3894(4)       2121(2)       4378(3)       46(2)  
          N(7)         3337(3)       2210(2)       3570(3)       40(1)  
          C(44)        3904(4)       2315(2)       3156(3)       47(2)  
          C(45)        3674(4)       2811(2)       2721(3)       43(1)  
          C(46)        4046(4)       2935(3)       2223(3)       52(2)  
          C(47)        3796(4)       3386(3)       1834(3)       57(2)  
          C(48)        3184(4)       3699(2)       1933(3)       51(2)  
          C(49)        2846(4)       3534(2)       2430(3)       47(2)  
          N(8)         3087(3)       3113(2)       2832(2)       39(1)  
          C(50)        2775(3)       1760(2)       3239(3)       40(1)  
          C(51)        2123(3)       1849(2)       2430(3)       37(1)  
          C(52)        2100(3)       1502(2)       1881(3)       40(1)  
          C(53)        1453(4)       1528(2)       1172(3)       39(1)  
          C(54)         835(3)       1903(2)        999(3)       37(1)  
          C(55)         885(3)       2264(2)       1539(3)       34(1)  
          C(56)        1534(3)       2253(2)       2263(3)       37(1)  
          O(4)         1549(2)       2602(1)       2761(2)       36(1)  
          I(5)         3746(1)       5520(1)       5285(1)       50(1)  
          I(6)          708(1)       4391(1)       3049(1)       37(1)  
          I(7)         1468(1)       1007(1)        360(1)       51(1)  
          I(8)          -28(1)       2857(1)       1252(1)       39(1)  
         ________________________________________________________________  
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Table C.2. Bond lengths [A] and angles [deg] for 1  
           _____________________________________________________________  
   
            Cl(1)-O(5)                    1.419(5)  
            Cl(1)-O(8)                    1.422(6)  
            Cl(1)-O(7)                    1.425(5)  
            Cl(1)-O(6)                    1.432(5)  
            Cl(2)-O(12)                   1.3984(10)  
            Cl(2)-O(10)                   1.3994(10)  
            Cl(2)-O(9)                    1.3997(10)  
            Cl(2)-O(11)                   1.4019(10)  
            Ga(1)-O(2)                    1.880(3)  
            Ga(1)-O(1)                    1.900(3)  
            Ga(1)-N(4)                    2.091(5)  
            Ga(1)-N(1)                    2.113(5)  
            Ga(1)-N(2)                    2.127(4)  
            Ga(1)-N(3)                    2.149(4)  
            N(1)-C(5)                     1.329(6)  
            N(1)-C(1)                     1.344(6)  
            C(1)-C(2)                     1.380(8)  
            C(2)-C(3)                     1.373(7)  
            C(3)-C(4)                     1.380(8)  
            C(4)-C(5)                     1.368(8)  
            C(5)-C(6)                     1.508(8)  
            C(6)-N(2)                     1.484(7)  
            N(2)-C(14)                    1.480(6)  
            N(2)-C(7)                     1.489(6)  
            C(7)-C(8)                     1.525(7)  
            C(8)-C(9)                     1.387(7)  
            C(8)-C(13)                    1.415(7)  
            C(9)-C(10)                    1.380(7)  
            C(10)-C(11)                   1.377(8)  
            C(10)-I(1)                    2.097(6)  
            C(11)-C(12)                   1.370(7)  
            C(12)-C(13)                   1.414(7)  
            C(12)-I(2)                    2.086(5)  
            C(13)-O(1)                    1.321(6)  
            C(14)-C(15)                   1.515(7)  
            C(15)-N(3)                    1.482(6)  
            N(3)-C(16)                    1.495(7)  
            N(3)-C(22)                    1.505(6)  
            C(16)-C(17)                   1.483(7)  
            C(17)-N(4)                    1.348(6)  
            C(17)-C(18)                   1.382(7)  
            C(18)-C(19)                   1.382(8)  
            C(19)-C(20)                   1.380(8)  
            C(20)-C(21)                   1.368(8)  
            C(21)-N(4)                    1.347(7)  
            C(22)-C(23)                   1.498(7)  
            C(23)-C(24)                   1.396(7)  
            C(23)-C(28)                   1.409(7)  
            C(24)-C(25)                   1.375(7)  
            C(25)-C(26)                   1.380(7)  
            C(25)-I(3)                    2.107(5)  
            C(26)-C(27)                   1.391(7)  
            C(27)-C(28)                   1.374(7)  
            C(27)-I(4)                    2.100(5)  
            C(28)-O(2)                    1.342(6)  
            Ga(2)-O(4)                    1.890(3)  
            Ga(2)-O(3)                    1.893(3)  
            Ga(2)-N(8)                    2.066(4)  
            Ga(2)-N(5)                    2.081(4)  
            Ga(2)-N(6)                    2.134(4)  
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            Ga(2)-N(7)                    2.153(4)  
            N(5)-C(33)                    1.334(6)  
            N(5)-C(29)                    1.345(7)  
            C(29)-C(30)                   1.390(8)  
            C(30)-C(31)                   1.366(8)  
            C(31)-C(32)                   1.380(8)  
            C(32)-C(33)                   1.384(8)  
            C(33)-C(34)                   1.486(8)  
            C(34)-N(6)                    1.478(7)  
            N(6)-C(35)                    1.486(7)  
            N(6)-C(42)                    1.496(7)  
            C(35)-C(36)                   1.498(7)  
            C(36)-C(37)                   1.398(7)  
            C(36)-C(41)                   1.410(7)  
            C(37)-C(38)                   1.380(8)  
            C(38)-C(39)                   1.381(7)  
            C(38)-I(5)                    2.108(5)  
            C(39)-C(40)                   1.372(7)  
            C(40)-C(41)                   1.393(7)  
            C(40)-I(6)                    2.106(5)  
            C(41)-O(3)                    1.337(6)  
            C(42)-C(43)                   1.500(8)  
            C(43)-N(7)                    1.491(7)  
            N(7)-C(50)                    1.487(7)  
            N(7)-C(44)                    1.496(7)  
            C(44)-C(45)                   1.514(8)  
            C(45)-N(8)                    1.349(7)  
            C(45)-C(46)                   1.381(8)  
            C(46)-C(47)                   1.377(9)  
            C(47)-C(48)                   1.389(8)  
            C(48)-C(49)                   1.368(8)  
            C(49)-N(8)                    1.320(7)  
            C(50)-C(51)                   1.534(7)  
            C(51)-C(52)                   1.388(7)  
            C(51)-C(56)                   1.399(7)  
            C(52)-C(53)                   1.376(7)  
            C(53)-C(54)                   1.371(7)  
            C(53)-I(7)                    2.094(5)  
            C(54)-C(55)                   1.389(7)  
            C(55)-C(56)                   1.394(7)  
            C(55)-I(8)                    2.100(5)  
            C(56)-O(4)                    1.324(6)  
   
            O(5)-Cl(1)-O(8)             108.7(4)  
            O(5)-Cl(1)-O(7)             109.4(3)  
            O(8)-Cl(1)-O(7)             108.7(3)  
            O(5)-Cl(1)-O(6)             109.7(3)  
            O(8)-Cl(1)-O(6)             110.5(3)  
            O(7)-Cl(1)-O(6)             109.7(3)  
            O(12)-Cl(2)-O(10)           112.7(4)  
            O(12)-Cl(2)-O(9)            113.0(4)  
            O(10)-Cl(2)-O(9)            115.4(4)  
            O(12)-Cl(2)-O(11)            99.6(5)  
            O(10)-Cl(2)-O(11)           106.4(4)  
            O(9)-Cl(2)-O(11)            108.1(4)  
            O(2)-Ga(1)-O(1)              96.65(15)  
            O(2)-Ga(1)-N(4)              96.31(16)  
            O(1)-Ga(1)-N(4)              90.62(16)  
            O(2)-Ga(1)-N(1)              87.07(16)  
            O(1)-Ga(1)-N(1)              97.62(16)  
            N(4)-Ga(1)-N(1)             170.69(16)  
            O(2)-Ga(1)-N(2)             164.47(17)  
            O(1)-Ga(1)-N(2)              88.83(15)  
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            N(4)-Ga(1)-N(2)              98.15(17)  
            N(1)-Ga(1)-N(2)              77.78(17)  
            O(2)-Ga(1)-N(3)              94.62(15)  
            O(1)-Ga(1)-N(3)             165.44(16)  
            N(4)-Ga(1)-N(3)              78.99(17)  
            N(1)-Ga(1)-N(3)              92.13(16)  
            N(2)-Ga(1)-N(3)              82.66(16)  
            C(5)-N(1)-C(1)              118.5(5)  
            C(5)-N(1)-Ga(1)             115.8(4)  
            C(1)-N(1)-Ga(1)             125.6(4)  
            N(1)-C(1)-C(2)              122.1(5)  
            C(3)-C(2)-C(1)              117.9(5)  
            C(2)-C(3)-C(4)              120.5(6)  
            C(5)-C(4)-C(3)              117.7(5)  
            N(1)-C(5)-C(4)              123.2(5)  
            N(1)-C(5)-C(6)              115.4(5)  
            C(4)-C(5)-C(6)              121.4(5)  
            N(2)-C(6)-C(5)              109.7(5)  
            C(6)-N(2)-C(14)             112.0(4)  
            C(6)-N(2)-C(7)              108.3(4)  
            C(14)-N(2)-C(7)             109.2(4)  
            C(6)-N(2)-Ga(1)             108.1(3)  
            C(14)-N(2)-Ga(1)            108.6(3)  
            C(7)-N(2)-Ga(1)             110.7(3)  
            N(2)-C(7)-C(8)              113.4(4)  
            C(9)-C(8)-C(13)             120.0(5)  
            C(9)-C(8)-C(7)              117.8(5)  
            C(13)-C(8)-C(7)             122.2(5)  
            C(10)-C(9)-C(8)             121.0(5)  
            C(11)-C(10)-C(9)            120.1(5)  
            C(11)-C(10)-I(1)            120.6(4)  
            C(9)-C(10)-I(1)             119.3(4)  
            C(12)-C(11)-C(10)           119.2(5)  
            C(11)-C(12)-C(13)           122.7(5)  
            C(11)-C(12)-I(2)            119.2(4)  
            C(13)-C(12)-I(2)            118.1(4)  
            O(1)-C(13)-C(12)            119.1(5)  
            O(1)-C(13)-C(8)             124.6(5)  
            C(12)-C(13)-C(8)            116.3(5)  
            C(13)-O(1)-Ga(1)            130.5(3)  
            N(2)-C(14)-C(15)            112.1(4)  
            N(3)-C(15)-C(14)            108.7(4)  
            C(15)-N(3)-C(16)            110.2(4)  
            C(15)-N(3)-C(22)            112.4(4)  
            C(16)-N(3)-C(22)            109.7(4)  
            C(15)-N(3)-Ga(1)            104.2(3)  
            C(16)-N(3)-Ga(1)            111.8(3)  
            C(22)-N(3)-Ga(1)            108.6(3)  
            C(17)-C(16)-N(3)            113.6(4)  
            N(4)-C(17)-C(18)            121.1(5)  
            N(4)-C(17)-C(16)            116.9(5)  
            C(18)-C(17)-C(16)           122.0(5)  
            C(19)-C(18)-C(17)           119.3(5)  
            C(20)-C(19)-C(18)           119.2(6)  
            C(21)-C(20)-C(19)           118.9(6)  
            N(4)-C(21)-C(20)            122.4(5)  
            C(17)-N(4)-C(21)            118.9(5)  
            C(17)-N(4)-Ga(1)            117.3(4)  
            C(21)-N(4)-Ga(1)            123.5(4)  
            C(23)-C(22)-N(3)            111.7(4)  
            C(24)-C(23)-C(28)           119.7(5)  
            C(24)-C(23)-C(22)           120.3(5)  
            C(28)-C(23)-C(22)           120.0(5)  
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            C(25)-C(24)-C(23)           119.9(5)  
            C(24)-C(25)-C(26)           121.4(5)  
            C(24)-C(25)-I(3)            120.4(4)  
            C(26)-C(25)-I(3)            118.1(4)  
            C(25)-C(26)-C(27)           118.1(5)  
            C(28)-C(27)-C(26)           122.5(5)  
            C(28)-C(27)-I(4)            118.0(4)  
            C(26)-C(27)-I(4)            119.5(4)  
            O(2)-C(28)-C(27)            120.6(5)  
            O(2)-C(28)-C(23)            121.1(5)  
            C(27)-C(28)-C(23)           118.3(5)  
            C(28)-O(2)-Ga(1)            122.0(3)  
            O(4)-Ga(2)-O(3)              96.24(14)  
            O(4)-Ga(2)-N(8)              92.72(16)  
            O(3)-Ga(2)-N(8)              91.87(16)  
            O(4)-Ga(2)-N(5)              88.66(16)  
            O(3)-Ga(2)-N(5)              97.40(16)  
            N(8)-Ga(2)-N(5)             170.43(17)  
            O(4)-Ga(2)-N(6)             166.78(17)  
            O(3)-Ga(2)-N(6)              88.86(15)  
            N(8)-Ga(2)-N(6)              99.32(18)  
            N(5)-Ga(2)-N(6)              78.57(17)  
            O(4)-Ga(2)-N(7)              94.27(16)  
            O(3)-Ga(2)-N(7)             166.99(16)  
            N(8)-Ga(2)-N(7)              79.98(18)  
            N(5)-Ga(2)-N(7)              90.47(17)  
            N(6)-Ga(2)-N(7)              82.55(17)  
            C(33)-N(5)-C(29)            119.9(5)  
            C(33)-N(5)-Ga(2)            115.5(4)  
            C(29)-N(5)-Ga(2)            124.7(4)  
            N(5)-C(29)-C(30)            121.3(5)  
            C(31)-C(30)-C(29)           118.6(6)  
            C(30)-C(31)-C(32)           120.2(6)  
            C(31)-C(32)-C(33)           118.8(6)  
            N(5)-C(33)-C(32)            121.4(5)  
            N(5)-C(33)-C(34)            116.1(5)  
            C(32)-C(33)-C(34)           122.5(5)  
            N(6)-C(34)-C(33)            111.2(4)  
            C(34)-N(6)-C(35)            110.1(4)  
            C(34)-N(6)-C(42)            111.7(4)  
            C(35)-N(6)-C(42)            108.9(4)  
            C(34)-N(6)-Ga(2)            107.3(3)  
            C(35)-N(6)-Ga(2)            109.9(3)  
            C(42)-N(6)-Ga(2)            108.9(3)  
            N(6)-C(35)-C(36)            114.2(4)  
            C(37)-C(36)-C(41)           119.4(5)  
            C(37)-C(36)-C(35)           116.8(5)  
            C(41)-C(36)-C(35)           123.8(5)  
            C(38)-C(37)-C(36)           121.4(5)  
            C(39)-C(38)-C(37)           120.2(5)  
            C(39)-C(38)-I(5)            120.3(4)  
            C(37)-C(38)-I(5)            119.5(4)  
            C(38)-C(39)-C(40)           117.9(5)  
            C(39)-C(40)-C(41)           124.5(5)  
            C(39)-C(40)-I(6)            117.4(4)  
            C(41)-C(40)-I(6)            118.0(4)  
            O(3)-C(41)-C(40)            120.4(4)  
            O(3)-C(41)-C(36)            123.1(5)  
            C(40)-C(41)-C(36)           116.4(5)  
            C(41)-O(3)-Ga(2)            130.7(3)  
            N(6)-C(42)-C(43)            111.6(4)  
            N(7)-C(43)-C(42)            109.9(5)  
            C(50)-N(7)-C(43)            110.8(4)  
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            C(50)-N(7)-C(44)            110.3(4)  
            C(43)-N(7)-C(44)            109.0(4)  
            C(50)-N(7)-Ga(2)            109.6(3)  
            C(43)-N(7)-Ga(2)            105.2(3)  
            C(44)-N(7)-Ga(2)            111.8(3)  
            N(7)-C(44)-C(45)            112.4(5)  
            N(8)-C(45)-C(46)            122.5(6)  
            N(8)-C(45)-C(44)            117.2(5)  
            C(46)-C(45)-C(44)           120.3(5)  
            C(47)-C(46)-C(45)           117.5(6)  
            C(46)-C(47)-C(48)           120.9(6)  
            C(49)-C(48)-C(47)           116.7(6)  
            N(8)-C(49)-C(48)            124.4(6)  
            C(49)-N(8)-C(45)            118.0(5)  
            C(49)-N(8)-Ga(2)            124.0(4)  
            C(45)-N(8)-Ga(2)            117.8(4)  
            N(7)-C(50)-C(51)            113.2(4)  
            C(52)-C(51)-C(56)           121.2(5)  
            C(52)-C(51)-C(50)           118.4(5)  
            C(56)-C(51)-C(50)           120.3(5)  
            C(53)-C(52)-C(51)           120.2(5)  
            C(52)-C(53)-C(54)           120.1(5)  
            C(52)-C(53)-I(7)            118.6(4)  
            C(54)-C(53)-I(7)            121.3(4)  
            C(53)-C(54)-C(55)           119.4(5)  
            C(54)-C(55)-C(56)           122.2(5)  
            C(54)-C(55)-I(8)            119.1(4)  
            C(56)-C(55)-I(8)            118.6(4)  
            O(4)-C(56)-C(55)            120.1(5)  
            O(4)-C(56)-C(51)            123.3(5)  
            C(55)-C(56)-C(51)           116.6(5)  
            C(56)-O(4)-Ga(2)            126.5(3)  
           _____________________________________________________________  
   
Symmetry transformations used to generate equivalent atoms. 
             
 
 
 
Table C.3. Anisotropic displacement parameters (A^2 x 10^3) for 1. The anisotropic 
displacement factor exponent takes the form:  -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    Cl(1)    28(1)      72(1)      73(1)      38(1)      12(1)       8(1)  
    O(5)     54(3)      78(4)     137(5)      59(3)      42(3)      19(3)  
    O(6)     42(3)      81(4)     152(5)      47(4)      38(3)      15(3)  
    O(7)     41(3)     103(4)      82(3)      26(3)      17(2)       3(3)  
    O(8)     44(3)     140(5)      78(4)       4(3)       0(3)       2(3)  
    Cl(2)    33(1)     119(2)      50(1)     -16(1)       6(1)      11(1)  
    O(9)     83(4)     142(6)      63(3)      31(3)     -19(3)     -42(4)  
    O(10)    50(3)     147(5)     100(4)     -17(4)      43(3)      -2(3)  
    O(11)    56(4)     244(10)    113(5)      69(6)      -6(4)      -4(5)  
    O(12)   127(6)     194(8)     130(6)     -51(5)      50(5)      57(6)  
    Ga(1)    28(1)      41(1)      39(1)       7(1)      11(1)       6(1)  
    N(1)     30(2)      41(3)      37(3)       7(2)      10(2)       8(2)  
    C(1)     34(3)      44(4)      38(3)       5(3)      15(3)       6(3)  
    C(2)     35(3)      44(4)      47(3)      12(3)      15(3)       2(3)  
    C(3)     52(4)      38(3)      56(4)      -1(3)      27(3)       3(3)  
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    C(4)     50(4)      49(4)      41(3)       4(3)      23(3)       6(3)  
    C(5)     36(3)      43(4)      35(3)      11(3)      14(3)       8(3)  
    C(6)     45(3)      48(4)      49(4)      11(3)      23(3)       9(3)  
    N(2)     30(2)      45(3)      42(3)      15(2)      16(2)       8(2)  
    C(7)     32(3)      50(4)      47(3)      14(3)      17(3)       8(3)  
    C(8)     28(3)      44(3)      36(3)       3(2)      10(2)       2(2)  
    C(9)     39(3)      43(3)      42(3)       8(3)      14(3)      -1(3)  
    C(10)    43(3)      47(4)      48(4)       5(3)      18(3)       0(3)  
    C(11)    38(3)      36(3)      40(3)       7(2)       7(3)      -2(3)  
    C(12)    31(3)      36(3)      41(3)       4(2)      11(2)       1(2)  
    C(13)    31(3)      45(3)      36(3)       2(2)      14(2)      -3(3)  
    O(1)     24(2)      48(2)      42(2)       8(2)       7(2)       7(2)  
    C(14)    39(3)      61(4)      44(3)      17(3)      18(3)      14(3)  
    C(15)    33(3)      44(3)      48(3)       5(3)      16(3)      14(3)  
    N(3)     30(2)      38(3)      42(3)      11(2)      13(2)       5(2)  
    C(16)    24(3)      50(4)      45(3)      14(3)       5(2)       4(3)  
    C(17)    33(3)      44(3)      38(3)       3(3)      17(3)       6(3)  
    C(18)    35(3)      45(4)      44(3)       2(3)      13(3)       3(3)  
    C(19)    52(4)      49(4)      53(4)       6(3)      19(3)       1(3)  
    C(20)    43(3)      48(4)      43(3)       5(3)      13(3)      16(3)  
    C(21)    31(3)      46(4)      34(3)       1(3)       9(2)       4(3)  
    N(4)     30(2)      43(3)      39(3)       7(2)       9(2)       6(2)  
    C(22)    32(3)      38(3)      38(3)      10(2)      11(2)       2(2)  
    C(23)    29(3)      32(3)      46(3)       6(2)      17(3)       2(2)  
    C(24)    30(3)      32(3)      48(3)       3(3)      15(3)      -1(2)  
    C(25)    36(3)      39(3)      39(3)      -5(2)      15(3)      -7(3)  
    C(26)    39(3)      33(3)      58(4)       2(3)      26(3)       1(3)  
    C(27)    26(3)      32(3)      51(3)       4(3)      15(3)      -3(2)  
    C(28)    33(3)      38(3)      45(3)       3(3)      20(3)      -1(3)  
    O(2)     28(2)      46(2)      43(2)       4(2)      13(2)       5(2)  
    I(1)     57(1)      85(1)      51(1)      20(1)      25(1)      14(1)  
    I(2)     34(1)      49(1)      52(1)      12(1)      10(1)       7(1)  
    I(3)     55(1)      41(1)      55(1)      -3(1)      26(1)      -2(1)  
    I(4)     32(1)      44(1)      59(1)       9(1)      12(1)       7(1)  
    Ga(2)    28(1)      36(1)      38(1)      -4(1)       9(1)       2(1)  
    N(5)     27(2)      37(3)      40(3)       0(2)       8(2)       4(2)  
    C(29)    35(3)      45(4)      47(3)       3(3)       9(3)      11(3)  
    C(30)    36(3)      47(4)      59(4)       5(3)      18(3)       2(3)  
    C(31)    45(4)      64(4)      58(4)       7(3)      30(3)       9(3)  
    C(32)    49(4)      48(4)      46(4)       0(3)      12(3)      15(3)  
    C(33)    39(3)      39(3)      33(3)       0(2)      11(3)      14(3)  
    C(34)    44(3)      49(4)      34(3)      -6(3)       6(3)       5(3)  
    N(6)     31(2)      36(3)      47(3)      -7(2)       4(2)       3(2)  
    C(35)    23(3)      56(4)      47(3)     -10(3)       5(3)       6(3)  
    C(36)    32(3)      47(4)      42(3)      -1(3)      14(3)       5(3)  
    C(37)    29(3)      47(4)      43(3)     -12(3)      11(2)      -7(3)  
    C(38)    38(3)      45(4)      43(3)     -10(3)      18(3)     -11(3)  
    C(39)    36(3)      31(3)      42(3)       2(2)      18(3)      -2(2)  
    C(40)    24(3)      41(3)      32(3)      -3(2)      11(2)      -1(2)  
    C(41)    23(3)      43(3)      33(3)      -6(2)       9(2)      -7(2)  
    O(3)     28(2)      38(2)      38(2)      -7(2)       8(2)       0(2)  
    C(42)    36(3)      46(4)      50(4)     -11(3)      -2(3)      12(3)  
    C(43)    35(3)      49(4)      47(3)      -2(3)       7(3)      11(3)  
    N(7)     28(2)      36(3)      51(3)      -5(2)      11(2)       4(2)  
    C(44)    33(3)      45(4)      62(4)     -11(3)      18(3)      -1(3)  
    C(45)    36(3)      41(3)      47(3)      -9(3)      13(3)      -3(3)  
    C(46)    39(3)      62(4)      52(4)      -9(3)      17(3)       2(3)  
    C(47)    57(4)      68(5)      48(4)       1(3)      22(3)      -8(4)  
    C(48)    52(4)      53(4)      47(4)      -1(3)      18(3)       8(3)  
    C(49)    45(3)      51(4)      47(3)      -2(3)      22(3)       5(3)  
    N(8)     32(2)      38(3)      46(3)      -2(2)      13(2)       2(2)  
    C(50)    31(3)      29(3)      54(3)       0(3)      11(3)       7(2)  
    C(51)    32(3)      38(3)      42(3)      -7(3)      16(3)      -9(3)  
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    C(52)    35(3)      39(3)      47(3)      -3(3)      17(3)      -3(3)  
    C(53)    44(3)      34(3)      46(3)      -3(3)      26(3)      -7(3)  
    C(54)    41(3)      32(3)      40(3)      -1(2)      19(3)       1(3)  
    C(55)    29(3)      34(3)      37(3)       2(2)      10(2)      -5(2)  
    C(56)    32(3)      40(3)      42(3)      -5(3)      19(3)      -6(3)  
    O(4)     29(2)      36(2)      37(2)      -8(2)       7(2)       1(2)  
    I(5)     45(1)      44(1)      55(1)     -12(1)      15(1)      -9(1)  
    I(6)     31(1)      38(1)      39(1)      -1(1)      11(1)       1(1)  
    I(7)     58(1)      47(1)      56(1)     -16(1)      30(1)      -5(1)  
    I(8)     38(1)      44(1)      35(1)       1(1)      13(1)       5(1)  
    _______________________________________________________________________  
 
 
 
 
Table C.4. Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 10^3) 
for 1.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)          -84          2369          2794          46  
          H(2)          368          3208          3120          51  
          H(3)         -273          3679          3784          57  
          H(4)        -1231          3281          4221          54  
          H(6A)       -1480          2163          4498          55  
          H(6B)       -2242          2553          4040          55  
          H(7A)       -2853          1237          3481          51  
          H(7B)       -3027          1677          3975          51  
          H(9)        -2614          1320          5147          50  
          H(11)        -322           617          6234          49  
          H(14A)      -3221          2413          2936          57  
          H(14B)      -3453          1846          2614          57  
          H(15A)      -3243          2327          1694          50  
          H(15B)      -2330          2536          2287          50  
          H(16A)      -3501          1491          1582          50  
          H(16B)      -2940          1309          1127          50  
          H(18)       -3772           484          1414          51  
          H(19)       -3328          -280          2082          62  
          H(20)       -1991          -310          3114          55  
          H(21)       -1187           429          3500          46  
          H(22A)      -2242          2026           993          44  
          H(22B)      -1427          2221          1712          44  
          H(24)       -1924          1407           276          45  
          H(26)         116           451          1183          50  
          H(29)        1204          2049          3604          53  
          H(30)         781          1686          4509          57  
          H(31)        1508          1920          5761          63  
          H(32)        2601          2536          6090          60  
          H(34A)       3000          3363          5210          54  
          H(34B)       3705          2948          5682          54  
          H(35A)       4187          3515          4160          54  
          H(35B)       4476          3581          5046          54  
          H(37)        4287          4427          5148          49  
          H(39)        1991          5139          4095          42  
          H(42A)       4572          2563          5299          60  
          H(42B)       4708          2735          4561          60  
          H(43A)       4365          1880          4423          56  
          H(43B)       3543          1967          4631          56  
          H(44A)       3849          2031          2803          56  
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          H(44B)       4516          2329          3520          56  
          H(46)        4459          2717          2153          62  
          H(47)        4046          3485          1493          69  
          H(48)        3009          4013          1670          61  
          H(49)        2408          3736          2489          56  
          H(50A)       2454          1674          3555          48  
          H(50B)       3146          1465          3248          48  
          H(52)        2532          1245          1997          48  
          H(54)         377          1916           514          44  
         ________________________________________________________________  
  
 
 
 
Table C.5. Torsion angles [deg] for 1  
         ________________________________________________________________  
   
          O(2)-Ga(1)-N(1)-C(5)                               -168.2(4)  
          O(1)-Ga(1)-N(1)-C(5)                                -71.9(4)  
          N(4)-Ga(1)-N(1)-C(5)                                 80.2(11)  
          N(2)-Ga(1)-N(1)-C(5)                                 15.2(3)  
          N(3)-Ga(1)-N(1)-C(5)                                 97.3(4)  
          O(2)-Ga(1)-N(1)-C(1)                                 13.4(4)  
          O(1)-Ga(1)-N(1)-C(1)                                109.7(4)  
          N(4)-Ga(1)-N(1)-C(1)                                -98.2(11)  
          N(2)-Ga(1)-N(1)-C(1)                               -163.1(4)  
          N(3)-Ga(1)-N(1)-C(1)                                -81.1(4)  
          C(5)-N(1)-C(1)-C(2)                                   0.6(7)  
          Ga(1)-N(1)-C(1)-C(2)                                179.0(4)  
          N(1)-C(1)-C(2)-C(3)                                  -2.8(8)  
          C(1)-C(2)-C(3)-C(4)                                   3.4(8)  
          C(2)-C(3)-C(4)-C(5)                                  -2.0(9)  
          C(1)-N(1)-C(5)-C(4)                                   1.0(8)  
          Ga(1)-N(1)-C(5)-C(4)                               -177.5(4)  
          C(1)-N(1)-C(5)-C(6)                                -178.6(5)  
          Ga(1)-N(1)-C(5)-C(6)                                  2.9(6)  
          C(3)-C(4)-C(5)-N(1)                                  -0.3(8)  
          C(3)-C(4)-C(5)-C(6)                                 179.2(5)  
          N(1)-C(5)-C(6)-N(2)                                 -28.5(6)  
          C(4)-C(5)-C(6)-N(2)                                 152.0(5)  
          C(5)-C(6)-N(2)-C(14)                                -80.6(5)  
          C(5)-C(6)-N(2)-C(7)                                 159.0(4)  
          C(5)-C(6)-N(2)-Ga(1)                                 39.0(5)  
          O(2)-Ga(1)-N(2)-C(6)                                -42.3(7)  
          O(1)-Ga(1)-N(2)-C(6)                                 68.8(3)  
          N(4)-Ga(1)-N(2)-C(6)                                159.2(3)  
          N(1)-Ga(1)-N(2)-C(6)                                -29.3(3)  
          N(3)-Ga(1)-N(2)-C(6)                               -123.1(3)  
          O(2)-Ga(1)-N(2)-C(14)                                79.4(7)  
          O(1)-Ga(1)-N(2)-C(14)                              -169.5(4)  
          N(4)-Ga(1)-N(2)-C(14)                               -79.1(4)  
          N(1)-Ga(1)-N(2)-C(14)                                92.4(4)  
          N(3)-Ga(1)-N(2)-C(14)                                -1.4(4)  
          O(2)-Ga(1)-N(2)-C(7)                               -160.7(5)  
          O(1)-Ga(1)-N(2)-C(7)                                -49.7(3)  
          N(4)-Ga(1)-N(2)-C(7)                                 40.8(4)  
          N(1)-Ga(1)-N(2)-C(7)                               -147.7(4)  
          N(3)-Ga(1)-N(2)-C(7)                                118.5(3)  
          C(6)-N(2)-C(7)-C(8)                                 -56.3(6)  
          C(14)-N(2)-C(7)-C(8)                               -178.5(5)  
          Ga(1)-N(2)-C(7)-C(8)                                 62.0(5)  
          N(2)-C(7)-C(8)-C(9)                                 139.9(5)  
          N(2)-C(7)-C(8)-C(13)                                -41.1(7)  
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          C(13)-C(8)-C(9)-C(10)                                -3.7(8)  
          C(7)-C(8)-C(9)-C(10)                                175.4(5)  
          C(8)-C(9)-C(10)-C(11)                                -3.7(9)  
          C(8)-C(9)-C(10)-I(1)                                176.8(4)  
          C(9)-C(10)-C(11)-C(12)                                6.0(9)  
          I(1)-C(10)-C(11)-C(12)                             -174.5(4)  
          C(10)-C(11)-C(12)-C(13)                              -1.1(9)  
          C(10)-C(11)-C(12)-I(2)                              177.5(4)  
          C(11)-C(12)-C(13)-O(1)                              172.8(5)  
          I(2)-C(12)-C(13)-O(1)                                -5.8(7)  
          C(11)-C(12)-C(13)-C(8)                               -6.0(8)  
          I(2)-C(12)-C(13)-C(8)                               175.4(4)  
          C(9)-C(8)-C(13)-O(1)                               -170.5(5)  
          C(7)-C(8)-C(13)-O(1)                                 10.4(9)  
          C(9)-C(8)-C(13)-C(12)                                 8.2(8)  
          C(7)-C(8)-C(13)-C(12)                              -170.8(5)  
          C(12)-C(13)-O(1)-Ga(1)                              170.9(4)  
          C(8)-C(13)-O(1)-Ga(1)                               -10.4(8)  
          O(2)-Ga(1)-O(1)-C(13)                              -167.9(5)  
          N(4)-Ga(1)-O(1)-C(13)                               -71.5(5)  
          N(1)-Ga(1)-O(1)-C(13)                               104.2(5)  
          N(2)-Ga(1)-O(1)-C(13)                                26.6(5)  
          N(3)-Ga(1)-O(1)-C(13)                               -27.4(9)  
          C(6)-N(2)-C(14)-C(15)                                93.4(6)  
          C(7)-N(2)-C(14)-C(15)                              -146.7(5)  
          Ga(1)-N(2)-C(14)-C(15)                              -25.9(6)  
          N(2)-C(14)-C(15)-N(3)                                52.2(6)  
          C(14)-C(15)-N(3)-C(16)                               70.8(5)  
          C(14)-C(15)-N(3)-C(22)                             -166.6(4)  
          C(14)-C(15)-N(3)-Ga(1)                              -49.2(5)  
          O(2)-Ga(1)-N(3)-C(15)                              -136.9(3)  
          O(1)-Ga(1)-N(3)-C(15)                                82.5(7)  
          N(4)-Ga(1)-N(3)-C(15)                               127.6(3)  
          N(1)-Ga(1)-N(3)-C(15)                               -49.6(3)  
          N(2)-Ga(1)-N(3)-C(15)                                27.8(3)  
          O(2)-Ga(1)-N(3)-C(16)                               104.2(3)  
          O(1)-Ga(1)-N(3)-C(16)                               -36.5(8)  
          N(4)-Ga(1)-N(3)-C(16)                                 8.7(3)  
          N(1)-Ga(1)-N(3)-C(16)                              -168.6(3)  
          N(2)-Ga(1)-N(3)-C(16)                               -91.2(3)  
          O(2)-Ga(1)-N(3)-C(22)                               -16.9(3)  
          O(1)-Ga(1)-N(3)-C(22)                              -157.6(6)  
          N(4)-Ga(1)-N(3)-C(22)                              -112.5(3)  
          N(1)-Ga(1)-N(3)-C(22)                                70.3(3)  
          N(2)-Ga(1)-N(3)-C(22)                               147.7(3)  
          C(15)-N(3)-C(16)-C(17)                             -121.1(5)  
          C(22)-N(3)-C(16)-C(17)                              114.7(5)  
          Ga(1)-N(3)-C(16)-C(17)                               -5.8(5)  
          N(3)-C(16)-C(17)-N(4)                                -3.2(7)  
          N(3)-C(16)-C(17)-C(18)                              178.5(5)  
          N(4)-C(17)-C(18)-C(19)                               -3.3(8)  
          C(16)-C(17)-C(18)-C(19)                             174.9(5)  
          C(17)-C(18)-C(19)-C(20)                              -0.1(9)  
          C(18)-C(19)-C(20)-C(21)                               2.5(9)  
          C(19)-C(20)-C(21)-N(4)                               -1.9(8)  
          C(18)-C(17)-N(4)-C(21)                                4.0(7)  
          C(16)-C(17)-N(4)-C(21)                             -174.3(5)  
          C(18)-C(17)-N(4)-Ga(1)                             -170.5(4)  
          C(16)-C(17)-N(4)-Ga(1)                               11.3(6)  
          C(20)-C(21)-N(4)-C(17)                               -1.4(8)  
          C(20)-C(21)-N(4)-Ga(1)                              172.7(4)  
          O(2)-Ga(1)-N(4)-C(17)                              -104.7(4)  
          O(1)-Ga(1)-N(4)-C(17)                               158.6(4)  
170 
 
          N(1)-Ga(1)-N(4)-C(17)                                 6.3(13)  
          N(2)-Ga(1)-N(4)-C(17)                                69.7(4)  
          N(3)-Ga(1)-N(4)-C(17)                               -11.2(4)  
          O(2)-Ga(1)-N(4)-C(21)                                81.2(4)  
          O(1)-Ga(1)-N(4)-C(21)                               -15.6(4)  
          N(1)-Ga(1)-N(4)-C(21)                              -167.9(9)  
          N(2)-Ga(1)-N(4)-C(21)                              -104.5(4)  
          N(3)-Ga(1)-N(4)-C(21)                               174.7(4)  
          C(15)-N(3)-C(22)-C(23)                              173.6(4)  
          C(16)-N(3)-C(22)-C(23)                              -63.6(5)  
          Ga(1)-N(3)-C(22)-C(23)                               58.9(5)  
          N(3)-C(22)-C(23)-C(24)                              120.1(5)  
          N(3)-C(22)-C(23)-C(28)                              -62.1(6)  
          C(28)-C(23)-C(24)-C(25)                              -1.6(8)  
          C(22)-C(23)-C(24)-C(25)                             176.2(5)  
          C(23)-C(24)-C(25)-C(26)                              -0.4(8)  
          C(23)-C(24)-C(25)-I(3)                              175.5(4)  
          C(24)-C(25)-C(26)-C(27)                               1.0(8)  
          I(3)-C(25)-C(26)-C(27)                             -175.0(4)  
          C(25)-C(26)-C(27)-C(28)                               0.4(8)  
          C(25)-C(26)-C(27)-I(4)                              178.9(4)  
          C(26)-C(27)-C(28)-O(2)                              178.4(5)  
          I(4)-C(27)-C(28)-O(2)                                -0.1(7)  
          C(26)-C(27)-C(28)-C(23)                              -2.3(8)  
          I(4)-C(27)-C(28)-C(23)                              179.2(4)  
          C(24)-C(23)-C(28)-O(2)                             -177.8(5)  
          C(22)-C(23)-C(28)-O(2)                                4.4(7)  
          C(24)-C(23)-C(28)-C(27)                               2.9(7)  
          C(22)-C(23)-C(28)-C(27)                            -174.9(5)  
          C(27)-C(28)-O(2)-Ga(1)                             -135.6(4)  
          C(23)-C(28)-O(2)-Ga(1)                               45.2(6)  
          O(1)-Ga(1)-O(2)-C(28)                               137.2(4)  
          N(4)-Ga(1)-O(2)-C(28)                                45.9(4)  
          N(1)-Ga(1)-O(2)-C(28)                              -125.4(4)  
          N(2)-Ga(1)-O(2)-C(28)                              -112.7(6)  
          N(3)-Ga(1)-O(2)-C(28)                               -33.5(4)  
          O(4)-Ga(2)-N(5)-C(33)                              -166.6(4)  
          O(3)-Ga(2)-N(5)-C(33)                               -70.4(4)  
          N(8)-Ga(2)-N(5)-C(33)                                95.0(11)  
          N(6)-Ga(2)-N(5)-C(33)                                16.9(4)  
          N(7)-Ga(2)-N(5)-C(33)                                99.2(4)  
          O(4)-Ga(2)-N(5)-C(29)                                11.9(4)  
          O(3)-Ga(2)-N(5)-C(29)                               108.1(4)  
          N(8)-Ga(2)-N(5)-C(29)                               -86.5(11)  
          N(6)-Ga(2)-N(5)-C(29)                              -164.6(4)  
          N(7)-Ga(2)-N(5)-C(29)                               -82.3(4)  
          C(33)-N(5)-C(29)-C(30)                               -0.1(8)  
          Ga(2)-N(5)-C(29)-C(30)                             -178.6(4)  
          N(5)-C(29)-C(30)-C(31)                               -0.5(8)  
          C(29)-C(30)-C(31)-C(32)                               1.3(9)  
          C(30)-C(31)-C(32)-C(33)                              -1.4(9)  
          C(29)-N(5)-C(33)-C(32)                                0.0(8)  
          Ga(2)-N(5)-C(33)-C(32)                              178.6(4)  
          C(29)-N(5)-C(33)-C(34)                             -179.8(5)  
          Ga(2)-N(5)-C(33)-C(34)                               -1.2(6)  
          C(31)-C(32)-C(33)-N(5)                                0.7(8)  
          C(31)-C(32)-C(33)-C(34)                            -179.4(5)  
          N(5)-C(33)-C(34)-N(6)                               -23.8(7)  
          C(32)-C(33)-C(34)-N(6)                              156.3(5)  
          C(33)-C(34)-N(6)-C(35)                              154.9(4)  
          C(33)-C(34)-N(6)-C(42)                              -84.0(5)  
          C(33)-C(34)-N(6)-Ga(2)                               35.4(5)  
          O(4)-Ga(2)-N(6)-C(34)                               -43.1(9)  
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          O(3)-Ga(2)-N(6)-C(34)                                69.9(3)  
          N(8)-Ga(2)-N(6)-C(34)                               161.6(3)  
          N(5)-Ga(2)-N(6)-C(34)                               -27.9(3)  
          N(7)-Ga(2)-N(6)-C(34)                              -119.9(4)  
          O(4)-Ga(2)-N(6)-C(35)                              -162.8(6)  
          O(3)-Ga(2)-N(6)-C(35)                               -49.8(3)  
          N(8)-Ga(2)-N(6)-C(35)                                41.9(4)  
          N(5)-Ga(2)-N(6)-C(35)                              -147.6(4)  
          N(7)-Ga(2)-N(6)-C(35)                               120.4(3)  
          O(4)-Ga(2)-N(6)-C(42)                                78.0(8)  
          O(3)-Ga(2)-N(6)-C(42)                              -169.0(4)  
          N(8)-Ga(2)-N(6)-C(42)                               -77.3(4)  
          N(5)-Ga(2)-N(6)-C(42)                                93.2(4)  
          N(7)-Ga(2)-N(6)-C(42)                                 1.2(4)  
          C(34)-N(6)-C(35)-C(36)                              -56.4(6)  
          C(42)-N(6)-C(35)-C(36)                             -179.2(5)  
          Ga(2)-N(6)-C(35)-C(36)                               61.5(5)  
          N(6)-C(35)-C(36)-C(37)                              142.6(5)  
          N(6)-C(35)-C(36)-C(41)                              -38.9(8)  
          C(41)-C(36)-C(37)-C(38)                              -1.2(8)  
          C(35)-C(36)-C(37)-C(38)                             177.4(5)  
          C(36)-C(37)-C(38)-C(39)                              -2.1(8)  
          C(36)-C(37)-C(38)-I(5)                             -179.8(4)  
          C(37)-C(38)-C(39)-C(40)                               2.9(8)  
          I(5)-C(38)-C(39)-C(40)                             -179.4(4)  
          C(38)-C(39)-C(40)-C(41)                              -0.5(8)  
          C(38)-C(39)-C(40)-I(6)                             -179.4(4)  
          C(39)-C(40)-C(41)-O(3)                              175.9(5)  
          I(6)-C(40)-C(41)-O(3)                                -5.2(6)  
          C(39)-C(40)-C(41)-C(36)                              -2.7(8)  
          I(6)-C(40)-C(41)-C(36)                              176.2(4)  
          C(37)-C(36)-C(41)-O(3)                             -175.1(5)  
          C(35)-C(36)-C(41)-O(3)                                6.3(8)  
          C(37)-C(36)-C(41)-C(40)                               3.4(8)  
          C(35)-C(36)-C(41)-C(40)                            -175.1(5)  
          C(40)-C(41)-O(3)-Ga(2)                              174.0(3)  
          C(36)-C(41)-O(3)-Ga(2)                               -7.4(7)  
          O(4)-Ga(2)-O(3)-C(41)                              -166.1(4)  
          N(8)-Ga(2)-O(3)-C(41)                               -73.2(4)  
          N(5)-Ga(2)-O(3)-C(41)                               104.4(4)  
          N(6)-Ga(2)-O(3)-C(41)                                26.1(4)  
          N(7)-Ga(2)-O(3)-C(41)                               -22.4(10)  
          C(34)-N(6)-C(42)-C(43)                               90.9(6)  
          C(35)-N(6)-C(42)-C(43)                             -147.3(5)  
          Ga(2)-N(6)-C(42)-C(43)                              -27.5(6)  
          N(6)-C(42)-C(43)-N(7)                                51.1(7)  
          C(42)-C(43)-N(7)-C(50)                             -164.9(4)  
          C(42)-C(43)-N(7)-C(44)                               73.5(6)  
          C(42)-C(43)-N(7)-Ga(2)                              -46.6(5)  
          O(4)-Ga(2)-N(7)-C(50)                               -23.5(4)  
          O(3)-Ga(2)-N(7)-C(50)                              -167.4(6)  
          N(8)-Ga(2)-N(7)-C(50)                              -115.5(4)  
          N(5)-Ga(2)-N(7)-C(50)                                65.2(4)  
          N(6)-Ga(2)-N(7)-C(50)                               143.6(4)  
          O(4)-Ga(2)-N(7)-C(43)                              -142.7(3)  
          O(3)-Ga(2)-N(7)-C(43)                                73.5(8)  
          N(8)-Ga(2)-N(7)-C(43)                               125.3(4)  
          N(5)-Ga(2)-N(7)-C(43)                               -54.0(3)  
          N(6)-Ga(2)-N(7)-C(43)                                24.4(3)  
          O(4)-Ga(2)-N(7)-C(44)                                99.1(3)  
          O(3)-Ga(2)-N(7)-C(44)                               -44.8(9)  
          N(8)-Ga(2)-N(7)-C(44)                                 7.1(3)  
          N(5)-Ga(2)-N(7)-C(44)                              -172.2(4)  
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          N(6)-Ga(2)-N(7)-C(44)                               -93.8(4)  
          C(50)-N(7)-C(44)-C(45)                              112.4(5)  
          C(43)-N(7)-C(44)-C(45)                             -125.7(5)  
          Ga(2)-N(7)-C(44)-C(45)                               -9.8(6)  
          N(7)-C(44)-C(45)-N(8)                                 7.9(7)  
          N(7)-C(44)-C(45)-C(46)                             -170.9(5)  
          N(8)-C(45)-C(46)-C(47)                                0.0(9)  
          C(44)-C(45)-C(46)-C(47)                             178.7(5)  
          C(45)-C(46)-C(47)-C(48)                              -0.8(9)  
          C(46)-C(47)-C(48)-C(49)                              -0.4(9)  
          C(47)-C(48)-C(49)-N(8)                                2.6(9)  
          C(48)-C(49)-N(8)-C(45)                               -3.5(9)  
          C(48)-C(49)-N(8)-Ga(2)                             -178.1(4)  
          C(46)-C(45)-N(8)-C(49)                                2.1(8)  
          C(44)-C(45)-N(8)-C(49)                             -176.7(5)  
          C(46)-C(45)-N(8)-Ga(2)                              177.0(4)  
          C(44)-C(45)-N(8)-Ga(2)                               -1.7(6)  
          O(4)-Ga(2)-N(8)-C(49)                                77.7(5)  
          O(3)-Ga(2)-N(8)-C(49)                               -18.7(5)  
          N(5)-Ga(2)-N(8)-C(49)                               175.7(9)  
          N(6)-Ga(2)-N(8)-C(49)                              -107.8(5)  
          N(7)-Ga(2)-N(8)-C(49)                               171.5(5)  
          O(4)-Ga(2)-N(8)-C(45)                               -96.9(4)  
          O(3)-Ga(2)-N(8)-C(45)                               166.7(4)  
          N(5)-Ga(2)-N(8)-C(45)                                 1.2(12)  
          N(6)-Ga(2)-N(8)-C(45)                                77.6(4)  
          N(7)-Ga(2)-N(8)-C(45)                                -3.1(4)  
          C(43)-N(7)-C(50)-C(51)                              174.3(4)  
          C(44)-N(7)-C(50)-C(51)                              -64.9(5)  
          Ga(2)-N(7)-C(50)-C(51)                               58.6(5)  
          N(7)-C(50)-C(51)-C(52)                              126.5(5)  
          N(7)-C(50)-C(51)-C(56)                              -57.3(6)  
          C(56)-C(51)-C(52)-C(53)                              -4.7(8)  
          C(50)-C(51)-C(52)-C(53)                             171.5(5)  
          C(51)-C(52)-C(53)-C(54)                               1.0(8)  
          C(51)-C(52)-C(53)-I(7)                              178.5(4)  
          C(52)-C(53)-C(54)-C(55)                               2.1(8)  
          I(7)-C(53)-C(54)-C(55)                             -175.4(4)  
          C(53)-C(54)-C(55)-C(56)                              -1.6(8)  
          C(53)-C(54)-C(55)-I(8)                              177.0(4)  
          C(54)-C(55)-C(56)-O(4)                             -179.3(5)  
          I(8)-C(55)-C(56)-O(4)                                 2.2(7)  
          C(54)-C(55)-C(56)-C(51)                              -1.9(8)  
          I(8)-C(55)-C(56)-C(51)                              179.5(4)  
          C(52)-C(51)-C(56)-O(4)                             -177.7(5)  
          C(50)-C(51)-C(56)-O(4)                                6.2(8)  
          C(52)-C(51)-C(56)-C(55)                               5.0(7)  
          C(50)-C(51)-C(56)-C(55)                            -171.1(5)  
          C(55)-C(56)-O(4)-Ga(2)                             -149.7(4)  
          C(51)-C(56)-O(4)-Ga(2)                               33.2(7)  
          O(3)-Ga(2)-O(4)-C(56)                               151.2(4)  
          N(8)-Ga(2)-O(4)-C(56)                                59.0(4)  
          N(5)-Ga(2)-O(4)-C(56)                              -111.5(4)  
          N(6)-Ga(2)-O(4)-C(56)                               -96.6(8)  
          N(7)-Ga(2)-O(4)-C(56)                               -21.1(4)  
         ________________________________________________________________  
   
 Symmetry transformations used to generate equivalent atoms. 
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Crystal Structure Data for Complex 2 
Table C.6. Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for 2. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          I(1)         6051(1)       8016(1)       6499(1)       36(1)  
          I(2)         8882(1)       4591(1)       5324(1)       34(1)  
          Zn(1)        5000          4147(1)       7500          23(1)  
          O(1)         6046(2)       5408(2)       7309(1)       25(1)  
          C(1)         6626(2)       5208(3)       6894(2)       22(1)  
          C(2)         6836(3)       6232(3)       6482(2)       24(1)  
          C(3)         7493(3)       6087(4)       6052(2)       27(1)  
          C(4)         7943(3)       4852(4)       6006(2)       28(1)  
          C(5)         7742(3)       3789(4)       6382(2)       31(1)  
          C(6)         7092(3)       3945(3)       6819(2)       26(1)  
          C(7)         6841(3)       2773(4)       7204(2)       30(1)  
          C(8)         5544(3)       1263(3)       7476(2)       35(1)  
          C(9)         5484(3)       2199(4)       6449(2)       32(1)  
          N(1)         5795(2)       2427(3)       7098(1)       28(1)  
          C(10)        4825(3)       3280(3)       6170(2)       28(1)  
          C(11)        4652(3)       3427(4)       5537(2)       35(1)  
          C(12)        4012(3)       4387(4)       5307(2)       40(1)  
          C(13)        3571(3)       5217(4)       5705(2)       39(1)  
          C(14)        3777(3)       5016(4)       6322(2)       32(1)  
          N(2)         4392(2)       4068(3)       6551(1)       27(1)  
         ________________________________________________________________  
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           Table C.7. Bond lengths [A] and angles [deg] for 2. 
           _____________________________________________________________  
   
            I(1)-C(2)                     2.081(3)  
            I(2)-C(4)                     2.095(3)  
            Zn(1)-O(1)                    1.992(2)  
            Zn(1)-O(1)#1                  1.992(2)  
            Zn(1)-N(2)#1                  2.169(3)  
            Zn(1)-N(2)                    2.169(3)  
            Zn(1)-N(1)#1                  2.259(3)  
            Zn(1)-N(1)                    2.259(3)  
            O(1)-C(1)                     1.290(4)  
            C(1)-C(2)                     1.410(5)  
            C(1)-C(6)                     1.427(4)  
            C(2)-C(3)                     1.383(5)  
            C(3)-C(4)                     1.384(5)  
            C(4)-C(5)                     1.384(5)  
            C(5)-C(6)                     1.390(5)  
            C(6)-C(7)                     1.499(5)  
            C(7)-N(1)                     1.487(5)  
            C(8)-N(1)                     1.484(5)  
            C(8)-C(8)#1                   1.524(9)  
            C(9)-N(1)                     1.464(5)  
            C(9)-C(10)                    1.499(5)  
            C(10)-N(2)                    1.332(4)  
            C(10)-C(11)                   1.391(5)  
            C(11)-C(12)                   1.364(6)  
            C(12)-C(13)                   1.386(6)  
            C(13)-C(14)                   1.372(6)  
            C(14)-N(2)                    1.333(5)  
   
            O(1)-Zn(1)-O(1)#1           102.20(13)  
            O(1)-Zn(1)-N(2)#1            90.23(11)  
            O(1)#1-Zn(1)-N(2)#1          92.38(11)  
            O(1)-Zn(1)-N(2)              92.38(11)  
            O(1)#1-Zn(1)-N(2)            90.23(11)  
            N(2)#1-Zn(1)-N(2)           175.83(16)  
            O(1)-Zn(1)-N(1)#1           162.04(11)  
            O(1)#1-Zn(1)-N(1)#1          89.88(10)  
            N(2)#1-Zn(1)-N(1)#1          75.88(11)  
            N(2)-Zn(1)-N(1)#1           100.90(11)  
            O(1)-Zn(1)-N(1)              89.88(10)  
            O(1)#1-Zn(1)-N(1)           162.04(11)  
            N(2)#1-Zn(1)-N(1)           100.90(11)  
            N(2)-Zn(1)-N(1)              75.88(11)  
            N(1)#1-Zn(1)-N(1)            81.80(15)  
            C(1)-O(1)-Zn(1)             124.9(2)  
            O(1)-C(1)-C(2)              121.7(3)  
            O(1)-C(1)-C(6)              122.5(3)  
            C(2)-C(1)-C(6)              115.8(3)  
            C(3)-C(2)-C(1)              123.7(3)  
            C(3)-C(2)-I(1)              118.9(2)  
            C(1)-C(2)-I(1)              117.3(2)  
            C(2)-C(3)-C(4)              118.3(3)  
            C(3)-C(4)-C(5)              120.8(3)  
            C(3)-C(4)-I(2)              118.6(3)  
            C(5)-C(4)-I(2)              120.5(3)  
            C(4)-C(5)-C(6)              120.7(3)  
            C(5)-C(6)-C(1)              120.6(3)  
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            C(5)-C(6)-C(7)              120.4(3)  
            C(1)-C(6)-C(7)              118.9(3)  
            N(1)-C(7)-C(6)              111.7(3)  
            N(1)-C(8)-C(8)#1            109.1(3)  
            N(1)-C(9)-C(10)             113.3(3)  
            C(9)-N(1)-C(8)              111.2(3)  
            C(9)-N(1)-C(7)              112.0(3)  
            C(8)-N(1)-C(7)              111.9(3)  
            C(9)-N(1)-Zn(1)             112.8(2)  
            C(8)-N(1)-Zn(1)             102.7(2)  
            C(7)-N(1)-Zn(1)             105.7(2)  
            N(2)-C(10)-C(11)            121.4(4)  
            N(2)-C(10)-C(9)             117.3(3)  
            C(11)-C(10)-C(9)            121.3(3)  
            C(12)-C(11)-C(10)           118.9(4)  
            C(11)-C(12)-C(13)           119.6(4)  
            C(14)-C(13)-C(12)           118.3(4)  
            N(2)-C(14)-C(13)            122.4(4)  
            C(10)-N(2)-C(14)            119.3(3)  
            C(10)-N(2)-Zn(1)            117.9(3)  
            C(14)-N(2)-Zn(1)            120.5(2)  
           _____________________________________________________________  
   Symmetry transformations used to generate equivalent atoms:  
           #1 -x+1,y,-z+3/2      
 
 
 
 
Table C.8. Anisotropic displacement parameters (A^2 x 10^3) for 2. The anisotropic 
displacement factor exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    I(1)     40(1)      24(1)      48(1)       9(1)      18(1)      11(1)  
    I(2)     32(1)      41(1)      33(1)      -6(1)      15(1)       2(1)  
    Zn(1)    31(1)      16(1)      22(1)       0          9(1)       0  
    O(1)     32(1)      20(1)      25(1)       0(1)      13(1)       2(1)  
    C(1)     26(2)      20(1)      22(2)       1(1)       5(1)       4(1)  
    C(2)     30(2)      21(1)      23(2)       1(1)       7(1)       4(1)  
    C(3)     30(2)      27(2)      25(2)       2(1)       8(1)       4(1)  
    C(4)     31(2)      32(2)      23(2)      -2(1)      10(1)       5(1)  
    C(5)     33(2)      25(2)      36(2)      -2(1)       8(2)       9(1)  
    C(6)     32(2)      24(2)      24(2)       2(1)       6(1)       7(1)  
    C(7)     40(2)      24(2)      28(2)       6(1)       9(2)      10(1)  
    C(8)     52(2)      16(1)      38(2)       1(1)      14(2)       3(2)  
    C(9)     45(2)      24(2)      29(2)      -8(1)      11(2)       3(2)  
    N(1)     37(2)      17(1)      30(2)       0(1)       9(1)       3(1)  
    C(10)    38(2)      22(2)      26(2)      -3(1)       9(2)      -3(1)  
    C(11)    52(3)      29(2)      26(2)      -6(2)      13(2)      -6(2)  
    C(12)    58(3)      37(2)      24(2)      -2(2)       4(2)      -4(2)  
    C(13)    44(2)      37(2)      34(2)       1(2)       0(2)       2(2)  
    C(14)    38(2)      29(2)      30(2)      -1(1)       8(2)       2(2)  
    N(2)     34(2)      25(1)      24(2)      -2(1)       8(1)       0(1)  
    _______________________________________________________________________  
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Table C.9. Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 10^3) 
for 2.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(3)         7631          6817          5794          32  
          H(5)         8052          2945          6340          37  
          H(11)        4973          2868          5271          42  
          H(12)        3870          4486          4876          48  
          H(13)        3137          5908          5553          46  
          H(14)        3471          5573          6598          38  
          H(7A)        6940(30)      2920(40)      7549(19)      16(10)  
          H(7B)        7240(30)      1970(40)      7136(18)      26(10)  
          H(8A)        5780(30)       490(40)      7283(18)      24(10)  
          H(8B)        5990(30)      1410(40)      7909(18)      20(9)  
          H(9A)        5970(30)      2160(40)      6290(20)      25(11)  
          H(9B)        5080(30)      1430(40)      6399(17)      22(10)  
         ________________________________________________________________  
  
 
 
 
Table C.10. Torsion angles [deg] for 2.  
         ________________________________________________________________  
   
          O(1)#1-Zn(1)-O(1)-C(1)                             -143.4(3)  
          N(2)#1-Zn(1)-O(1)-C(1)                              124.1(3)  
          N(2)-Zn(1)-O(1)-C(1)                                -52.7(3)  
          N(1)#1-Zn(1)-O(1)-C(1)                               85.2(4)  
          N(1)-Zn(1)-O(1)-C(1)                                 23.2(3)  
          Zn(1)-O(1)-C(1)-C(2)                                134.5(3)  
          Zn(1)-O(1)-C(1)-C(6)                                -45.2(5)  
          O(1)-C(1)-C(2)-C(3)                                 176.4(4)  
          C(6)-C(1)-C(2)-C(3)                                  -3.9(5)  
          O(1)-C(1)-C(2)-I(1)                                  -7.0(5)  
          C(6)-C(1)-C(2)-I(1)                                 172.7(3)  
          C(1)-C(2)-C(3)-C(4)                                   2.6(6)  
          I(1)-C(2)-C(3)-C(4)                                -174.0(3)  
          C(2)-C(3)-C(4)-C(5)                                  -0.1(6)  
          C(2)-C(3)-C(4)-I(2)                                 176.8(3)  
          C(3)-C(4)-C(5)-C(6)                                  -0.8(6)  
          I(2)-C(4)-C(5)-C(6)                                -177.6(3)  
          C(4)-C(5)-C(6)-C(1)                                  -0.7(6)  
          C(4)-C(5)-C(6)-C(7)                                 177.1(4)  
          O(1)-C(1)-C(6)-C(5)                                -177.4(4)  
          C(2)-C(1)-C(6)-C(5)                                   2.9(5)  
          O(1)-C(1)-C(6)-C(7)                                   4.8(6)  
          C(2)-C(1)-C(6)-C(7)                                -174.9(3)  
          C(5)-C(6)-C(7)-N(1)                                -117.6(4)  
          C(1)-C(6)-C(7)-N(1)                                  60.3(5)  
          C(10)-C(9)-N(1)-C(8)                                123.7(3)  
          C(10)-C(9)-N(1)-C(7)                               -110.3(4)  
          C(10)-C(9)-N(1)-Zn(1)                                 8.9(4)  
          C(8)#1-C(8)-N(1)-C(9)                               -73.6(4)  
          C(8)#1-C(8)-N(1)-C(7)                               160.3(3)  
          C(8)#1-C(8)-N(1)-Zn(1)                               47.4(4)  
          C(6)-C(7)-N(1)-C(9)                                  54.1(4)  
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          C(6)-C(7)-N(1)-C(8)                                 179.7(3)  
          C(6)-C(7)-N(1)-Zn(1)                                -69.3(3)  
          O(1)-Zn(1)-N(1)-C(9)                                -92.6(3)  
          O(1)#1-Zn(1)-N(1)-C(9)                               40.2(5)  
          N(2)#1-Zn(1)-N(1)-C(9)                              177.2(3)  
          N(2)-Zn(1)-N(1)-C(9)                                 -0.1(3)  
          N(1)#1-Zn(1)-N(1)-C(9)                              103.4(3)  
          O(1)-Zn(1)-N(1)-C(8)                                147.6(3)  
          O(1)#1-Zn(1)-N(1)-C(8)                              -79.6(4)  
          N(2)#1-Zn(1)-N(1)-C(8)                               57.4(3)  
          N(2)-Zn(1)-N(1)-C(8)                               -119.9(3)  
          N(1)#1-Zn(1)-N(1)-C(8)                              -16.4(2)  
          O(1)-Zn(1)-N(1)-C(7)                                 30.2(2)  
          O(1)#1-Zn(1)-N(1)-C(7)                              163.0(3)  
          N(2)#1-Zn(1)-N(1)-C(7)                              -60.0(2)  
          N(2)-Zn(1)-N(1)-C(7)                                122.7(2)  
          N(1)#1-Zn(1)-N(1)-C(7)                             -133.8(3)  
          N(1)-C(9)-C(10)-N(2)                                -18.2(5)  
          N(1)-C(9)-C(10)-C(11)                               163.6(4)  
          N(2)-C(10)-C(11)-C(12)                               -1.0(6)  
          C(9)-C(10)-C(11)-C(12)                              177.1(4)  
          C(10)-C(11)-C(12)-C(13)                               1.8(6)  
          C(11)-C(12)-C(13)-C(14)                              -1.7(7)  
          C(12)-C(13)-C(14)-N(2)                                0.8(6)  
          C(11)-C(10)-N(2)-C(14)                                0.1(5)  
          C(9)-C(10)-N(2)-C(14)                              -178.0(4)  
          C(11)-C(10)-N(2)-Zn(1)                             -163.0(3)  
          C(9)-C(10)-N(2)-Zn(1)                                18.9(4)  
          C(13)-C(14)-N(2)-C(10)                                0.0(6)  
          C(13)-C(14)-N(2)-Zn(1)                              162.6(3)  
          O(1)-Zn(1)-N(2)-C(10)                                79.1(3)  
          O(1)#1-Zn(1)-N(2)-C(10)                            -178.7(3)  
          N(2)#1-Zn(1)-N(2)-C(10)                             -49.8(3)  
          N(1)#1-Zn(1)-N(2)-C(10)                             -88.8(3)  
          N(1)-Zn(1)-N(2)-C(10)                               -10.2(3)  
          O(1)-Zn(1)-N(2)-C(14)                               -83.8(3)  
          O(1)#1-Zn(1)-N(2)-C(14)                              18.4(3)  
          N(2)#1-Zn(1)-N(2)-C(14)                             147.3(3)  
          N(1)#1-Zn(1)-N(2)-C(14)                             108.3(3)  
          N(1)-Zn(1)-N(2)-C(14)                              -173.1(3)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
         #1 -x+1,y,-z+3/2      
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Least-squares planes (x,y,z in crystal coordinates) and deviations from them (* indicates atom 
used to define plane). 
 
  9.4973 (0.0156) x + 2.9408 (0.0146) y + 13.0276 (0.0271) z = 16.7863 (0.0065)  
 
 *    0.0189 (0.0025)  C1 
 *   -0.0172 (0.0026)  C2 
 *    0.0035 (0.0027)  C3 
 *    0.0082 (0.0028)  C4 
 *   -0.0054 (0.0028)  C5 
 *   -0.0079 (0.0028)  C6 
      0.0671 (0.0051)  O1 
     -1.0474 (0.0063)  Zn1 
     -0.0885 (0.0065)  C7 
 
 Rms deviation of fitted atoms =   0.0117 
 
 
  10.5097 (0.0154) x + 6.4780 (0.0128) y - 1.4924 (0.0346) z = 6.2755 (0.0208)  
 
 Angle to previous plane (with approximate esd) = 44.15 ( 0.14 ) 
 
 *   -0.0007 (0.0026)  C10 
 *    0.0066 (0.0028)  C11 
 *   -0.0092 (0.0030)  C12 
 *    0.0058 (0.0030)  C13 
 *    0.0001 (0.0028)  C14 
 *   -0.0027 (0.0025)  N2 
      0.5465 (0.0054)  Zn1 
     -0.0500 (0.0065)  C9 
 
 Rms deviation of fitted atoms =   0.0053 
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Figure C.1. Unit cell crystal structure for complex 2. 
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APPENDIX D 
Supplementary Material for Chapter 6 
 
 
Figure D.6.2.1 Isotopic distribution for complex 3 (left) and 4 (right). Experimental results are 
represented by the bars, whereas simulated results are designated by the continuous spectra. 
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Figure D.6.2.3.1 
1
H- and 
13
C-NMR spectra for complex 1 recorded in DMSO-d6 at room 
temperature. 
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Figure D.6.2.3.2 Time dependent 
1
H-NMR spectra for complex 1 recorded in DMSO-d6 at room 
temperature. 
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Figure D.6.2.3.3 
1
H-NMR spectra for complexes 2 (top) and 4 (bottom) in DMSO-d6 at room 
temperature. 
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Figure D.6.2.3.4 
1
H- and 
13
C-NMR spectra for complex 5 recorded in DMSO-d6 at room 
temperature. 
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Crystal Structure Data for Complex 3 
 
Table D.6.5.2.1 Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters 
(A^2 x 10^3) for 3.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          Hg(1)        5000          5000          5000          16(1)  
          I(1)          464(1)       1348(1)       4018(1)       24(1)  
          I(2)         3227(1)       4852(1)        768(1)       23(1)  
          N(1)         4209(2)       7004(2)       5971(2)       19(1)  
          C(1)         4375(3)       8209(3)       5643(3)       25(1)  
          C(2)         3859(3)       9204(3)       6306(3)       27(1)  
          C(3)         3152(3)       8947(3)       7344(3)       26(1)  
          C(4)         2972(3)       7701(3)       7676(3)       21(1)  
          C(5)         3512(3)       6756(3)       6967(3)       17(1)  
          C(6)         3408(3)       5350(3)       7333(3)       18(1)  
          N(2)         3399(2)       4710(2)       6288(2)       16(1)  
          C(7)         2050(3)       5212(3)       5598(3)       17(1)  
          C(8)         2032(3)       4504(3)       4571(3)       16(1)  
          C(9)         1457(3)       3481(3)       4730(3)       17(1)  
          C(10)        1394(3)       2844(3)       3769(3)       20(1)  
          C(11)        1892(3)       3239(3)       2627(3)       19(1)  
          C(12)        2477(3)       4244(3)       2486(3)       17(1)  
          C(13)        2606(3)       4919(3)       3431(3)       16(1)  
          O(1)         3177(2)       5843(2)       3285(2)       18(1)  
          S(1)         5052(1)        966(1)       8338(1)       24(1)  
          O(2)         4033(2)       1924(2)       7332(2)       23(1)  
          C(14)        5707(4)       1942(3)       9124(3)       32(1)  
          C(15)        6568(4)        320(4)       7583(4)       43(1)  
          S(2)          267(1)       1820(1)       9379(1)       31(1)  
          O(3)         1513(2)        631(2)       9824(2)       40(1)  
          C(16)        -389(4)       1545(3)       8017(3)       33(1)  
          C(17)         879(4)       3147(3)       8646(4)       35(1)  
         ________________________________________________________________  
 
 
 
 
Table D.6.5.2.2  Bond lengths [A] and angles [deg] for 3.  
           _____________________________________________________________  
   
            Hg(1)-N(2)#1                  2.225(2)  
            Hg(1)-N(2)                    2.225(2)  
            Hg(1)-N(1)                    2.505(2)  
            Hg(1)-N(1)#1                  2.505(2)  
            Hg(1)-O(1)#1                  2.5063(19)  
            Hg(1)-O(1)                    2.5063(19)  
            I(1)-C(10)                    2.096(3)  
            I(2)-C(12)                    2.095(3)  
            N(1)-C(5)                     1.334(4)  
            N(1)-C(1)                     1.335(4)  
            C(1)-C(2)                     1.384(4)  
            C(2)-C(3)                     1.378(5)  
            C(3)-C(4)                     1.384(4)  
            C(4)-C(5)                     1.383(4)  
            C(5)-C(6)                     1.519(4)  
            C(6)-N(2)                     1.462(4)  
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            N(2)-C(7)                     1.487(4)  
            C(7)-C(8)                     1.495(4)  
            C(8)-C(9)                     1.390(4)  
            C(8)-C(13)                    1.432(4)  
            C(9)-C(10)                    1.389(4)  
            C(10)-C(11)                   1.390(4)  
            C(11)-C(12)                   1.380(4)  
            C(12)-C(13)                   1.419(4)  
            C(13)-O(1)                    1.291(3)  
            S(1)-O(2)                     1.509(2)  
            S(1)-C(15)                    1.777(4)  
            S(1)-C(14)                    1.779(3)  
            S(2)-O(3)                     1.501(2)  
            S(2)-C(16)                    1.775(4)  
            S(2)-C(17)                    1.781(4)  
   
            N(2)#1-Hg(1)-N(2)           180.000(1)  
            N(2)#1-Hg(1)-N(1)           107.58(8)  
            N(2)-Hg(1)-N(1)              72.42(8)  
            N(2)#1-Hg(1)-N(1)#1          72.42(8)  
            N(2)-Hg(1)-N(1)#1           107.58(8)  
            N(1)-Hg(1)-N(1)#1           180.00(9)  
            N(2)#1-Hg(1)-O(1)#1          87.14(8)  
            N(2)-Hg(1)-O(1)#1            92.86(7)  
            N(1)-Hg(1)-O(1)#1            83.49(7)  
            N(1)#1-Hg(1)-O(1)#1          96.51(7)  
            N(2)#1-Hg(1)-O(1)            92.86(7)  
            N(2)-Hg(1)-O(1)              87.14(8)  
            N(1)-Hg(1)-O(1)              96.51(7)  
            N(1)#1-Hg(1)-O(1)            83.49(7)  
            O(1)#1-Hg(1)-O(1)           180.0  
            C(5)-N(1)-C(1)              118.8(3)  
            C(5)-N(1)-Hg(1)             110.67(17)  
            C(1)-N(1)-Hg(1)             130.5(2)  
            N(1)-C(1)-C(2)              122.3(3)  
            C(3)-C(2)-C(1)              119.1(3)  
            C(2)-C(3)-C(4)              118.4(3)  
            C(5)-C(4)-C(3)              119.3(3)  
            N(1)-C(5)-C(4)              122.0(3)  
            N(1)-C(5)-C(6)              116.6(2)  
            C(4)-C(5)-C(6)              121.3(3)  
            N(2)-C(6)-C(5)              114.2(2)  
            C(6)-N(2)-C(7)              112.4(2)  
            C(6)-N(2)-Hg(1)             110.61(17)  
            C(7)-N(2)-Hg(1)             109.96(16)  
            N(2)-C(7)-C(8)              112.0(2)  
            C(9)-C(8)-C(13)             121.6(3)  
            C(9)-C(8)-C(7)              120.1(3)  
            C(13)-C(8)-C(7)             118.2(2)  
            C(10)-C(9)-C(8)             120.7(3)  
            C(9)-C(10)-C(11)            120.1(3)  
            C(9)-C(10)-I(1)             119.8(2)  
            C(11)-C(10)-I(1)            120.0(2)  
            C(12)-C(11)-C(10)           118.6(3)  
            C(11)-C(12)-C(13)           124.5(3)  
            C(11)-C(12)-I(2)            119.0(2)  
            C(13)-C(12)-I(2)            116.5(2)  
            O(1)-C(13)-C(12)            123.5(3)  
            O(1)-C(13)-C(8)             122.2(3)  
            C(12)-C(13)-C(8)            114.3(2)  
            C(13)-O(1)-Hg(1)            103.89(15)  
            O(2)-S(1)-C(15)             105.92(15)  
            O(2)-S(1)-C(14)             107.61(14)  
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            C(15)-S(1)-C(14)             95.48(18)  
            O(3)-S(2)-C(16)             106.34(16)  
            O(3)-S(2)-C(17)             105.60(16)  
            C(16)-S(2)-C(17)             97.48(17)  
           _____________________________________________________________  
   
      Symmetry transformations used to generate equivalent atoms:  
           #1 -x+1,-y+1,-z+1      
  
 
 
 
    Table D.6.5.2.3 Anisotropic displacement parameters (A^2 x 10^3) for 3.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    Hg(1)    16(1)      21(1)      15(1)      -8(1)       1(1)      -8(1)  
    I(1)     23(1)      22(1)      34(1)     -12(1)       3(1)     -12(1)  
    I(2)     30(1)      27(1)      15(1)      -7(1)       1(1)     -13(1)  
    N(1)     25(1)      20(1)      15(1)      -5(1)       0(1)      -9(1)  
    C(1)     33(2)      23(2)      22(2)      -3(1)      -1(1)     -13(1)  
    C(2)     36(2)      16(1)      29(2)      -5(1)      -7(1)      -9(1)  
    C(3)     25(2)      20(2)      32(2)     -12(1)      -7(1)      -2(1)  
    C(4)     22(2)      23(2)      19(2)      -8(1)      -2(1)      -5(1)  
    C(5)     18(1)      17(1)      16(1)      -7(1)      -3(1)      -3(1)  
    C(6)     23(2)      18(1)      15(1)      -7(1)       2(1)      -9(1)  
    N(2)     20(1)      13(1)      15(1)      -3(1)       0(1)      -5(1)  
    C(7)     18(1)      20(1)      14(1)      -9(1)       1(1)      -6(1)  
    C(8)     14(1)      17(1)      17(1)      -6(1)      -1(1)      -2(1)  
    C(9)     14(1)      19(1)      19(2)      -6(1)       0(1)      -5(1)  
    C(10)    16(1)      18(1)      27(2)      -7(1)      -2(1)      -5(1)  
    C(11)    18(2)      19(1)      20(2)      -8(1)      -3(1)      -3(1)  
    C(12)    17(1)      20(1)      12(1)      -4(1)      -2(1)      -4(1)  
    C(13)    14(1)      15(1)      16(1)      -2(1)      -5(1)      -2(1)  
    O(1)     22(1)      18(1)      17(1)      -2(1)      -3(1)      -8(1)  
    S(1)     29(1)      16(1)      24(1)      -2(1)      -4(1)      -7(1)  
    O(2)     23(1)      16(1)      27(1)      -2(1)      -3(1)      -5(1)  
    C(14)    40(2)      26(2)      29(2)     -11(1)     -11(2)      -6(2)  
    C(15)    30(2)      52(2)      41(2)     -26(2)     -11(2)       7(2)  
    S(2)     27(1)      31(1)      28(1)      -1(1)      -1(1)      -4(1)  
    O(3)     34(1)      36(1)      36(2)       6(1)     -15(1)      -1(1)  
    C(16)    31(2)      28(2)      37(2)      -2(2)     -11(2)      -7(1)  
    C(17)    31(2)      31(2)      41(2)      -5(2)      -3(2)      -9(2)  
    _______________________________________________________________________  
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Table D.6.5.2.4 Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 
10^3) for 3.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         4864          8389          4930          30  
          H(2)         3991         10053          6050          32  
          H(3)         2795          9610          7820          31  
          H(4)         2483          7497          8383          26  
          H(6A)        4186          4779          7918          21  
          H(6B)        2564          5395          7777          21  
          H(2A)        3599          3793          6601          19  
          H(7A)        1821          6188          5249          20  
          H(7B)        1346          5082          6181          20  
          H(9)         1102          3214          5504          21  
          H(11)        1831          2826          1958          23  
          H(14A)       6020          2573          8516          39  
          H(14B)       6471          1348          9696          39  
          H(14C)       4989          2444          9591          39  
          H(15A)       6422          -257          7055          51  
          H(15B)       7308          -205          8207          51  
          H(15C)       6809          1066          7072          51  
          H(16A)        308          1445          7403          40  
          H(16B)      -1193          2312          7674          40  
          H(16C)       -644           726          8224          40  
          H(17A)       1262          3468          9279          42  
          H(17B)        126          3887          8172          42  
          H(17C)       1586          2816          8085          42  
         ________________________________________________________________  
  
 
 
 
 
 
    Table D.6.5.2.5 Torsion angles [deg] for 3.  
         ________________________________________________________________  
   
          N(2)#1-Hg(1)-N(1)-C(5)                             -164.42(18)  
          N(2)-Hg(1)-N(1)-C(5)                                 15.58(18)  
          N(1)#1-Hg(1)-N(1)-C(5)                              -32(100)  
          O(1)#1-Hg(1)-N(1)-C(5)                              -79.51(19)  
          O(1)-Hg(1)-N(1)-C(5)                                100.49(19)  
          N(2)#1-Hg(1)-N(1)-C(1)                               15.9(3)  
          N(2)-Hg(1)-N(1)-C(1)                               -164.1(3)  
          N(1)#1-Hg(1)-N(1)-C(1)                              148(100)  
          O(1)#1-Hg(1)-N(1)-C(1)                              100.8(3)  
          O(1)-Hg(1)-N(1)-C(1)                                -79.2(3)  
          C(5)-N(1)-C(1)-C(2)                                   0.6(5)  
          Hg(1)-N(1)-C(1)-C(2)                               -179.8(2)  
          N(1)-C(1)-C(2)-C(3)                                   0.2(5)  
          C(1)-C(2)-C(3)-C(4)                                  -0.7(5)  
          C(2)-C(3)-C(4)-C(5)                                   0.4(4)  
          C(1)-N(1)-C(5)-C(4)                                  -0.8(4)  
          Hg(1)-N(1)-C(5)-C(4)                                179.5(2)  
          C(1)-N(1)-C(5)-C(6)                                -177.3(3)  
          Hg(1)-N(1)-C(5)-C(6)                                  3.0(3)  
          C(3)-C(4)-C(5)-N(1)                                   0.3(4)  
          C(3)-C(4)-C(5)-C(6)                                 176.7(3)  
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          N(1)-C(5)-C(6)-N(2)                                 -31.5(4)  
          C(4)-C(5)-C(6)-N(2)                                 152.0(3)  
          C(5)-C(6)-N(2)-C(7)                                 -78.2(3)  
          C(5)-C(6)-N(2)-Hg(1)                                 45.2(3)  
          N(2)#1-Hg(1)-N(2)-C(6)                             -166(100)  
          N(1)-Hg(1)-N(2)-C(6)                                -30.91(16)  
          N(1)#1-Hg(1)-N(2)-C(6)                              149.09(16)  
          O(1)#1-Hg(1)-N(2)-C(6)                               51.34(17)  
          O(1)-Hg(1)-N(2)-C(6)                               -128.66(17)  
          N(2)#1-Hg(1)-N(2)-C(7)                              -42(100)  
          N(1)-Hg(1)-N(2)-C(7)                                 93.83(18)  
          N(1)#1-Hg(1)-N(2)-C(7)                              -86.17(18)  
          O(1)#1-Hg(1)-N(2)-C(7)                              176.08(17)  
          O(1)-Hg(1)-N(2)-C(7)                                 -3.92(17)  
          C(6)-N(2)-C(7)-C(8)                                -177.2(2)  
          Hg(1)-N(2)-C(7)-C(8)                                 59.1(3)  
          N(2)-C(7)-C(8)-C(9)                                 100.7(3)  
          N(2)-C(7)-C(8)-C(13)                                -80.0(3)  
          C(13)-C(8)-C(9)-C(10)                                -1.4(4)  
          C(7)-C(8)-C(9)-C(10)                                177.9(2)  
          C(8)-C(9)-C(10)-C(11)                                -0.9(4)  
          C(8)-C(9)-C(10)-I(1)                               -178.0(2)  
          C(9)-C(10)-C(11)-C(12)                                1.7(4)  
          I(1)-C(10)-C(11)-C(12)                              178.9(2)  
          C(10)-C(11)-C(12)-C(13)                              -0.3(4)  
          C(10)-C(11)-C(12)-I(2)                             -179.8(2)  
          C(11)-C(12)-C(13)-O(1)                              178.9(3)  
          I(2)-C(12)-C(13)-O(1)                                -1.6(3)  
          C(11)-C(12)-C(13)-C(8)                               -1.8(4)  
          I(2)-C(12)-C(13)-C(8)                               177.68(18)  
          C(9)-C(8)-C(13)-O(1)                               -178.0(2)  
          C(7)-C(8)-C(13)-O(1)                                  2.6(4)  
          C(9)-C(8)-C(13)-C(12)                                 2.7(4)  
          C(7)-C(8)-C(13)-C(12)                              -176.7(2)  
          C(12)-C(13)-O(1)-Hg(1)                             -124.2(2)  
          C(8)-C(13)-O(1)-Hg(1)                                56.6(3)  
          N(2)#1-Hg(1)-O(1)-C(13)                             128.95(18)  
          N(2)-Hg(1)-O(1)-C(13)                               -51.05(18)  
          N(1)-Hg(1)-O(1)-C(13)                              -122.99(17)  
          N(1)#1-Hg(1)-O(1)-C(13)                              57.01(17)  
          O(1)#1-Hg(1)-O(1)-C(13)                              69(100)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
         #1 -x+1,-y+1,-z+1      
  
 
 Table D.6.5.2.6 Hydrogen bonds for 3 [A and deg.].  
 ____________________________________________________________________________  
   
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N2-H2A         0.930    1.911   176.84    2.840    O2  
  
 
 
Least-squares planes (x,y,z in crystal coordinates) and deviations from them (* indicates atom 
used to define plane) 
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  8.1882 (0.0081) x + 0.3929 (0.0136) y + 5.7482 (0.0118) z = 7.1494 (0.0147)  
 
 *    0.0044 (0.0019)  N1 
 *   -0.0010 (0.0022)  C1 
 *   -0.0031 (0.0022)  C2 
 *    0.0040 (0.0021)  C3 
 *   -0.0008 (0.0021)  C4 
 *   -0.0034 (0.0020)  C5 
      0.0668 (0.0048)  C6 
      0.0153 (0.0048)  Hg1 
     -0.5669 (0.0052)  N2 
 
 Rms deviation of fitted atoms =   0.0031 
 
 
  7.3811 (0.0080) x - 3.9666 (0.0109) y + 2.0290 (0.0119) z = 0.6539 (0.0078)  
 
 
 Angle to previous plane (with approximate esd) = 27.92 ( 0.14 ) 
 
 *   -0.0132 (0.0019)  C8 
 *    0.0002 (0.0019)  C9 
 *    0.0113 (0.0019)  C10 
 *   -0.0090 (0.0019)  C11 
 *   -0.0041 (0.0019)  C12 
 *    0.0147 (0.0018)  C13 
     -0.0727 (0.0043)  C7 
      0.0402 (0.0037)  O1 
      2.0679 (0.0040)  Hg1 
 
 Rms deviation of fitted atoms =   0.0101 
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Crystal Structure Data for Complex 5 
 
 
Table D.6.5.2.7 Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters 
(A^2 x 10^3) for 5. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          I(1)         4318(1)       2107(1)       7919(1)       24(1)  
          I(2)        -3230(1)       -769(1)       5830(1)       23(1)  
          Sn(1)       -1840(1)      -4119(1)       7998(1)       13(1)  
          N(1)         -218(3)      -3743(2)       6749(2)       15(1)  
          C(1)         -959(4)      -3690(3)       5620(2)       17(1)  
          C(2)           71(4)      -3212(3)       4931(3)       22(1)  
          C(3)         1878(4)      -2766(3)       5415(3)       24(1)  
          C(4)         2633(4)      -2807(3)       6582(3)       21(1)  
          C(5)         1536(4)      -3313(3)       7233(3)       17(1)  
          C(6)         2253(4)      -3458(3)       8487(3)       19(1)  
          N(2)          912(3)      -3276(2)       9185(2)       16(1)  
          C(7)         1039(4)      -1819(3)       9815(2)       19(1)  
          C(8)          852(4)       -929(3)       8937(2)       16(1)  
          C(9)         2282(4)         36(3)       8924(2)       19(1)  
          C(10)        2130(4)        756(3)       8035(2)       18(1)  
          C(11)         542(4)        537(3)       7168(3)       19(1)  
          C(12)        -905(4)       -414(3)       7188(2)       16(1)  
          C(13)        -784(4)      -1179(3)       8062(2)       15(1)  
          O(1)        -2151(3)      -2133(2)       8055(2)       16(1)  
          Cl(4)       -1029(1)      -6343(1)       7942(1)       19(1)  
          Cl(5)       -4489(1)      -5014(1)       6495(1)       23(1)  
          Cl(6)       -3034(1)      -4176(1)       9641(1)       20(1)  
         ________________________________________________________________  
  
 
 
 
 
  Table D.6.5.2.8 Bond lengths [A] and angles [deg] for 5.  
           _____________________________________________________________  
   
            I(1)-C(10)                    2.092(3)  
            I(2)-C(12)                    2.079(3)  
            Sn(1)-O(1)                    2.0564(18)  
            Sn(1)-N(1)                    2.215(2)  
            Sn(1)-N(2)                    2.243(2)  
            Sn(1)-Cl(5)                   2.3479(7)  
            Sn(1)-Cl(6)                   2.3561(7)  
            Sn(1)-Cl(4)                   2.4227(7)  
            N(1)-C(5)                     1.340(4)  
            N(1)-C(1)                     1.351(4)  
            C(1)-C(2)                     1.379(4)  
            C(2)-C(3)                     1.377(5)  
            C(3)-C(4)                     1.390(4)  
            C(4)-C(5)                     1.391(4)  
            C(5)-C(6)                     1.513(4)  
            C(6)-N(2)                     1.489(4)  
            N(2)-C(7)                     1.505(4)  
            C(7)-C(8)                     1.503(4)  
            C(8)-C(9)                     1.389(4)  
            C(8)-C(13)                    1.413(4)  
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            C(9)-C(10)                    1.389(4)  
            C(10)-C(11)                   1.384(4)  
            C(11)-C(12)                   1.393(4)  
            C(12)-C(13)                   1.407(4)  
            C(13)-O(1)                    1.339(3)  
   
            O(1)-Sn(1)-N(1)              83.87(8)  
            O(1)-Sn(1)-N(2)              87.27(8)  
            N(1)-Sn(1)-N(2)              76.41(9)  
            O(1)-Sn(1)-Cl(5)             93.22(6)  
            N(1)-Sn(1)-Cl(5)             94.14(7)  
            N(2)-Sn(1)-Cl(5)            170.44(6)  
            O(1)-Sn(1)-Cl(6)             91.50(6)  
            N(1)-Sn(1)-Cl(6)            167.24(6)  
            N(2)-Sn(1)-Cl(6)             91.54(6)  
            Cl(5)-Sn(1)-Cl(6)            97.99(3)  
            O(1)-Sn(1)-Cl(4)            171.76(6)  
            N(1)-Sn(1)-Cl(4)             90.00(6)  
            N(2)-Sn(1)-Cl(4)             85.94(6)  
            Cl(5)-Sn(1)-Cl(4)            92.70(3)  
            Cl(6)-Sn(1)-Cl(4)            93.34(2)  
            C(5)-N(1)-C(1)              120.6(2)  
            C(5)-N(1)-Sn(1)             115.79(18)  
            C(1)-N(1)-Sn(1)             122.4(2)  
            N(1)-C(1)-C(2)              121.1(3)  
            C(3)-C(2)-C(1)              119.0(3)  
            C(2)-C(3)-C(4)              119.8(3)  
            C(3)-C(4)-C(5)              118.8(3)  
            N(1)-C(5)-C(4)              120.7(3)  
            N(1)-C(5)-C(6)              116.8(2)  
            C(4)-C(5)-C(6)              122.5(3)  
            N(2)-C(6)-C(5)              110.9(2)  
            C(6)-N(2)-C(7)              113.7(2)  
            C(6)-N(2)-Sn(1)             109.63(17)  
            C(7)-N(2)-Sn(1)             110.29(17)  
            C(8)-C(7)-N(2)              110.0(2)  
            C(9)-C(8)-C(13)             120.8(2)  
            C(9)-C(8)-C(7)              121.2(3)  
            C(13)-C(8)-C(7)             117.8(2)  
            C(8)-C(9)-C(10)             120.3(3)  
            C(11)-C(10)-C(9)            120.2(3)  
            C(11)-C(10)-I(1)            118.6(2)  
            C(9)-C(10)-I(1)             121.1(2)  
            C(10)-C(11)-C(12)           119.7(3)  
            C(11)-C(12)-C(13)           121.4(3)  
            C(11)-C(12)-I(2)            118.4(2)  
            C(13)-C(12)-I(2)            120.0(2)  
            O(1)-C(13)-C(12)            121.5(2)  
            O(1)-C(13)-C(8)             121.0(2)  
            C(12)-C(13)-C(8)            117.5(2)  
            C(13)-O(1)-Sn(1)            120.51(17)  
           _____________________________________________________________  
   
Symmetry transformations used to generate equivalent atoms. 
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Table D.6.5.2.9 Anisotropic displacement parameters (A^2 x 10^3) for 5.   
The anisotropic displacement factor exponent takes the form:  
   -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    I(1)     25(1)      22(1)      23(1)       5(1)       7(1)      -7(1)  
    I(2)     18(1)      23(1)      27(1)      13(1)      -2(1)       3(1)  
    Sn(1)    13(1)      13(1)      14(1)       6(1)       3(1)       0(1)  
    N(1)     19(1)      12(1)      18(1)       6(1)       6(1)       4(1)  
    C(1)     23(2)      14(1)      17(1)       6(1)       5(1)       5(1)  
    C(2)     34(2)      16(1)      19(1)       7(1)       9(1)       8(1)  
    C(3)     30(2)      20(1)      29(2)      11(1)      18(1)       5(1)  
    C(4)     20(2)      17(1)      29(2)       8(1)      11(1)       4(1)  
    C(5)     17(1)      13(1)      22(1)       7(1)       7(1)       4(1)  
    C(6)     13(1)      23(1)      23(1)      11(1)       3(1)       3(1)  
    N(2)     16(1)      17(1)      16(1)       7(1)       3(1)       2(1)  
    C(7)     21(2)      16(1)      17(1)       6(1)       0(1)      -1(1)  
    C(8)     17(1)      13(1)      16(1)       5(1)       2(1)       1(1)  
    C(9)     18(1)      17(1)      18(1)       3(1)       0(1)      -1(1)  
    C(10)    18(1)      13(1)      20(1)       5(1)       5(1)      -1(1)  
    C(11)    25(2)      12(1)      21(1)       8(1)       6(1)       3(1)  
    C(12)    16(1)      14(1)      18(1)       6(1)       2(1)       4(1)  
    C(13)    15(1)      13(1)      17(1)       4(1)       4(1)       1(1)  
    O(1)     14(1)      13(1)      23(1)       8(1)       5(1)       1(1)  
    Cl(4)    23(1)      15(1)      20(1)       9(1)       6(1)       5(1)  
    Cl(5)    19(1)      23(1)      22(1)       8(1)      -2(1)      -2(1)  
    Cl(6)    21(1)      22(1)      19(1)       8(1)       8(1)       2(1)  
    _______________________________________________________________________  
 
 
 
 
Table D.6.5.2.10 Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 
10^3) for 5.  
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         -116         -4653          6539          18  
          H(1A)       -2209         -3985          5296          21  
          H(2)         -458         -3192          4134          26  
          H(3)         2605         -2431          4953          28  
          H(4)         3876         -2495          6928          25  
          H(6A)        2562         -4374          8466          23  
          H(6B)        3353         -2767          8878          23  
          H(7A)          86         -1763         10235          22  
          H(7B)        2205         -1495         10412          22  
          H(9)         3367           205          9526          23  
          H(11)         439          1032          6562          22  
         ________________________________________________________________  
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 Table D.6.5.2.11 Torsion angles [deg] for 5.  
         ________________________________________________________________  
   
          O(1)-Sn(1)-N(1)-C(5)                                 92.88(19)  
          N(2)-Sn(1)-N(1)-C(5)                                  4.21(18)  
          Cl(5)-Sn(1)-N(1)-C(5)                              -174.32(18)  
          Cl(6)-Sn(1)-N(1)-C(5)                                23.7(4)  
          Cl(4)-Sn(1)-N(1)-C(5)                               -81.61(18)  
          O(1)-Sn(1)-N(1)-C(1)                                -74.7(2)  
          N(2)-Sn(1)-N(1)-C(1)                               -163.4(2)  
          Cl(5)-Sn(1)-N(1)-C(1)                                18.1(2)  
          Cl(6)-Sn(1)-N(1)-C(1)                              -143.9(2)  
          Cl(4)-Sn(1)-N(1)-C(1)                               110.8(2)  
          C(5)-N(1)-C(1)-C(2)                                   1.1(4)  
          Sn(1)-N(1)-C(1)-C(2)                                168.1(2)  
          N(1)-C(1)-C(2)-C(3)                                  -1.0(4)  
          C(1)-C(2)-C(3)-C(4)                                   0.2(4)  
          C(2)-C(3)-C(4)-C(5)                                   0.5(4)  
          C(1)-N(1)-C(5)-C(4)                                  -0.3(4)  
          Sn(1)-N(1)-C(5)-C(4)                               -168.1(2)  
          C(1)-N(1)-C(5)-C(6)                                -177.9(2)  
          Sn(1)-N(1)-C(5)-C(6)                                 14.3(3)  
          C(3)-C(4)-C(5)-N(1)                                  -0.5(4)  
          C(3)-C(4)-C(5)-C(6)                                 177.0(3)  
          N(1)-C(5)-C(6)-N(2)                                 -33.2(3)  
          C(4)-C(5)-C(6)-N(2)                                 149.2(3)  
          C(5)-C(6)-N(2)-C(7)                                 -89.6(3)  
          C(5)-C(6)-N(2)-Sn(1)                                 34.4(3)  
          O(1)-Sn(1)-N(2)-C(6)                               -105.54(17)  
          N(1)-Sn(1)-N(2)-C(6)                                -21.19(17)  
          Cl(5)-Sn(1)-N(2)-C(6)                               -12.3(5)  
          Cl(6)-Sn(1)-N(2)-C(6)                               163.03(16)  
          Cl(4)-Sn(1)-N(2)-C(6)                                69.79(16)  
          O(1)-Sn(1)-N(2)-C(7)                                 20.37(17)  
          N(1)-Sn(1)-N(2)-C(7)                                104.72(17)  
          Cl(5)-Sn(1)-N(2)-C(7)                               113.6(4)  
          Cl(6)-Sn(1)-N(2)-C(7)                               -71.06(16)  
          Cl(4)-Sn(1)-N(2)-C(7)                              -164.30(16)  
          C(6)-N(2)-C(7)-C(8)                                  57.1(3)  
          Sn(1)-N(2)-C(7)-C(8)                                -66.5(2)  
          N(2)-C(7)-C(8)-C(9)                                -111.5(3)  
          N(2)-C(7)-C(8)-C(13)                                 63.6(3)  
          C(13)-C(8)-C(9)-C(10)                                -1.1(4)  
          C(7)-C(8)-C(9)-C(10)                                173.8(3)  
          C(8)-C(9)-C(10)-C(11)                                 1.3(4)  
          C(8)-C(9)-C(10)-I(1)                               -175.3(2)  
          C(9)-C(10)-C(11)-C(12)                               -0.3(4)  
          I(1)-C(10)-C(11)-C(12)                              176.5(2)  
          C(10)-C(11)-C(12)-C(13)                              -1.0(4)  
          C(10)-C(11)-C(12)-I(2)                             -177.5(2)  
          C(11)-C(12)-C(13)-O(1)                             -177.3(2)  
          I(2)-C(12)-C(13)-O(1)                                -0.9(4)  
          C(11)-C(12)-C(13)-C(8)                                1.2(4)  
          I(2)-C(12)-C(13)-C(8)                               177.65(19)  
          C(9)-C(8)-C(13)-O(1)                                178.4(2)  
          C(7)-C(8)-C(13)-O(1)                                  3.3(4)  
          C(9)-C(8)-C(13)-C(12)                                -0.2(4)  
          C(7)-C(8)-C(13)-C(12)                              -175.2(2)  
          C(12)-C(13)-O(1)-Sn(1)                              122.5(2)  
          C(8)-C(13)-O(1)-Sn(1)                               -56.0(3)  
          N(1)-Sn(1)-O(1)-C(13)                               -39.33(19)  
          N(2)-Sn(1)-O(1)-C(13)                                37.28(19)  
          Cl(5)-Sn(1)-O(1)-C(13)                             -133.16(19)  
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          Cl(6)-Sn(1)-O(1)-C(13)                              128.75(19)  
          Cl(4)-Sn(1)-O(1)-C(13)                                2.8(5)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
  
 
 
Table D.6.5.2.12  Hydrogen bonds for 5 [A and deg.].  
 ____________________________________________________________________________  
   
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1          0.930    2.746   117.64    3.283    Cl4  
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ABSTRACT 
PROBING PROTEASOME INHIBITON BY METAL COMPLEXES AS A NEW 
MECHANISM FOR ANTICANCER THERAPY 
by 
DAJENA TOMCO 
December 2014 
Advisor: Dr. Cláudio N. Verani 
Major: Chemistry (Inorganic) 
Degree: Doctor of Philosophy 
The scope of this thesis is focused towards the development of metal-containing 
coordination compounds as potential therapeutic agents. Efforts of this research involve 
the design, synthesis, and purification of these complexes, as well as their evaluation by 
spectroscopic, spectrometric, and electrochemical characterization. The antineoplastic 
properties of these metal-containing pro-drugs are tested against the inhibition activity of 
the 26S proteasome. Selected metal ions ranging from transition to main group elements 
have been incorporated in various ligand systems containing phenolate and pyridyl donor 
sets. The mechanistic behavior of these complexes in solution has been thoroughly 
investigated along with their in vitro anticancer properties against the growth of prostate 
cancer PC-3 cells. It has been demonstrated that apoptosis induction of the PC-3 cells is 
due to the inhibition activity of the 26S proteasome upon treatment of various 
concentrations of these metal-based pro-drugs. The antiproliferative effects of these 
complexes are highly dependent on the charge, redox activity of the metal ions, as well as 
the nature of the chelating ligands.   
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